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ABSTRACT 
At  the  beginning  of  this  study,  knowledge  of  autotransporter  proteins  was  in  its  infancy 
and  the  B.  pertussis  proteins  pertactin  , 
BrkA  and  tracheal  colonisation  factor  (Tcf)  had 
not  been  recognised  as  members  of  this  family.  However,  the  sequence  similarity 
between  these  Bordetella  proteins  and  a  number  of  other  proteins  from  different  genera 
soon  became  apparent  and  the  Bordetella  proteins  were  also  included  in  the 
autotransporter  protein  family.  It  was  the  similarity  between  pertactin  and  other  B. 
pertussis  proteins  that,  due  to  a  mis-primed  PCR  amplification,  led  to  the  preliminary 
data  for  this  project.  A  B.  pertussis  genomic  library  was  screened,  using  this  amplicon 
as  a  Southern  blot  probe,  and  a  cosmid  was  identified  and  subcloned.  Analysis  of  the 
sequence  led  to  the  identification  of  a  larger  open  reading  frame  which  had  not  been 
previously  recognised.  The  cosmid  did  not  contain  the  entire  open  reading  frame  and  a 
further  200  bp  was  obtained  using  an  adapter-linked  single  specific  primer-PCR  (SSP- 
PCR).  An  open  reading  frame  was  predicted  and  the  amino  acid  similarity  strongly 
suggests  that  this  gene  product  represents  another  member  of  the  autotransporter 
family.  This  protein  was  named  Bap-5  as  the  fifth  member  of  the  Bordetella 
autotransporter  protein  family.  Motif  analysis  revealed  an  RGD  integrin-binding  motif 
and  an  SGSG  glycosaminoglycan-binding  motif,  which  implicates  this  protein  as  a 
putative  adhesin.  No  upstream  regulatory  sequences  were  identified  although  a  Rho- 
independent  terminator  sequence  was  predicted  downstream.  The  bap-5  sequence  was 
deposited  in  GenBank  on  11/08/1998  (accession  number  AF081494). 
Although  not  begun  at  the  start  of  this  study,  the  B.  pertussis  genome  sequence  was  near 
completion  during  the  final  stages  of  this  work  and  a  sequence  identical  to  bap-5  was 
located  in  the  sequence  data.  A  similar  sequence  to  bap-5  was  also  identified  in  the 
genome  of  B.  bronchiseptica,  for  which  a  sequencing  project  was  initiated  during  this 
study.  Progress  was  made  towards  the  construction  of  a  bap-5  deficient  mutant, 
although  the  final  stages  were  not  completed.  Such  a  mutant  would  allow  the  role  of xx 
Bap-5  to  be  characterised.  Sequences  which  hybridised  to  a  bap-5  Southern  blot  probe 
were  identified  in  B.  bronchiseptica  and  B.  parapertussis  but  not  in  B.  avium.  The 
expression  of  Bap-5  was  confirmed  by  RT-PCR  and  Western  blotting,  and  shown  to  be 
Bvg-regulated.  Such  regulation  implies  a  role  for  Bap-5  in  pathogenicity  of  B.  pertussis. 
The  Westen  blotting  results  also  suggested  that  Bap-5  is  processed  in  a  similar  way  to 
pertactin. 
Recombinant  expression  systems  were  set  up  for  Bap-5,  a  specific  portion  of  Bap-5  and 
the  carboxy-terminal  domains  of  pertactin,  BrkA,  Tcf  and  Bap-5.  Most  expression 
vectors  used  allowed  the  construction  of  histidine  fusion  proteins  which  could  be  readily 
purified.  These  autotransporter  domains  provided  material  for  mouse  protection  tests 
and  antibody  production.  Under  the  conditions  tested,  however,  these  recombinant 
strains  did  not  protect  against  lung  colonisation  after  intranasal  challenge  with 
B.  pertussis  although  mature  pertactin  (P69)  gave  some  protection.  In  addition,  a 
heterologous  antigen  display  system,  based  on  the  pertactin  sequence  was  created.  A 
sec-dependent  signal  sequence  was  fused  to  the  pertactin  C-terminus  along  with  some 
upstream  sequence  which  allowed  targeting  of  this  domain  to  the  outer  membrane  of 
E.  coll.  Future  development  of  this  vector,  ie.  fusion  of  a  passenger  domain  which  could 
be  displayed  on  the  bacterial  surface,  may  prove  useful  in  vaccine  or  other 
biotechnological  applications. 1.0  Introduction Blackburn  P.  E. 
1.1  Genus  and  species  characteristics 
1.1.1  Definition 
Introduction 
Bordetella  species  are  small,  aerobic,  non-sporing  Gram-negative  cocco-bacilli  (0.3-0.5 
µm  x  0.5-2.0  µm).  The  optimum  growth  temperature  for  bordetellae  is  35-37°C  and 
carbohydrates  are  not  fermented  (Parton  1998).  The  genus  Bordetella  comprises  a 
closely-related  group  of  pathogens  that  are  capable  of  infecting  the  respiratory  tracts  of 
warm-blooded  vertebrates.  With  the  exception  of  laboratory  cultivation,  they  are 
considered  to  be  obligate  respiratory  tract  pathogens.  However,  the  survival  and  growth 
of  B.  bronchiseptica  and  B.  parapertussis  in  natural  waters  and  other  low  nutrient 
conditions  suggests  that  these  species  have  an  environmental  reservoir  (Porter  et  al. 
1991;  Porter  and  Wardlaw  1993).  The  primary  habitat  of  B.  pertussis  is  the  surface  of 
the  ciliated  epithelial  cells  in  the  human  respiratory  tract  although  it  has  been  suggested 
that  invasion  of  mammalian  cells  may  provide  an  alternative,  intracellular  niche  (Lee  et 
al.  1990;  Friedman  et  al.  1992;  Forde  et  al.  1998). 
1.1.2  Taxonomy 
Bordetella  species  have  been  previously  assigned  to  various  different  bacterial  genera 
including  Alcaligenes,  Bacillus,  Haemophilus  and  Brucella  (Parton  1998).  A  new 
family,  Alcaligenaceae,  was  suggested  on  the  basis  of  DNA-rRNA  hybridisations  and 
phenotypic  analyses  (De  Ley  et  al.  1986).  Recent  evidence  from  phylogenetic  16S 
rRNA  sequence  analysis  has  confirmed  that  Bordetella  most  closely  resembles 
Alcaligenes  and  these  genera  are  now  assigned  to  the  beta-2  subdivision  of 
Proteobacteria  (Weyant  et  al.  1995).  To  date,  seven  species  have  been  included  in  the 
genus  Bordetella.  B.  pertussis  (originally  Bacillus  pertussis)  was  identified  as  the  cause 
of  whooping  cough  (pertussis)  in  1906  (Bordet  and  Gengou  1906).  B.  bronchiseptica 
(originally  Bacillus  bronchicanis)  has  been  recognised  as  a  cause  of  kennel  cough  in  dogs 
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and  also  causes  respiratory  disease  in  other  wild  and  domestic  mammals  (Ferry  1910). 
Occasionally,  B.  bronchiseptica  is  responsible  for  causing  disease  in  man. 
B.  parapertussis  (originally  Bacillus  parapertussis)  is  responsible  for  causing  a  generally 
mild  form  of  whooping  cough  in  man  (Eldering  and  Kendrick  1938)  and  related  strains 
have  been  isolated  from  the  respiratory  tracts  of  sheep  (Cullinane  et  al.  1987;  Khelef  et 
al.  1993).  B.  avium  was  isolated  as  a  B.  bronchiseptica-like  organism  and  the  causative 
agent  of  turkey  rhinitis  (Filion  et  al.  1967)  although  this  species  designation  was  not 
suggested  until  1984  (Kersters  et  al.  1984). 
Recently,  three  more  species  have  been  included  in  the  genus  Bordetella  on  the  basis  of 
genotypic  and  phenotypic  comparisons.  B.  holmesii  was  isolated  originally  from  the 
blood  cultures  of  patients,  some  of  whom  were  immunocompromised  (Weyant  et  al. 
1995).  B.  hinzii  was  the  name  proposed  for  a  non-pathogenic  B.  avium-like  group  of 
organisms  that  has  been  isolated  from  the  respiratory  tract  of  chickens  and  turkeys  and 
also  from  immunocompromised  humans  (Cookson  et  al.  1994;  Vandamme  et  al.  1995). 
The  most  recent  addition  to  the  genus  is  Bordetella  trematum,  which  has  been  isolated 
from  wounds  and  ear  infections  in  humans  (Vandamme  et  al.  1996).  There  is  little 
information  regarding  the  properties  and  characteristics  of  these  three  recently-described 
species. 
1.2  Clinical  disease-pertussis 
Pertussis  is  a  highly  communicable  disease  and  has  an  attack  rate  of  over  90%  among 
unimmunized  individuals  (Lambert  1965).  Although  B.  pertussis  is  a  world-wide 
pathogen,  an  intensive  vaccination  programme  has  proved  effective  in  drastically 
reducing  the  number  of  pertussis  cases  in  developed  countries.  It  has  been  estimated 
that  the  vast  majority  of  unvaccinated  children  are  infected  with  B.  pertussis  by  the  age 
of  five  years  (Fine  and  Clarkson  1987).  The  disease  may  be  life  threatening  in  young 
infants  under  6  months  of  age  and  the  variable  severity  of  disease  is  influenced  by  the 
age,  general  health  and  immune  status  of  the  patient  (Parton  1991). 
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Typical  pertussis  disease  can  be  divided  into  three  symptomatic  stages,  1)  catarrhal,  2) 
paroxysmal  and  3)  convalescent  (Cherry  et  al.  1988).  Following  infection  with 
B.  pertussis  there  is  an  incubation  period  of  6  to  20  days  (Lapin  1943).  The  catarrhal 
stage  lasts  1-2  weeks  and  symptoms  include  a  mild  cough.  During  the  paroxysmal  stage 
(1-20  weeks)  the  cough  is  more  forceful  and  more  frequent.  In  approximately  50%  of 
patients  coughing  paroxysms  often  end  in  a  characteristic  inspiratory  "whoop", 
sometimes  with  vomiting,  apnoea  and  cyanotic  attacks  which  are  the  most  frequent 
cause  of  pertussis  hospital  admissions  (Cherry  et  al.  1988).  Most  complications,  for 
example  brain  damage  which  is  thought  to  be  caused  by  cerebral  anoxia,  and  also  deaths 
occur  at  this  stage.  The  convalescent  stage  is  characterised  by  a  reduction  in  the  number 
and  frequency  of  paroxysms,  which  may  still  occur  sporadically  for  up  to  6  months 
post-infection. 
1.3  Mechanisms  of  pathogenesis 
Bordetella  spp.  produce  a  plethora  of  pathogenic  factors  that  are  co-ordinately  regulated 
during  infection.  A  number  of  toxins,  such  as  pertussis  toxin  and  tracheal  cytotoxin  are 
secreted  from  the  B.  pertussis  cell  surface  and  these  proteins  have  unusual  activities 
associated  with  them.  In  addition  B.  pertussis  also  produce  a  range  of  adhesins,  some  of 
which  may  also  act  as  invasins. 
Proteins  suggested  to  be  involved  in  adhesion  include  fimbriae  (Robinson  et  al  1990), 
filamentous  haemagglutinin  (FHA)  (Stibitz  et  al.  1988),  tracheal  colonisation  factor 
(Tcf)  (Finn  and  Stevens  1995),  Bordetella  resistance  to  killing  protein  A  (BrkA) 
(Fernandez  and  Weiss  1994)  and  pertactin  (Prn)  (Charles  et  al.  1989).  The  list  also 
includes  pertussis  toxin  which,  although  secreted  from  the  cell,  still  facilitates  adhesion 
and  presumably  must,  therefore,  also  be  surface  located  (Sandros  and  Tuomanen  1993). 
Flagella  on  the  surface  of  B.  bronchiseptica  also  appear  to  play  a  role  in  adhesion  to 
eukaryotic  cells  (Leigh  et  al.  1993;  Savelkoul  et  al.  1996).  It  is  likely  that  other  yet 
uncharacterised  proteins  facilitate  adhesion  and  therefore  colonisation  of  the  respiratory 
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mucosal  surface.  Adherence  appears  to  be  multifactorial  and  relies  on  a  number  of 
outer-membrane  components  i.  e.  those  anchored  to  the  membrane,  and  cell-associated 
proteins  (Leininger  et  al.  1990).  It  is  not  known  why  B.  pertussis  produces  so  many 
different  adhesins,  although  it  is  tempting  to  speculate  that  they  are  expressed  at 
different  stages  in  the  pathogenesis  of  B.  pertussis  infection  and  therefore  allow 
adaption  to  adhere  to,  or  release  from,  various  surfaces  during  the  infection  cycle. 
Possession  of  an  array  of  adhesins  may  enable  the  bacteria  to  adhere  to  host  cells  when 
antibodies  to  specific  adhesins  are  present.  This  is  known  as  "immune  exclusion" 
(Weiss  1997). 
1.3.1  Regulation  of  virulence 
The  expression  profile  of  bordetellae  can  change  dramatically  in  vitro  in  response  to 
growth  conditions.  This  adaption  may  be  indicative  of  their  potential  to  colonise,  and 
potentially  invade,  distinct  areas  of  the  respiratory  tract,  to  evade  immune  responses 
(by  altering  the  antigens  expressed)  and  possibly  to  inhabit  other  unrecognised  niches 
(Parton  1991;  Cotter  and  Miller  1996).  Co-ordinate  regulation  of  proteins  is  presumed 
to  be  important  in  the  life  cycle  of  B.  pertussis  but  at  what  stage  is  unclear. 
Bordetella  species  are  able  to  switch  between  virulent  (Bvg+)  and  avirulent  (Bvg)  forms. 
The  bvgAS  locus  (Bordetella  virulence  gene)  encodes  a  two  component  regulatory 
system  which  is  responsible  for  the  control  of  many  virulence-activated  genes  (vags), 
some  of  which  encode  the  virulence  factors  outlined  in  Table  1.  Several  virulence- 
repressed  genes  (vrgs)  have  also  been  identified  but  are  not  well  characterised  (Stibitz  et 
al.  1988;  1989;  Coote  1991).  The  BvgS  protein  is  located  in  the  cytoplasmic  membrane 
and  acts  as  a  sensor  of  environmental  signals. 
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These  signals  are  then  transferred  to  the  cytoplasmic  BvgA  protein  by 
phosphorylation.  BvgA  then  activates  the  transcription  of  the  vags  and  represses  the 
expression  of  the  vrgs.  The  BvgA  binding  site  has  been  identified  upstream  from  the 
open  reading  frames  of  several  virulence-associated  genes  including  adenylate  cyclase, 
pertussis  toxin,  FHA  and  pertactin  (Karimova,  et  al.  1996;  Karimova  and  Ullmann 
1997;  Kinnear  et  al.  1999).  This  global  control  of  virulence  factors  appears  to  be 
autoregulated  (Melton  and  Weiss  1989;  Scarlato  et  al.  1990;  Scarlato  et  al.  1991). 
The  expression  of  several  Bordetella  virulence  factors  is  dependent  on  the  phase  and 
mode  of  the  organism,  which  thus  reflects  the  virulence  of  the  strains.  The  two 
mechanisms  involved  have  been  termed  phase  variation  and  antigenic  modulation.  Phase 
variation  results  in  the  production  of  an  avirulent  strain  which  is  due  to  a  frameshift 
mutation  or  a  deletion  in  the  bvgS  gene  and  occurs  at  a  frequency  of  1  per  103-106 
organisms.  Avirulent  strains  that  result  are  described  as  Phase  IV,  whereas  virulent 
strains  are  described  as  Phase  I.  This  process  is  rarely  reversible.  Antigenic 
modulation,  however,  is  readily  reversible  and  also  results  in  a  change  in  virulence  state 
(Lacey  1960).  In  antigenic  modulation  an  avirulent  form  (cyanic  or  C-mode)  results 
from  a  virulent  form  (xanthic  or  X-mode)  as  an  in  vitro  response  to  growth  conditions 
such  as  high  levels  of  certain  salts,  organic  acids  or  at  low  temperatures.  The  BvgAS 
regulatory  system  is  thought  to  be  responsible  for  the  alteration  of  expression  which  is 
observed  antigenic  modulation.  Phase  I  and  X-mode  strains  strains  are  phenotypically 
identical,  as  are  Phase  IV  and  C-mode  strains. 
1.4  Vaccination  against  pertussis 
Immunisation  of  infants  with  inactivated  whole-cell  vaccines  (WCVs)  has,  in  countries 
with  good  vaccination  coverage,  dramatically  reduced  the  morbidity  and  mortality  from 
pertussis.  However,  in  recent  years  there  has  been  an  increase  in  the  incidence  of 
pertussis,  particularly  in  older  children  and  adults,  in  a  number  of  countries  including  the 
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US  and  several  countries  in  Europe.  The  reasons  for  this  increase  are  unknown, 
although  immunity  as  a  result  of  childhood  vaccination  decreases  after  about  12  years  of 
age.  According  to  World  Health  Organisation  (WHO)  statistics,  the  number  of  deaths 
due  to  pertussis  worldwide  has  been  estimated  at  450,000  for  the  year  1997  and  a 
further  700,000  were  prevented  by  vaccination  (further  details  can  be  found  at  the 
WHO  website  http:  www.  who.  int/gpv-surv/graphics/Jan99graphics/estdeaths.  htm). 
Although  whole  cell  vaccination  programmes  against  pertussis  have  been  very  effective 
in  reducing  the  incidence  of  this  disease,  there  are  concerns  that  current  WCVs  do  not 
prevent  infection  (Willems  and  Mooi  1996).  The  circulation  of  B.  pertussis  in  the 
human  population  has  not  been  significantly  affected  by  the  WCVs  (Fine  and  Clarkson 
1987;  Grenfell  and  Anderson  1989).  This  may  lead  to  those  with  waning  immunity 
becoming  a  significant  reservoir  of  infection  for  others  who  are  susceptible  (Aoyama  et 
al.  1992).  Such  a  reservoir  may  explain  the  peaks  in  pertussis  every  3-4  years  which 
occur  in  countries  with  high  vaccine  uptake  (Fine  1988). 
Frequent,  but  usually  mild,  adverse  reactions,  and  a  fear  of  rare  but  serious  neurological 
events  associated  with  WCVs,  and  an  increase  in  the  understanding  of  the  pathogenesis 
of  pertussis  have  prompted  the  development  of  a  new  generation  of  better  defined 
pertussis  vaccines,  the  acellular  vaccines  (ACVs).  Acellular  vaccines  have  been  used  in 
Japan  since  1981  and  have  been  shown  to  be  effective  and  have  fewer  side  effects 
compared  to  WCVs  (Kimura  and  Kuno-Saki  1990).  Early  double-blind,  placebo- 
controlled  ACV  trials  in  Sweden  (1986-1987)  were  performed  with  either 
monocomponent  chemically-inactivated  pertussis  toxoid  (PTd)  or  a  two  component 
PTd  and  filamentous  haemagglutinin  (FHA)  vaccine  (Ad  Hoc  Group  1988).  The 
reactogenicity  of  these  vaccines  was  low  but  the  efficacy  was  less  than  would  have  been 
expected  for  WCVs.  More  recent  vaccine  trials  have  highlighted  the  importance  of 
including  other  components  (Plotkins  and  Cadoz  1997).  Although  the  composition  of 
current  ACV  formulations  varies  widely  between  manufacturers,  important  components 
include  PTd,  FHA,  P.  69  and  fimbriae  (fim  2  and  3)  (Willems  et  al.  1998). 
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The  results  of  recent  clinical  trials  indicate  that  ACVs  offer  the  prospect  of  reduced 
reactogenicity  relative  to  WCVs  and  for  some  preparations  may  achieve  comparable 
efficacy  (Cherry  1997;  Halperin  1999).  One  drawback  of  current  acellular  vaccine 
preparations  is  that,  like  WCVs,  infection  with  B.  pertussis  does  not  appear  to  be 
prevented  and  therefore  the  problem  of  a  reservoir  in  the  human  population  remains. 
Acellular  vaccines  have  been  shown  to  predilict  a  Th2  response,  whereas  intracellular 
infection  of  macrophages  with  B.  pertussis  or  stimulation  with  killed  B.  pertussis 
induces  an  IL-12  driven  Thl  response  which  is  more  protective  in  such  murine  models 
(Mahon  et  al.  1996).  Therefore  the  use  of  IL-12  as  an  adjuvant  is  under  study  in  ACV 
trials  (Mahon  et  al.  1996). 
It  is  evident  from  a  recent  Dutch  trial  that  the  optimal  composition  of  ACV 
preparations  has  not  yet  been  found  (Mooi  et  al.  1998).  The  whole-cell  vaccine  used  in 
this  Dutch  vaccination  programme  appears  to  have  driven  antigenic  shifts  in  the  PT  and 
P.  69  antigens  within  the  B.  pertussis  population.  This  immune  selection  has  caused  the 
re-emergence  of  pertussis  in  highly  vaccinated  populations  and  may  have  major 
implications  for  the  long  term  efficacy  of  both  whole  cell  vaccines  and  acellular  vaccines. 
These  findings  highlight  the  limitations  of  clinical  trials  which  have  already  led  to  the  use 
of  several  ACV  preparations.  It  is  essential  that  further  virulence  factors  are  sought  as 
acellular  vaccine  components  in  an  attempt  to  combat  such  problems. 
1.5  The  nature  of  the  bacterial  outer  membrane 
Most  of  the  important  virulence  factors  and  vaccine  components  of  B.  pertussis  are 
either  surface  located  or  exported  (Table  1).  It  has  been  demonstrated  that  the  envelope 
protein  profile  of  bordetellae  alters  markedly  following  exposure  to  different  growth 
conditions  and  this  is  related  to  the  alteration  of  virulence  state  (section  1.3.1)  (Wardlaw 
et  al.  1976;  Ezzell  et  al.  1981).  Therefore  the  production,  assembly  and  export  of 
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surface  components  of  B.  pertussis  are  important  subjects  for  study.  Many  features  of 
the  B.  pertussis  outer  membrane  are  common  to  Gram-negative  bacteria  in  general. 
The  distinction  between  outer-membrane  proteins  and  secreted  proteins  is  not  clear-cut. 
Secreted  proteins  such  as  pertussis  toxin  (PT),  FHA  and  Tcf  have  been  shown  to 
function  as  adhesins  and  must  therefore  be  associated  with  the  bacterial  outer  membrane 
in  some  way.  Other  surface-located proteins,  such  as  pertactin,  are  perceived  as  outer 
membrane  proteins,  although  proteolytic  processing  probably  allows  release  from  the 
C-terminal  anchor  domain. 
The  outer  membrane  of  Gram-negative  bacteria  provides  a  structural  and  functional 
interface  between  the  environment  and  the  interior  of  the  cell.  Initially  the  outer 
membrane  was  perceived  as  a  simple  and  static  lipopolysaccharide-containing  layer, 
although  intense  study  over  the  last  thirty  years  has  shown  the  outer  membrane  to  be  a 
dynamic  entity  that  is  intimately  involved  with  many  cellular  processes  (Hancock 
1991).  The  asymmetrical  character  of  the  outer  membrane,  with  the  outer  monolayer 
containing  heterogeneous  LPS  molecules,  provides  a  unique  barrier  and  a  site  of 
association  with  proteins  (Moran  1996).  The  outer  membrane  functions  as  an  exclusion 
barrier  with  selective  permeability  which  allows  the  control  of  substances  moving  into 
and  out  of  the  cell.  In  Gram-negative  bacteria,  the  major  porin  is  involved  in  such 
control  (Hannah  et  al.  1990).  This  porin  consists  of  complexes  of  a  monomer  of 
approximately  40  KDa  that  assembles  in  the  outer  membrane  and  allows  the  passage  of 
ionic  molecules  (Armstrong  and  Parker  1986;  Li,  et  al.  1991).  The  B.  pertussis  major 
porin  has  been  characterised  (Hannah  et  al.  1990).  The  porin  prevents  passage  of 
hydrophobic  and  large  hydrophilic  molecules  into  the  cell,  and  numerous  proteins, 
peptides,  carbohydrates  and  hydrophobic  drugs  are  actively  exported  by  other  means 
from  the  cytoplasm  into  the  extracellular  medium  (Dinh  et  al.  1994). 
The  presence  of  an  outer  membrane  is  therefore  very  useful,  but  such  benefits  come  at  a 
price.  Mechanisms  must  exist  for  the  translocation  of  excreted  proteins  and  the  outer 
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membrane  must  also  provide  anchor  facilities  for  external  structures  such  as  adhesins 
and  transport  channels  (Wandersman  1992;  Pugsley  1993). 
1.6  Protein  translocation  to  the  cell  exterior 
It  is  clear  that  no  one  mechanism  is  responsible  for  protein  translocation,  and  those  that 
have  been  suggested  have  been  reviewed  in  detail  elsewhere  (Pugsley  and  Schwartz 
1985;  Hirst  and  Welch  1988;  Lory  1992;  Nikaido  and  Saier  1992;  Wandersman  1992; 
Pugsley  1993;  Salmond  and  Reeves  1993).  The  transport  of  proteins  across  the  Gram- 
negative  envelope  has  been  categorised  into  five  pathways: 
1.6.1  Type  I  secretion 
This  group  of  sec-independent  proteins  mediate  their  own  transport  via  several 
accessory  proteins  which  form  a  transmembrane  channel  through  which  the  secreted 
molecule  moves.  This  pathway  is  totally  independent  of  the  sec-dependent  pathway 
and  no  typical  signal  sequences  can  be  identified  on  the  protein.  Type  I  machinery 
consists  of  an  ATP-binding  cassette  transporter,  an  outer  membrane  component  related 
to  the  To1C  protein  of  E.  coli,  and  a  dimeric  protein  which  spans  the  cytoplasmic  and 
outer  membranes  of  the  cell.  The  prototype  member  of  this  family  is  the  E.  coli 
haemolysin  (Femlee  et  al.  1985).  B.  pertussis  adenylate  cyclase  toxin  and  FHA  are  also 
transported  via  this  secretion  mechanism  (Coote  1992).  The  secretion  of  FHA  is 
described  in  more  detail  in  section  1.8.7.  The  C-terminal  domain  of  proteins  which  use 
this  pathway  encodes  the  information  neccessary  for  secretion. 
1.6.2  Type  II  secretion 
This  is  thought  to  be  the  major  export  pathway  in  most  Gram-negative  organisms  and  is 
known  as  the  "general  secretory  pathway"  or  "sec-dependent  pathway"  as  it  is 
10 Blackburn  P.  E.  Introduction 
dependent  on  several  sec  proteins  (Sec  A,  B,  D,  E,  F  and  Y).  The  amino  terminal  region 
of  type  II-secreted  protein  precursors  are  homologous  and  act  as  a  signal  sequence 
which  plays  a  role  in  delivery  of  these  proteins  to  the  sec  machinery  (Perlman  and 
Halvorson  1983).  Following  cleavage  of  the  signal  sequence,  proteins  then  rely  on 
specialised  secretion  machinery,  comprising  12  or  more  proteins,  and  probably  includes 
a  gated  channel.  This  pathway  allows  a  variety  of  outcomes,  known  as  terminal 
branches,  for  the  secreted  proteins  ie.  they  may  be  excreted,  periplasmic  or  envelope 
associated  (Figure  1). 
1.6.3  Type  III  secretion 
This  highly  conserved  export  system  also  plays  a  major  role  in  the  export  of  virulence 
factors  in  a  number  of  pathogens  (Van  Gijsegem  et  al.  1993;  Hueck  1998).  This 
secretion  system  is  contact  mediated  and  delivers  bacterial  virulence  factors  directly  into 
the  host  cell  cytoplasm  which  can  affect  host  cell  signalling  (Kerr  1999).  A  large 
number  of  genes  appear  to  be  responsible  for  this  export  mechanism  (approximately  20) 
and  there  is  thought  to  be  some  overlap  with  type  II  export  (d'Enfert  1993).  This 
mechanism  is,  however,  sec-independent.  The  prototype  is  the  Yops  (Yersinia  outer 
membrane  proteins)  secretion  pathway  in  Yersinia  species  (Michiels  et  al.  1990), 
although  more  recently  homologues  have  been  identifed  in  B.  bronchiseptica  (Yuk  et  al. 
1999)  and  B.  pertussis  (Kerr  et  al.  1999)  that  are  under  the  control  of  the  bvgAS-locus 
and  may modulate  immune  responses  during  infection  by  inhibiting  NF-KB  activation 
by  TNFoc  (Yuk  et  al.  2000). 
1.6.4  Type  IV  secretion 
Recently,  type  IV  secretion  has  been  used  to  describe  the  autotransporter  secretion 
system  (Finlay  and  Falkow  1997;  Henderson  et  al.  1998;  Holland  1998).  The 
prototype  member  is  the  IgA  protease  of  Neisseria  gonorrhoeae.  Type  IV  secretion  is 
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described  in  detail  in  section  1.7  Confusingly,  type  N  secretion  has  also  been  assigned 
to  the  totally  unrelated  secretion  of  the  type  utilised  to  mobilise  DNA,  or  the  pertussis 
toxin  secretion  pathway  (section  1.8.1)  (Burns  1999).  This  is,  however,  more  often 
referred  to  as  type  V  secretion. 
1.6.5  Type  V  secretion 
This  mechanism  involves  export  of  an  assembled  protein  complex  through  the  outer 
membrane,  in  contrast  to  the  type  I-type  IV  secretion  pathways  which  are  presumed  to 
transport  unfolded  proteins  (Weiss  1994).  The  pertussis  toxin  operon  of  B.  pertussis  is 
perhaps  the  best  described  example  of  type  V  secretion  and  is  described  in  more  detail 
in  section  1.8.1. 
Although  several  mechanisms  have  been  suggested  for  protein  translocation  across  the 
Gram-negative  cytoplasmic  membrane,  there  is  a  lack  of  knowledge  regarding  the 
transport  of  outer-membrane  proteins  and  secreted  proteins  through  the  outer 
membrane.  There  is  very  little  evidence  regarding  the  kinetics  of  the  events  that 
accompany  outer  membrane  translocation  and  protein  folding  (unlike  the  inner 
membrane  there  is  no  ATP  and  no  electrochemical  gradient)  (Nikaido  and  Saier  1992; 
Weiss  1994).  Consequently,  there  is  interest  in  the  export,  location  and  integration  of 
proteins  into  the  outer  membrane.  It  has  been  suggested  that  targeting  to  the  outer 
membrane  and  correct  assembly  may  be  distinct  events.  The  precursor  protein  is  likely 
to  dictate  such  events,  either  at  the  amino  or  carboxy  terminus  or  due  to  protein 
conformation. 
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Figure  1:  The  main  terminal  branches  in  the  general  secretory  pathway  (GSP)  of 
Gram-negative  bacteria.  Adapted  from  Pugsley  (1993). 
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1.7  Autotransporter  systems  in  Gram-negative  bacteria 
A  newly  described  family  of  outer  membrane  proteins  is  emerging,  with  members 
present  not  only  in  Bordetella  but  also  in  other  bacterial  genera  (Table  2).  These 
autotransporters,  or  processed  outer-membrane  proteins  (POMPs),  have  homology  in 
their  carboxy-terminus  domains  which  are  approximately  30  KDa.  This  conserved 
domain  may  be  processed  from  the  precursor  protein  and  remains  in  the  outer 
membrane.  The  amino  terminal  portions  of  these  proteins  have  a  wide  variety  of 
functions,  ranging  from  protease  activity  to  adhesion.  The  amino  terminus  of  these 
proteins  may  be  proteolytically  processed  and  released  from  the  cell  surface,  may  not 
be  processed,  or  may  be  processed  yet  remain  cell-associated.  Prior  to  this  study,  three 
B.  pertussis  proteins  which  can  now  be  included  in  the  autotransporter  family  had  been 
described  -  pertactin  (Prn),  tracheal  colonisation  factor  (Tcf)  and  Bordetella  resistance  to 
killing  A  (BrkA). 
This  family  of  processed  (autotransporter)  outer  membrane  proteins  are  linked  by  their 
abilitiy  to  traverse  the  outer  membrane,  apparently  without  the  use  of  separate 
chaperone  proteins.  The  putative  amphipathic  ß-barrel  structure  formed  by  the  carboxy 
terminal  domain  is  grossly  consistent  with  the  structure  of  bacterial  porins  i.  e.  an  even 
number  of  antiparallel  ß-sheets,  with  the  first  and  last  transmembrane  segments  in 
opposite  directions  to  close  the  barrel  (Weiss  et  al.  1991;  Cowan  et  al.  1992).  Models 
have  been  suggested  for  the  structure  and  function  of  the  C-terminal  domains,  although 
little  has  been  justified  experimentally.  The  conserved  nature  and  abundance  of  these 
domains  implies  functional  importance.  The  portion  displaying  the  highest  level  of 
conservation  is  the  last  nine-twelve  amino  acids  at  the  C-terminus  (C-terminal 
consensus,  Table  2)  which  consist  of  alternating  hydrophobic  amino  acids  and 
terminates  in  a  hydrophobic,  aromatic  amino  acid.  The  presence  of  this  residue  such  as 
phenylalanine  (or  tryptophan)  at  the  carboxy  terminus  appears  to  be  essential  for  the 
correct  assembly  of  these,  and  other,  bacterial  outer-membrane  proteins  (Stuyve  et  al. 
1991).  The  hydrophobicity  of  this  residue  probably  ensures  correct  orientation  of  the 
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outer-membrane  protein,  the  reason  for  the  aromatic  character  of  the  amino  acid  is  less 
obvious  (Stuyve,  Moons  et  al.  1991).  The  region  of  greatest  similarity  between  SepA, 
Tsh,  Hsr,  BrkA  and  Pm  is  at  the  N-terminal  side  of  the  region  supposed  to  form  ß- 
sheets  i.  e.  immediately  adjacent  to  the  carboxy  terminal  domain  (Benjelloun-Toulmi, 
Sansonetti  et  al.  1995).  It  is  suggested  that  this  region  is  essential  for  correct 
presentation  of  the  passenger  domain  to  the  carboxy  terminal  pore,  and  in  the  case  of 
IgA  protease  of  Neisseria  gonorrhoeae,  the  term  linker  region  has  been  used  (see  Figure 
2).  The  N.  gonorrhoeae  IgA  protease  is  the  prototype  autotransporter  and  has 
extensive  similarities  with  several  recently  identified  proteins  (Table  2)  (Klauser  et  al. 
1993;  Benjelloun-Toulmi  et  al.  1995).  Figure  2  outlines  the  secretion  pathway 
proposed  for  the  export  of  autotransporter  proteins. 
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1.7.1  The  IgA  protease  of  N.  gonorrhoeae 
This  exopolyprotein  (secreted  protein)  exhibits  much  of  the  gross  structural  homology 
described  for  Prn,  BrkA  and  Tcf  (Jose  et  al.  1995).  The  role  of  the  carboxy  terminal 
domain  in  targeting  of  the  protein  to  the  outer  membrane  and  secretion  to  the  cell 
exterior  has  been  studied  (Klauser  et  al.  1992;  Klauser  et  al.  1993).  The  term  helper 
domain  was  suggested  initially  to  describe  the  function  of  this  region  (Pohlner  et  al. 
1987),  although  the  term  Igaß  is  now  used  (Klauser  et  al.  1992). 
A  three  step  mechanism  for  secretion  of  IgA  protease  has  been  suggested  and  is 
depicted  in  Figure  2.  It  is  likely  that  other  members  of  the  autotransporter  protein 
family  share  some  of  the  features  of  this  model.  The  first  stage  involves  the  sec- 
dependent  targeting  of  the  pre-pro-protein  to  the  cytoplasmic  membrane  and  this 
process  is  therefore  dependent  on  a  signal  sequence  motif  at  the  amino  terminus 
(Perlman  and  Halvorson  1983).  During  the  second  process  it  is  assumed  that  the 
carboxy  terminal  domain  forms  a  ß-barrel  in  the  outer  membrane.  The  tertiary  structure 
of  the  protein  is  likely  (based  on  computer  predictions)  to  consist  of  fourteen 
amphipathic,  antiparallel  ß-sheets,  forming  a  channel  with  a  closed  hydrophilic  interior 
and  a  hydrophobic  exterior  (Klauser  et  al.  1992).  During  the  final  stage  it  is  suggested 
that  the  N-terminal  passenger  domain  is  translocated  to  the  cell  exterior  via  the  pore 
formed  (Pohlner  et  al.  1987). 
17 Blackburn  P.  E. 
Exterior 
)j 
. 
i'ý  9-1 
--\----------.  ' 
Figure  2:  A  model  proposed  for  translocation  of  the  IgA  protease  of  N.  gonorrhoeae.  The 
other  proteins  outlined  in  Table  2  may  also  be  processed  in  this  manner. 
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Following  translocation  across  the  outer  membrane  to  the  cell  exterior  the  mature 
protein  may  be  released  into  the  extracellular  environment.  Benz  et  al.  (1992) 
speculated  that  this  cleavage  event  (in  AIDA-I)  may  be  a  essential  part  of  the 
translocation  across  the  outer  membrane.  Once  the  IgA  protease  reaches  the  exterior  of 
the  cell,  autoproteolysis  occurs  and  the  mature  protease  is  released.  When  the 
autoproteolytic  activity  of  the  IgAse  is  blocked  in  recombinant  E.  coli  strains,  cleavage 
occurs  in  trans  as  a  result  of  the  surface  located  protease  OmpT  (Klauser  et  al.  1992). 
Evidence  to  support  this  role  of  OmpT  is  that  processing  did  not  occur  in  the  E.  coli 
OmpT  mutant  strains  used. 
1.8  Virulence  determinants  of  Bordetella  species 
Although  much  information  regarding  the  putative  roles  of  these  virulence  factors  has 
been  derived  from  animal  models  and  interaction  with  tissue  culture  cells,  their  exact  role 
in  the  pathogenesis  of  pertussis  has  not  been  defined.  In  addition  to  studies  using  wild 
type  B.  pertussis  and  B.  pertussis  mutants,  recombinant  E.  coli  and  Salmonella  spp. 
strains  have  been  used  for  expression  of  several  of  these  virulence  factors  and  has 
alleviated  the  need  for  growing  fastidious  B.  pertussis  in  the  laboratory  (Shareck  and 
Cameron  1984;  Fairweather  et  al.  1990;  Makoff  et  al.  1990;  Strugnell  et  al.  1992; 
Charles  et  al.  1994;  Anderson  et  al.  1996).  Such  models  have  further  aided 
characterisation  of  the  role  of  individual  virulence  factors  in  B.  pertussis.  Table  1 
outlines  the  virulence  factors  present  in  bordetellae.  Not  all  virulence  factors  are  present 
in  each  species.  Most  virulence  factors  have  been  best  characterised  in  B.  pertussis.  A 
review  on  virulence  factors  has  been  published  by  Parton  (1996). 
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1.8.1  Pertussis  toxin 
The  most  extensively  studied  B.  pertussis  virulence  factor  is  pertussis  toxin  (PT),  which 
has  a  range  of  biological  activities,  and  is  implicated  as  having  a  fundamental  role  in  the 
pathogenesis  of  pertussis. 
PT  is  composed  of  five  subunits  that  are  the  products  of  five  genes,  which  form  a  105 
KDa  complex  with  ADP  ribosylating  activity.  The  A  (enzymic)  subunit  is  associated 
with  five  B  subunits  that  are  responsible  for  binding  of  the  toxin  to  the  target  eukaryotic 
cell  and  insertion  of  the  A  subunit  into  the  cytoplasm.  This  interaction  also  enables 
B.  pertussis  to  bind  to  eukaryotic  cells  including  human  respiratory  ciliated  cells  and 
macrophages  (Sandros  and  Tuomanen  1993).  The  nature  of  the  lectin-like  interaction 
between  the  B-subunits  and  the  eukaryotic  cell  mimics  the  relationship  between  the 
leukocyte  surface  and  the  capillary  wall  that  occurs  during  early  diapedesis  (Sandros  and 
Tuomanen  1993).  The  A  subunit  acts  on  the  G-proteins  of  target  eukaryotic  cells  and 
alters  the  response  of  these  cells  to  external  stimuli.  This  results  in  a  variety  of 
consequences  including  inhibition  of  chemotactic  detection  by  leukocytes, 
lymphocytosis  and  increased  vascular  permeability  (Craig  et  al.  1988).  The  exact  role  of 
PT  in  the  pathogenesis  of  whooping  cough  remains  obscure,  although  its  absence  in 
B.  parapertussis  implies  that  it  may  have  only  a  minor  role  in  causing  the  typical 
whooping  cough  symptoms  (Parton  1996). 
Secretion  of  PT  is  dependent  on  an  N-terminal  signal  sequence  on  each  subunit  that  is 
removed  during  protein  maturation  (Ricci  et  al.  1996).  The  B.  pertussis  equivalent  of 
the  sec-mediated  pathway  is  probably  responsible  for  transfer  of  these  subunits  to  the 
periplasmic  space  (Weiss  1994).  Translocation  across  the  outer  membrane  is  mediated 
by  an  operon  of  seven  genes  (ptlB  to  pt1H-pertussis  toxin  liberation)  that  have  extensive 
homology  with  the  outer  membrane  complex  responsible  for  the  transfer  of  DNA  from 
the  plant  pathogen  Agrobacterium  tumefaciens  (Weiss  1994;  Ricci  et  al.  1996).  In  the 
latter  system,  the  DNA  is  secreted  in  the  form  of  a  complex  of  protein  that  coats  the 
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DNA.  PT  is  also  secreted  as  an  assembled  protein  complex  and  novel  machinery  is 
needed  (Weiss  1994).  This  export  pathway  has  been  termed  type  V  secretion  (section 
1.6.5).  Most  proteins  are  presented  to  the  translocation  apparatus  in  the  form  of  a  long 
slender  structure,  which  is  secreted  in  an  unfolded  state  and  folds  following  secretion. 
Pertussis  toxin  is  an  exception.  The  export  of  a  functional  toxin  complex  prevents 
energy  from  being  wasted  on  producing  subunits  that  do  not  become  part  of  a  functional 
toxin.  Secretion  of  protein  complexes  has  not  yet  been  identified  in  Gram-positive 
bacteria,  probably  because  the  outer  membrane  is  essential  in  blocking  the  transport  of 
unassembled  subunits  (Weiss  1994). 
1.8.2  Adenylate  cyclase  toxin 
Adenylate  cyclase  toxin  (ACT)  is  a  200  KDa  toxin  which  has  homology  to  the  RTX 
(repeats  in  toxin)  family  of  proteins.  This  bifunctional  protein  is  capable  of  haemolysis 
as  well  as  adenylate  cyclase  activity  (Wolff  et  al.  1980).  Most  of  the  toxin  remains  on 
the  cell  surface  of  the  bacterium  and  acts  as  a  contact  toxin.  Most  toxins  in  the  RTX 
family  are  pore  forming,  cytolytic  toxins  and  the  C-terminal  portion  of  ACT  allows  the 
N-terminus  to  penetrate  a  wide  range  of  eukaryotic  cells  and  cause  unregulated 
synthesis  of  cyclic  AMP  (Hewlett  and  Gordon,  1988).  Immune  effector  cells  such  as 
monocytes,  macrophages  and  natural  killer  cells  are  thought  to  be  the  primary  targets 
and  this  toxin.  The  range  of  effects  of  the  toxin  include  apoptosis  and  inhibition  of 
phagocytosis,  chemotaxis  and  microbial  killing.  Adenylate  cyclase  toxin  does  appear  to 
be  protective  in  a  mouse  model  and  may  constitute  a  future  acellular  vaccine  component, 
although  fears  that  cross  reaction  to  a  human  brain  adenylate  cyclase  has  raised  doubts 
about  its  suitability  (Guiso  et  al.  1989;  Parton,  1998)  An  antigenically  distinct  yet 
functionally  similar  adenylate  cyclase  toxin  is  also  secreted  by  B.  parapertussis  and  B. 
bronchiseptica  (Hewlett  and  Gordon,  1988). 
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1.8.3  Tracheal  cytotoxin 
Tracheal  cytotoxin  (TCT)  is  produced  by  B.  pertussis,  B.  bronchiseptica, 
B.  parapertussis  and  B.  avium  and  belongs  to  the  muramyl  di-peptide  toxin  family 
(Goldman,  1988).  TCT  is  an  unusually  small  toxin  (921  Da)  which  is  a  disaccharide- 
tetrapeptide  derived  from  peptidoglycan  which  is  released  from  the  cell  envelope.  This 
toxin  causes  ciliostasis  and  cell  extrusion  in  hamster  tracheal  organ  cultures  and 
inhibition  of  DNA  synthesis  in  hamster  trachea  epithelial  cultures  (Goldman  and 
Herwaldt,  1985).  These  effects  may  be  due  to  stimulation  of  IL-1  production  from 
tracheal  cells  which  in  turn  stimulates  nitric  oxide  synthesis  (Heiss  et  al.  1994).  TCT  is 
also  toxic  for  human  neutrophils  and  may  therefore  contribute  to  persistence  of  the 
bacteria  within  the  airways  (Cundell  et  al.  1994). 
1.8.4  Heat-labile  toxin 
Heat-labile  toxin  (HLT),  also  known  as  dermonecrotic  toxin,  is  produced  by 
B.  pertussis,  B.  bronchiseptica,  B.  parapertussis  and  B.  avium  and  was  the  first 
Bordetella  toxin  to  be  described  (lida  and  Okonogi,  1971;  Walker  and  Weiss,  1994). 
HLT  remains  within  the  bacterial  cell  cytoplasm  as  a  single  polypeptide  of 
approximately  160  KDa.  Studies  using  B.  bronchiseptica  suggest  that  HLT  deaminates 
host  cell  Rho  which  causes  cytoskeletal  effects  (Horiguchi  et  al.  1997).  B.  pertussis 
mutants  deficient  in  HLT  production  were  unaltered  in  their  ability  to  cause  lethal 
infection  in  mice  (Weiss  and  Goodwin,  1989).  However,  the  toxin  is  extremely  potent 
in  a  number  of  bioassays  and  exhibits  potent  vasoconstrictive  activity  on  smooth 
muscle.  Such  a  local  inflammatory  reaction  on  the  highly  vascularised  tissues  in  the 
respiratory  tract  could  account  for  some  of  the  pathology  of  pertussis.  However,  the 
exact  role  of  this  toxin  in  disease  has  not  yet  been  defined. 
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1.8.5  Endotoxin 
Endotoxin,  also  known  as  lipopolysaccharide  (LPS),  is  present  in  many  bacterial 
pathogens  and  is  a  major  component  of  the  Gram-negative  outer  membrane.  In 
B.  pertussis,  the  0  side  chain  is  short  and  the  LPS  is  referred  to  as  lipooligosaccharide 
(LOS).  At  present  there  is  no  clear  role  for  LOS  in  B.  pertussis  although  it  has  the  usual 
properties  of  endotoxins  such  as  pyrogenicity,  adjuvanticity  and  general  toxicity.  In 
addition,  the  B.  pertussis  LOS  has  some  unusual  properties  in  LPS  resistant  mice  such 
as  lymphocyte  mitogenicity  and  polyclonal  B-cell  activation  (Watanabe  et  al.  1990). 
LOS  may  be  responsible  for  the  mild  fever  in  early  pertussis.  Much  of  the 
reactogenicity  of  the  whole-cell  vaccine  preparations  may  be  due  to  endotoxin. 
1.8.6  Fimbriae 
Fimbriae  (pili;  agglutinogens)  are  produced  by  B.  pertussis,  B.  bronchiseptica, 
B.  parapertussis  and  B.  avium.  Four  fimbrial  genes  have  been  identified  (fim1,2,3  and 
X).  Fiml  is  present  on  all  B.  pertussis  strains  whereas  Fim2  and  Fim3  may  be  absent  or 
expressed  in  various  combinations  on  virulent  cells  (Livey  et  al.  1987;  Robinson  et  al. 
1990;  Savelkoul  et  al.  1996).  FimX  is  expressed  only  in  B.  bronchiseptica.  Unlike  the 
fimbriae  of  other  bacteria  the  role  of  fimbriae  in  Bordetella  infection  has  not  been  defined 
and,  in  B.  pertussis,  do  not  enable  the  bacteria  to  bind  to  human  respiratory  ciliated 
cells.  A  fimbrial  mutant  of  B.  bronchiseptica  appeared  to  be  altered  in  its  ability  to  cause 
respiratory  tract  infections  in  rats,  although  adhesion  to  cell  lines  (including  human 
laryngeal  Hep-2  cells)  was  not  affected  (Mattoo  et  al.  2000).  It  appears  that  the  binding 
of  fimbriae  to  non-ciliated  cells  including  monocytes  may  promote  phagocytosis. 
Fimbriae  on  B.  pertussis  interact  with  very  late  antigen-5  (VLA-5)  on  monocytes  which 
activates  complement  receptor  3  (CR3)  on  monocytes,  which  is  a  receptor  for  FHA 
(section  1.8.7).  Purified  fimbriae  appear  to  confer  serospecific  protection  against 
B.  pertussis  infection  in  mice  (Willems  et  al.  1998).  This  is  consistent  with  the  fording 
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that,  to  some  extent,  serospecific  protection  occurs  when  children  are  immunised  with 
whole-cell  vaccine  preparations  (Mooi  1998). 
1.8.7  Filamentous  haemagglutinin 
The  major  secreted  product  of  B.  pertussis  is  filamentous  haemagglutinin  (FHA),  which 
undergoes  postranslational  processing  of  the  amino  and  carboxy  terminal  domains  to 
yield  a  220  KDa  secreted  protein  (Brown  and  Parker  1987;  Stibitz  et  al.  1988; 
Domenighini  et  al.  1990;  Locht  et  al.  1993;  Makhov  et  al.  1994).  Recently,  it  has  been 
demonstrated  that  FHA  in  B.  bronchiseptica  is  both  necessary  and  sufficient  for 
mediating  adherence  to  a  rat  lung  epithelial  cell  line,  and  necessary  but  not  sufficient  for 
tracheal  colonisation  in  a  healthy  anaesthetised  rat  (Cotter  et  al.  1998).  Cotter  et  al. 
(1998)  suggested  that  the  role  of  FHA  was  to  overcome  the  clearance  mechanism  of  the 
mucociliary  escalator.  The  mature  protein  acts  as  an  adhesin  and  forms  a  rigid  rod  based 
hairpin  structure  (Makhov  et  al.  1994).  FHA  contains  the  triplet  Arg-Gly-Asp  (RGD) 
which  appears  to  be  involved  in  binding  of  FHA  to  the  leukocyte  integrin  CR3  (Relman, 
Wright  et  al.  1990;  Sandros  and  Tuomanen  1993;  Ishibashi  et  al.  1994).  This  binding 
may  promote  internalisation  of  B.  pertussis  into  macrophages  and  allow  persistence,  as 
this  uptake  mechanism  does  not  trigger  an  oxidative  burst.  FHA,  fimbriae  and  PT 
appear  to  function  in  adhesion,  as  PT  and  fimbriae  are  thought  to  cause  upregulation  of 
the  CR3  integrin  on  the  leukocyte  surface  (Locht  and  Cabezon  1990;  Sandros  and 
Tuomanen  1993;  Hazenbos  et  al.  1995). 
The  secondary  infections  often  associated  with  pertussis  may  be  attributable  to  the 
adhesive  aspects  of  PT  and  FHA.  When  secreted  from  B.  pertussis,  other  bacteria, 
notably  Haemophilus  influenzae,  may  ultilise  them  to  adhere  to  human  ciliated  cells. 
This  has  been  termed  "piracy  of  adhesins"  (Tuomanen  1988). 
Carbohydrate  recognition  moeities  have  been  identified  within  FHA  that  are  crucial  in 
allowing  adhesion  to  both  ciliated  epithelial  cells  and  cultured  Chinese  hamster  ovary 
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cells  (Domenighini  et  al.  1990).  In  addition,  a  heparin-binding  domain  is  thought  to  bind 
glycosaminoglycans  which  facilitates  adherence  to  non-ciliated  cells  (Sandros  and 
Tuomanen  1993). 
Targeting  of  the  FHA  precursor,  FhaB,  to  the  cytoplasmic  membrane  is  probably 
performed  in  a  sec-dependent  manner  and  a  short  (22  residue)  signal  sequence  is  present 
(Jacob-Dubuisson  et  al.  1996).  Its  translocation  across  the  outer  membrane  depends  on 
an  accessory  protein  in  the  outer  membrane,  designated  FhaC  (Stibitz  et  al.  1988; 
Domenighini,  et  al.  1990).  During  the  maturation  of  FHA,  the  C-terminal  domain  of 
FhaB  is  cleaved. 
The  function  of  this  cleaved  carboxy  terminus  (150  KDa)  in  this  instance  is  probably  to 
prevent  the  formation  of  a  hairpin  structure  within  the  periplasmic  space,  and  possibly 
to  aid  presentation  of  the  N-terminal  domain  to  FhaC  (Renauld-Mongenie  et  al.  1996). 
The  C-terminal  domain  may  also  prevent  premature  interaction  between  the  N-terminal 
region  and  FhaC  during  export  of  these  proteins  towards  the  outer  membrane  (Renauld- 
Mongenie  et  al.  1996).  The  C-terminal  domain  of  FHA  is  probably  therefore  an 
intramolecular  chaperone  of  FhaB  (Jacob-Dubuisson  et  al.  1996).  The  fate  of  the 
carboxy  terminal  domain  is  unlike  that  of  Prn,  BrkA  and  Tcf  (see  below  sections)  and, 
following  cleavage,  is  probably  degraded  in  the  periplasm.  It  has  been  predicted  that  the 
FhaB  C-terminal  domain  anchors  FHA  in  the  cell  envelope,  perhaps  by  spanning  the 
periplasmic  space  and  in  this  way  linking  the  inner  and  outer  membranes  (Domenighini 
et  al.  1990).  Proline  rich  repeats  have  been  identified  in  the  carboxy  terminal  domain  of 
FhaB  (Domenighini  et  al.  1990).  Such  a  proline  rich  region  exists  in  the  mature  Prn 
protein,  close  to  the  putative  C-terminal  processing  site  (Charles  et  al.  1989).  These 
regions  are  thought  to  be  characteristic  of  proteins  that  act  as  anchor  regions  and  span 
the  periplasm  and  therefore  this  may  be  an  additional  function  of  the  FhaB  C-terminus. 
The  proteases  responsible  for  processing  FHA  are  not  specific  to  bordetellae  (the  same 
processing  can  occur  in  E.  coke  and  cleavage  is  likely  to  be  the  result  of  ubiquitous 
25 Blackburn  P.  E.  Introduction 
envelope  proteases  (Lambert-Buisine  et  al.  198;  Jacob-Dubuisson  et  al.  1996).  SDS- 
PAGE  of  purified  FHA  results  in  multiple  bands,  all  of  which  react  with  anti-FHA 
mAbs  which  suggests  multiple  cleavage  sites  (Irons  et  al.  1983;  Jacob-Dubuisson  et  al. 
1996).  Autoproteolytic  activity  of  FHA  has  not  been  eliminated  and  remains  a 
possibility  (Jacob-Dubuisson  et  al.  1996). 
1.9  Autotransporter  proteins  of  Bordetella  species 
On  the  basis  of  amino  acid  similarity  three  proteins,  Prn,  BrkA  and  Tcf  have  been 
classified  as  autotransporter  proteins  (Figure  3).  The  more  recently  described  Vag  8 
(section  1.13)  can  also  be  included  in  the  autotransporter  family.  The  receptor  motifs 
encoded  by  these  bordetellae  adhesins  are  not  well  characterised.  The  tripeptide  Arg- 
Gly-Asp  (RGD)  (Ruoslachti  and  Pierschbacher  1986;  Hynes  1987)  is  present  on  FHA, 
Prn,  Tcf  and  BrkA  and  may  be  important  in  promoting  the  adhesion  of  bordetellae  to 
mammalian  cells  (Relman  et  al.  1990;  Leininger  et  al.  1992).  This  motif  is  the  cell 
attatchment  site  of  mammalian  adhesion  proteins  such  as  fibronectin,  vitronectin  and 
fibrinogen.  BrkA  and  Tcf  also  contain  Ser-Gly-X-Gly  (SGXG)  glycosaminoglycan 
binding  motifs.  Recently,  the  importance  of  proteoglycans  (glycosaminoglycans 
attatched  to  a  protein  core),  such  as  heparin,  as  co-receptors  in  microbial  adherence  and 
invasion  have  been  reviewed  (Rostrand  and  Esko  1997).  It  has  also  been  suggested  that 
binding  to  proteoglycans  may  result  in  host  cell  responses  that  lead  to  internalisation  of 
adherent  microbes  (Falkow  1991). 
Previously,  the  cell  envelope  of  virulent  strains  of  B.  pertussis  was  reported  to  contain 
at  least  two  heat  modifiable  outer  membrane  proteins  (OMPs)  of  approximately  30 
KDa  (Parton  and  Wardlaw  1975;  Wardlaw  et  al.  1976;  Ezzell  et  al.  1981;  Armstrong  and 
Parker  1986).  These  proteins,  designated  30  KDa  and  32  KDa,  have  since  been 
identified  as  the  carboxy  terminal  domains  of  BrkA  and  Tcf  respectively  (Fernandez  and 
Weiss  1994;  Finn  and  Stevens  1995).  The  sites  of  proteolytic  processing  of  the 
Bordetella  autotransporter  proteins  has  been  established  by  N-terminal  sequencing 
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(Below)  (Hamstra  et  al.  1995;  Hamstra  and  Poolman  Unpublished).  It  is  also  known 
that  these  proteins  are  heat  modifiable  and  correspond  to  the  major  bands  designated  B 
and  C  by  Parton  and  Wardlaw  (1975)  (Parton,  personal  communication).  The 
processing  sites  of  Prn,  Tcf  and  BrkA  are  highlighted  by  //  below.  The  main  features  of 
these  proteins  can  be  seen  in  Figure  3. 
Prn:  YAESN  //  ALSKRLGELRLNPDAGGAW 
Tcf:  QAEMN  //  ALSKRMGELRLTPVAGGVWGRAF 
BrkA:  LAESN  //  ALDKRLGELRLNADAGG 
27 Blackburn  P.  E.  Introduction 
llý-f  -71  Prn 
RGD  RGD 
01 
BrkA 
fttt 
SGXG  RGD  SGXG  RGD 
Tcf 
SGXG  SGXG  SGXG  RGD 
Vag8 
SGXG  RGD  SGXG 
0 
0 
Signal  sequence 
Proteolytic  processing  site 
Putative  Beta-  barrel 
Outer  membrane  localisation  signal 
RGD  (Arg-Gly-Asp)  Integrin  binding/Cell  adhesion  motif 
SGXG  Glycosaminoglycan  binding  motif 
Figure  3:  The  gross  structural  similarities  between  Pm,  BrkA,  Tcf  and  Vag8. 
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1.10  Pertactin 
1.10.1  Structure  and  function 
Introduction 
Pertactin  was  originally  isolated  as  a  68  KDa  protein  from  the  outer  membrane  of 
B.  bronchiseptica  and  was  associated  with  adenlylate  cyclase  activity  (Novotny  et  al. 
1985;  Montaraz  et  al.  1985).  Pertactin  is  not  responsible  for  adenylate  cyclase  activity, 
however,  and  was  described  as  a  virulence-associated,  nonfimbrial  agglutinogen  of 
B.  pertussis  by  Brennan  (1988).  The  prn  gene  from  B.  pertussis  was  later  cloned  and 
characterised  by  Charles  et  al  (1989).  P.  69  is  referred  to  as  pertactin  to  reflect  its 
adhesive  nature  (per-pertussis,  tactin  [tactus]-to  touch),  and  a  93  KDa  precursor  is 
transcribed  from  the  prn  gene  (Capiau  et  al.  1990;  Leininger  et  al.  1991).  In  fact,  P.  69  is 
actually  a  protein  of  60-61  KDa  and  its  misleading  migration  on  SDS-PAGE  is  probably 
a  result  of  a  high  proline  content  (Makoff  et  al.  1990;  Capiau  et  al.  1990).  The  crystal 
structure  of  P.  69  has  been  determined,  and  the  ß-helical  structure  is  the  longest  reported 
to  date  (Emsley  et  al.  1996). 
Pertactin  (P.  69),  in  B.  pertussis,  is  the  representative  member  of  the  family  of 
immunologically  cross-reactive,  closely-related  proteins  of  reported  molecular  mass  68- 
70  KDa  that  are  also  present  in  B.  parapertussis  and  B.  bronchiseptica  (Kobisch  and 
Novotny,  1990;  Charles  et  al.  1990;  Li  et  al.  1991).  The  C-terminal  domain  is  the  most 
conserved  region  of  the  Prn  precursor  proteins.  The  BvgAS  regulation  system  controls 
expression  of  the  pertactin  gene  family.  The  relatively  higher  GC  content  of  the  P.  93 
gene  (71.3%)  could  suggest  that  this  gene  evolved  in  a  different  way  to  other  members 
of  the  bvg-controlled  family  of  genes  (Charles  et  al.  1994). 
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1.10.2  Proteolytic  processing  of  pertactin 
The  prn  gene  encodes  a  polypeptide  with  an  predicted  molecular  weight  of  93478  Da 
(P.  93).  The  post  translational  processing  site  is  suggested  to  be  amino  acid  597-598 
(lys-arg)  in  the  pertactin  proprecursor.  The  cleavage  site  of  the  native  protein  was 
determined  by  Capiau  (1990)  who  confirmed  earlier  work  on  recombinant  P.  93  (Makoff 
et  al.  1990).  In  addition  there  is  a  characteristic  amino  terminal  signal  peptide  of  34 
amino  acids  that  is  removed  post  translationally  (Charles  et  al.  1989).  Such  a  sequence 
is  typical  for  proteins  that  are  targetted  through  a  membrane  either  to  the  periplasm  or 
to  the  outside  of  the  cell  (Perlman  and  Halvorson  1983;  Charles  et  al.  1989). 
1.10.3  Adhesive  properties  of  pertactin 
Pertactin  is  exposed  on  the  surface  of  B.  pertussis  and  is  a  non-fimbrial  antigen 
(Brennan  et  al.  1988;  Charles  et  al.  1989).  Physically  longer  adhesins  in  B.  pertussis 
such  as  FHA  or  fimbriae  that  are  capable  of  overcoming  an  electrostatic  barrier  probably 
bring  bordetellae  into  close  enough  contact  with  the  host  cell  to  allow  P.  69  to  act 
(Everest  et  al.  1996). 
Adhesion  of  B.  pertussis  to  Hep2  (human  epithelium-like)  cells  is  probably  mediated,  at 
least  in  part  by  pertactin,  although  such  studies  are  complicated  by  the  presence  of 
other  adhesins,  notably  FHA,  that  compensate  in  prn-  mutant  strains  (Ewanowich  et  al. 
1990;  Leininger  et  al.  1992).  However,  Roberts  et  al.  (1991)  were  able  to  show  in  a 
Hep-2  adhesion  assay  that  prn-  mutants  are  cabable  of  binding  and  invading  cells  to  the 
same  extent  as  wild-type  Bordetella  strains.  When  Chinese  hamster  ovary  (CHO)  and 
HeLa  (Human  epithelial)  cell  types  were  used  for  adhesion  studies,  P.  69  mutants  were 
seen  to  adhere  30-40%  less  and  entry  of  Staphylococcus  aureus  into  HeLa  cells 
increased  following  coating  with  P.  69  (Leininger  et  al.  1991). 
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The  RGD  integrin  binding  motif  has  been  identified  in  mature  P.  69  and  also  in  the 
carboxy-terminal  domain  (Figure  3)  (Makoff  et  al.  1990).  The  role  of  the  P.  69  RGD  is 
at  present  unclear.  Althought  Leininger  et  al.  (1991;  1992)  found  that  synthetic 
peptides  containing  RGD  could  partially  inhibit  bacterial  adhesion  to  eukaryotic  cells, 
an  RGD.  -URGE  P.  69  mutant  developed  by  Everest  et  al.  (1996)  did  not  show  altered 
adhesive  properties.  Also,  the  3D  structure  of  pertactin  indicates  that  the  RGD  within 
the  N-terminus  of  pertactin  may  not  be  functional  (Emsley  et  al.  1994;  Emsley  et  al 
1996).  Pertactin  also  has  two  proline  rich  regions,  (PQP)5  and  (GGXXP)5  which  are 
immunodominant  and  may  be  involved  in  fast,  weak  binding  of  P.  69  to  the  cells  of  the 
respiratory  tract  (Domenighini  et  al.  1990;  M.  Roberts,  personal  communication). 
It  has  been  suggested  that  binding  of  P.  69  may  activate  intracellular  signalling  pathways 
in  eukaryotic  cells  and  cause  upregulation  of  the  P.  69  receptor.  The  prerequisite  for 
metabolically-active  eukaryotic  cells  to  bind  E.  coli  expressing  P.  69  supports  this 
theory  (Everest  et  al.  1996).  Such  upregulation  of  receptor  expression  is  not  unique  to 
Bordetella  species  and  enteropathogenic  E.  coli  and  Salmonella  species  are  able  to 
influence  receptor  expression  in  a  similar  fashion  (Biska  et  al.  1993). 
The  C-terminal  domain  of  pertactin,  P.  30,  has  been  identified  as  a  major  component  of 
the  outer  membrane  of  B.  pertussis  and  of  E.  coli  strains  which  have  been  transformed 
with  a  P.  93  expression  construct  (Charles  et  al.  1994).  There  is  no  evidence  (from  cell 
agglutination  assays  and  ELISA)  that  the  C-terminal  domain  is  surface  exposed  (Charles 
et  al.  1994).  When  a  truncated  gene  lacking  the  region  P.  30  was  expressed  in 
B.  pertussis  and  E.  coli,  P.  69  could  not  be  detected  at  the  cell  surface,  and  appeared  to 
accumulate  in  the  periplasm  (Charles  et  al.  1994).  The  role  of  the  RGD  in  the  P.  30 
domain  (Figure  3)  has  not  been  evaluated. 
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1.10.4  Invasive  properties  of  pertactin 
There  are  contradictory  results  regarding  the  invasive  properties  of  P.  69  and  analysis  of 
results  is  often  difficult  as  adhesion  is  often  considered  as  a  prerequisite  for  invasion. 
Studies  using  synthetic  RGD-containing  peptides  in  a  competitive  adhesion  assay  by 
Leininger  et  al.  (1992)  suggest  that  the  RGD  sequence  of  pertactin  may  play  a  role  in 
entry  of  B.  pertussis  into  HeLa  cells.  A  Salmonella  strain  expressing  P.  69  showed 
increased  invasion  of  CHO  and  Hep-2  cells,  and  the  effect  was  enhanced  when  a  rough 
strain  was  utilised  (Everest  et  al.  1996).  This  may  be  due  to  shorter  LPS  in  these  rough 
strains,  as  seen  in  Bordetella  wild  types  which  allows  better  exposure  of  Prn.  However, 
expression  of  P.  69  in  a  non-invasive  E.  coli  strain  did  not  confer  invasive  properties, 
although  adhesion  was  enhanced.  Recent  studies  using  human  tracheal  epithelial  cells 
(HTE)  suggests  that  pertactin  inhibits  invasion,  perhaps  by  interacting  with  the 
adenylate  cyclase  toxin  (Bassinet  et  al.  2000).  The  nature  of  this  interaction  has  not 
been  described.  At  present  it  appears  likely  that  the  role  of  pertactin  in  invasion  is 
confined  to  adhesion. 
1.10.5  Immunogenicity  of  pertactin 
Pertactin  is  also  immunogenic  in  humans  as  can  be  determined  by  the  high  level  of  anti- 
P.  69  circulating  and  secretory  antibodies  in  individuals  that  are  recovering  from 
pertussis  or  who  have  received  the  whole-cell  vaccine  (Brennan  et  al.  1988;  Charles  et  al. 
1989;  Anwar  1991).  There  appears  to  be  two  repeated  sequences  within  pertactin  that 
are  immunodominant  i.  e.  are  recognised  by  several  anti-pertactin  monoclonal  antibodies 
and  polyvalent  antibodies  (Charles  et  al.  1990).  These  repeat  regions,  (PQP)5  and 
(GGXXP)5,  may  serve  as  protective  epitopes.  In  addition  to  a  humoral  response, 
several  T-cell  clones  that  recognise  P.  69  have  been  identified  in  an  individual  who 
suffered  from  pertussis  during  childhood  (Magistris  et  al.  1986).  A  quarter  of  T-cell 
clones  responsive  to  phase  I  B.  pertussis  recognised  P.  69.  The  possibility  of  using  the 
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P.  30  domain  in  vaccine  preparations  either  alone  or  combined  with  other  antigens  has 
not  been  evaluated. 
Vaccine  studies  in  mice  have  uncovered  the  potential  importance  of  including  Pm  in 
future  vaccine  formulations  (Lipscombe  et  al.  1991;  Roberts  et  al.  1992;  Strugnell  et  al. 
1992).  Oral  or  intravenous  immunnisation  of  mice  with  a  live  attenuated  vaccine  strain 
of  S.  typhimurium  expressing  P.  69  induced  significant  protection  against  an  aerosol  B. 
pertussis  challenge  (Strugnell  et  al.  1992).  Such  vaccine  strains  contained  the  entire  P.  93 
open  reading  frame  and  cellular  responses  appeared  to  be  responsible  for  protection 
(Strugnell  et  al.  1992).  Purified  P.  69  also  conferred  protection  against  an  aerosol 
challenge  with  B.  pertussis  (Strugnell  et  al.  1992).  P.  69  fused  to  the  B  subunit  of  E.  coli 
labile  toxin  (LTB)  was  immunogenic  when  this  chimera  was  administered  intranasally  in 
a  mouse  model  (Lipscombe  et  al.  1991).  The  lungs  of  mice  vaccinated  with  this  P.  69- 
LTB  fusion  protein  contained  anti-P.  69  antibodies  and  P.  69-specific  antibody-secreting 
cells.  Mucosal  immunity  is  considered  an  important  aspect  of  protective  immunity  to 
B.  pertussis  (Lipscombe  et  al.  1991). 
1.11  Tracheal  colonisation  factor 
In  1995,  a  protein  which  contained  significant  homology  to  the  pertactin  carboxy- 
terminus  was  identified  in  B.  pertussis  but  not  B.  parapertussis  or  B.  bronchiseptica. 
(Finn  and  Stevens  1995).  As  in  other  autotransporters,  the  processing  site  is  present 
and  a  90  KDa  form  appears  to  be  cell  associated,  whereas  a  60  KDa  form  appears  as  a 
major  component  of  culture  supernatant  fractions  (Finn  and  Stevens  1995).  The  N- 
terminal  domain  is  approximately  60  KDa  and  an  RGD  motif  has  been  identified  (Figure 
3).  Three  SGXG  glycosaminoglycan  binding  motifs  are  also  present  within  Tcf. 
Therefore,  Tcf  may  represent  an  adhesin  which,  unlike  pertactin,  is  not  anchored  to  the 
membrane  and  is  released  by  proteolysis  into  the  culture  supernatant  (Finn  and  Stevens 
1995).  The  properties  of  Tcf-deficient  mutants  have  been  studied  in  murine  models, 
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and  have  been  found  to  show  reduced  ability  to  colonise  the  trachea  although  such 
strains  retained  the  ability  to  survive  in  the  lower  respiratory  tract  (Finn  and  Stevens 
1995).  No  other  studies  on  this  protein  have  been  reported. 
1.12  Bordetella  resistance  to  killing  (Brk) 
The  Bordetella  resistance  to  killing  locus  (brk)  encodes  two  separate  open  reading 
frames,  brkA  and  brkB  (Fernandez  and  Weiss  1994).  The  gene  products  BrkA  and 
BrkB  appear  to  be  essential  for  resistance  to  killing  by  the  classical  (antibody- 
dependent)  complement  pathway.  BrkA  and  BrkB  also  reduce  the  susceptibility  of 
B.  pertussis  to  antimicrobial  preptides  such  as  the  defensins  that  are  an  important 
feature  of  the  mucosal  immune  system  (Fernandez  and  Weiss  1994;  Fernandez  and 
Weiss  1996).  BrkA  is  similar  in  sequence  to  P.  93  and,  like  pertactin,  a  role  in  adhesion 
and  invasion  of  eukaryotic  cells  has  been  suggested  (Fernandez  and  Weiss  1994). 
Unlike  the  Brk  proteins,  however,  Pm  appears  to  have  no  role  in  serum  resistance  of 
bordetellae.  The  BrkA  protein  has  most  homology  with  the  Pm  at  its  C-terminus  and  it 
contains  the  putative  cleavage  region  as  well  as  the  characteristic  outer  membrane 
localisation  motif.  There  is  no  amino  terminal  signal  sequence  as  in  the  other  processed 
outer  membrane  proteins  and  it  is  supposed  that  the  protein  is  translocated  across  the 
cytoplasmic  membrane  via  the  BrkB  gene  product  (Fernandez  and  Weiss  1994).  BrkB 
has  homology  with  ORFs  of  unknown  function  that  have  been  identified  in  E.  coli  and 
Mycobacterium  leprae  (Fernandez  and  Weiss  1994).  In  addition  to  two  RGD  motifs, 
there  are  also  two  glycosaminoglycan  (heparin)  binding  sites  which  may  mimic  the 
FHA-heparin  interaction  or  have  a  role  in  inhibiting  the  polymerisation  of  C9.  Recent 
evidence  suggests  that  although  some  B.  bronchiseptica  strains,  express  BrkA, 
complement  resistance  is  not  mediated  by  this  protein  (Rambow  et  al.  1998). 
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1.13  Virulence-activated  gene  8 
An  additional  bvg-regulated  protein  may  now  be  included  in  the  autotransporter  family 
on  the  basis  of  sequence  similarity,  virulence-activated  gene  8  (Vag8)  (Finn  and 
Amsbaugh  1998).  It  appears  that  Vag8  is  not  processed  at  the  outer  membrane  and 
remains  as  a  92  KDa  form  (Finn  and  Amsbaugh  1998).  It  was  suggested  previously  that 
Vag8  may  be  important  in  persistence  in  the  mouse  respiratory  tract  as  a  mutant  B. 
pertussis  (SK8)  harbouring  a  disrupted  vag8  gene  was  reduced  in  its  ability  to  colonise 
mouse  lungs  (Finn  et  al.  1991).  Like  the  other  B.  pertussis  autotransporters  described  to 
date,  Vag8  possesses  an  RGD  motif.  The  role  of  this  protein  has  not  been 
characterised,  although  Vag8  mutants  of  B.  pertussis  were  able  to  colonise  mice  as 
efficiently  as  the  wild  type.  The  authors  demonstrated  that  this  protein  is  the  same  as 
the  91  KDa  protein  decribed  by  Armstrong  and  Parker  (1986)  and  the  92  KDa  protein 
described  by  Hamstra  et  al.  (1995).  Hamsta  et  al.  (1995)  found  that  this  protein  was 
protective  in  the  mouse  intracerebral  protection  assay  only  when  non-protective  levels 
of  pertussis  toxin  were  present. 
1.14  Protective  capacity  of  B.  pertussis  autotransporter  C-terminal 
domains 
There  is  a  lack  of  knowledge  regarding  the  use  of  autotransporter  C-terminal  domains  in 
vaccine  preparations.  Hamstra  et  al.  (1995)  and  Hamstra  and  Poolman  (unpublished) 
determined  the  N-terminal  sequences  of  two  proteins  they  were  evaluating  in  a  murine 
intracerebral  vaccine  model.  It  was  later  established  that  these  proteins  were  the  C- 
terminal  portions  of  BrkA  and  Tcf.  The  C-terminal  domains  of  Tcf  and  BrkA  were 
purified  from  B.  pertussis  outer  membranes  and  were  not  protective  in  the  intracerebral 
mouse  tests.  However,  the  Tcf  C-terminus  was  protective  when  this  protein  was 
presented  as  mixed  protein-detergent  micelles  (outer-membrane  complexes). 
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1.15  Heterologous  antigen  display 
During  the  course  of  this  study,  several  reviews  have  been  published  regarding 
heterologous  antigen  display  (Maurer  et  al.  1997;  Stahl  and  Uhlen  1997;  Henderson  et 
al.  1998).  The  use  of  heterologous  antigen  display  using  autotransporter  domains  has 
previously  been  highlighted  using  the  IgA  protease  and  AIDA-I  (Klauser  et  al.  1993; 
Maurer  1997).  Such  systems  have  proved  useful  for  the  surface  display  of  some 
proteins  in  E.  coli.  There  is  a  particular  interest  in  the  construction  of  multivalent 
hybrid  attenuated  vaccine  strains  of  bacteria  that  express  protective  antigens  from  a 
number  of  different  pathogens.  Additional  uses  for  heterologous  display  that  have  been 
suggested  include  the  generation  of  whole  cell  bioadsorbants  for  environmental 
purposes;  as  microbial  biocatalysts  (enzymes  displayed  on  cell  surface),  or  as  diagnostic 
tools  (bacteria  with  surface  located  antibody  fragments)  (Stahl  and  Uhlen  1997). 
Various  models  have  been  developed  which  allow  the  export  of  heterologous  antigens. 
The  processing  of  these  proteins  has  been  investigated.  Independent  proteases  may  be 
responsible  for  the  release  of  mature  proteins  in  several  autotransporter  systems.  The 
presence  of  additional  proteases  capable  of  cleaving  the  putative  proteolysis  site  was 
confirmed  using  Cholera  toxin  B-subunit  (CtxB)  as  a  heterologous  passenger  protein 
fused  to  the  IgA  protease  carboxy  terminus  and  expressed  in  E.  coli  (Klauser  et  al. 
1992).  A  feature  of  the  autotransporter  secretion  system  is  the  inability  to  allow 
passage  to  artificially  fused  domains  that  have  stable  tertiary  structures,  for  example 
intramolecular  disulphide  bonds  (Klauser  et  al.  1992).  Proteins  that  use  the 
autotransporter  secretion  system  to  reach  the  cell  exterior  are  assumed  to  do  so  in  an 
unfolded  state  and  the  number  of  cysteine  residues  is  low  (Jose  et  al.  1995).  The  CtxB 
cannot  be  transported  using  an  autotransporter  domain  unless  intramolecular  disulphide 
bond  formation  can  be  prevented  in  the  periplasm  (Klauser  et  al.  1992).  Recently, 
however,  a  single  chain  antibody  has  been  fused  to  IgA  protease  beta  domain  and 
translocation  of  this  protein,  with  some  tertiary  structure,  was  demonstrated  (Veiga  et 
al.  1999). 
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1.16  Aims  of  the  project 
The  general  aim  of  the  investigation  was  to  characterise  members  of  the  newly 
discovered  family  of  processed  outer  membrane  proteins  of  Bordetella  species.  Three 
virulence  factors  within  this  family  had  been  identified  i.  e.  Prn,  BrkA  and  Tcf.  During 
the  course  of  this  study  a  fourth  member  of  this  family,  Vag8,  was  identified  in 
B.  pertussis  (Finn  and  Amsbaugh  1998)  but  has  yet  to  be  fully  characterised. 
The  primary  aim  was  to  identify  and  characterise  a  potentially  new  member  of  the 
Bordetella  autotransporter  protein  family.  Using  primers  directed  towards  the  3'  region 
of  the  pertactin  open  reading  frame,  a  similar  but  not  identical  sequence  was  amplified 
by  PCR  and  cloned.  Use  of  this  PCR  product  as  a  probe  against  an  existing  cosmid  gene 
library  would  identify  the  corresponding  gene  which  could  be  sequenced  and  compared 
with  existing  sequences  (Prn,  BrkA,  Tcf  and  Vag8).  This  C-terminus  encoding  region 
may  be  part  of  a  larger  precursor  encoding  gene,  and  subcloning  of  this  gene  into  E.  coli 
or  Salmonella  spp.  for  overexpression  of  the  putative  OMP  may  provide  sufficient 
material  for  further  characterisation  of  this  protein  e.  g.  as  a  vaccine  antigen  and  virulence 
factor.  Site-directed  mutagenesis  of  the  cloned  OMP  gene  and  the  construction  of 
OMP-deficient  mutants  would  also  allow  an  assessment  of  its  importance  in  host- 
pathogen  interactions.  It  would  also  be  interesting  to  determine  the  presence  of  the  gene 
in  other  bordetellae.  Furthermore,  the  expression  of  the  bap-5  gene  should  be 
determined  in  these  bordetellae  under  a  variety  of  growth  conditions. 
The  role  of  the  autotransporter  C-terminal  fragments  (ß-domains)  was  also  to  be 
assessed,  with  an  emphasis  on  the  vaccine  potential  of  these  regions  in  a  murine  model. 
In  many  studies,  particularly  with  knockout  mutants,  it  is  possible  that  the  functions 
that  have  been  assigned  to  the  mature  protein  (N-terminal  product)  could,  in  fact,  be 
properties  of  the  C-terminal  moieties.  The  mechanisms  of  cleavage  and  regulation  of 
cleavage  during  processing  was  also  to  be  assessed  along  with  the  use  of  the  C-terminal 
domains  in  heterologous  antigen  display. 
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2.1  General  bacteriological  procedures 
2.1.1  Source  of  bacteria,  storage,  growth  and  media 
Materials  and  Methods 
All  bacterial  strains  used  in  this  study  are  given  in  Table  3  Unless  stated,  all  strains 
were  available  from  culture  collections  within  the  Division  of  Infection  and  Immunity, 
University  of  Glasgow.  The  compositions  of  the  following  media  are  given  in  Appendix 
I:  Luria  Bertani  broth  (LB);  Luria  Bertani  agar  (LBA);  Bordet-Gengou  agar  (BGA);  2x 
Yeast  Tryptone  (2x  YT);  Casamino  acids  (CAA);  Cyclodextrin  liquid  (CL);  SOC  and 
Minimal  medium  (MM).  All  media  were  sterilised  by  autoclaving  at  15  p.  s.  i.  (121°C) 
for  15  min  exept  where  stated.  Heat  labile  ingredients  such  as  antibiotics  were  sterilised 
by  filtration  through  a  sterile  0.22  µm  filter  (Gelman  Sciences,  USA).  Glassware  was 
sterilised  by  heating  to  160°C  for  2  h.  Long  term  storage  of  E.  coli  was  at  -70°C  in  LB 
broth  supplemented  with  glycerol  50%  (v/v).  Bordetellae  were  resuspended  in  1% 
CAA  containing  glycerol  20%  (v/v)  and  stored  at  -70°C. 
2.1.2  Growth  of  E.  coli 
E.  coli  strains  were  routinely  grown  overnight  at  37°C  on  LB  agar.  Where  necessary, 
500  ml  LB  broth  in  a2L  dimpled  flask  (unless  otherwise  stated)  was  inoculated  from 
such  plates  and  incubated  overnight  at  37°C  with  shaking  at  150-200rpm.  Antibiotics 
were  added  at  appropriate  concentrations. 
2.1.3  Growth  of  B.  pertussis 
B.  pertussis  was  grown  on  BG  agar  containing  15%  defibrinated  horse  blood  (E  and  0 
Laboratories,  Scotland)  and  10%  (w/v)  glycerol.  Plates  were  placed  in  a  humidified  box 
and  incubated  for  2  -3  days  at  37°C.  Where  necessary,  a  heavy  inoculum  was  made  into 
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500  ml  of  CL  medium  in  a  2L  dimpled  flask  which  was  incubated  for  2-3  days  at  37°C 
with  shaking  at  150-200  rpm. 
2.1.4  Growth  of  B.  bronchiseptica 
B.  bronchiseptica  was  grown  overnight  at  37°C  on  LB  agar.  Where  necessary,  500  ml 
LB  broth  in  a2L  dimpled  flask  was  inoculated  from  such  plates  and  incubated 
overnight  at  37°C  with  shaking  at  150-200rpm. 
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Table  3:  The  bacterial  strains  used  during  this  study. 
Materials  and  Methods 
Strain  Genotype  Source/Remarks 
E.  coil  F-ompT  hsdSB(rB  ms)  gal  dcm  (XDE3)  Invitrogen;  Recombinant 
BL21(DE3)  protein  expression  strain 
E.  coil  Nals,  Str', Rif,  Thi,  Ara,  Ga,  Mtt,  RecA  , 
Qiagen;  Recombinant 
Ml  5p(REP4) 
Uvr+,  Lon+  protein  expression  strain 
E.  coli  F'  {lacl9,  Tn1O(Tet  )}  mcrA  A(mrr-hsdRMS-  Invitrogen;  General 
TOPIOF'  mcrBC)  4801acZAM15  AlacX74  deoR  recA  I  transformation  strain 
araD139  A(ara-leu)7639  galUgalK 
rspL(Str")  endAI  nupG 
E.  soli  supE44  AlacU169  (480lacZAM15)  hsdR17  Infection  and  Immunity, 
recAI  endA1  gyrA96  thi-1  re/Al  University  of  Glasgow; 
DH5a  General  transformation  strain 
E.  coil  recAlsupE44  endAl  hsdR17  gyrA96  re/Al  thi  Promega;  General 
JM109  A(lac  proAB)  transformation  strain 
E.  coil 
F-AlacX74  galE  thi  rpsL  AphoA  (PvuII)  Invitrogen.  This  strain  is 
LMG  194 
Aara714  leu::  Tn10  deleted  for  araBADC  and  is 
"  R  ;  Recombinant  and  Tet  Str 
protein  expression  strain 
B.  pertussis  Wild-type  Isolated  from  a  child  post- 
Taberman 
mortem.  Ruchill  Hospital, 
Glasgow  (1979) 
B.  pertussis  Wild-type  i.  c.  challenge  strain  for 
18-323  mouse  protection  tests. 
Manclark  C.  Center  for 
Biologics  Evaluation  and 
Research,  Bethedsa,  MD 
20892 
B.  pertussis  Avirulent  mutant.  Tn  insertion  of  Tohama.  Weiss,  A. 
BP347 
Bvg  (Vif)  Molecular  Genetics. 
University  of  Cincinnati 
B.  pertussis  Wild-type  Roberts,  M.  Veterinary 
BBC29 
Pathology,  University  of 
Glasgow 
B.  pertussls  Deletion  mutant  of  BBC29.  Prn  Roberts,  M.  Veterinary 
BBC30 
Pathology,  University  of 
Glasgow 
B.  pertussis  2041  Deletion  mutant-brkA"  Weiss,  A. 
Molecular  Genetics. 
University  of  Cincinnati 
B.  parapertussis  Wild-type  ,  NCTC5952  Infection  and  Immunity, 
University  of  Glasgow 
B.  bronchiseptica  Wild-type,  214  Infection  and  Immunity, 
University  of  Glasgow 
B.  avium  Wild-type,  4480  R.  Rimler,  Ames,  Iowa 
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2.2  DNA  extraction 
2.2.1  Genomic  DNA  extraction 
After  growth  of  the  bacteria  in  appropriate  broth  culture,  the  genomic  DNA  was 
extracted  according  to  the  following  method.  Cells  from  10  ml  of  stationary  phase 
culture  were  harvested  by  centrifugation  at  3,000  xg  for  15  min  in  a  Heraeus  medifuge. 
The  pellet  was  resuspended  in  500  gl  of  50  mM  Tris,  1  mM  EDTA  (pH  7.5)  and 
placed  at  -20°C.  When  frozen,  50  gl  of  fresh  lysozyme  (Sigma)  solution  (10  mg/ml  in 
0.25  M  Tris,  pH  8.0)  was  added  and  the  solution  thawed  with  mixing  at  room 
temperature.  When  just  thawed  the  solution  was  placed  on  ice  for  45  min  and  100  gl  of 
fresh  step  solution  (Appendix  I)  was  added.  The  tubes  were  then  incubated  at  50°C 
with  occasional  inversion.  When  the  suspension  cleared  (after  1-5  h),  60  gl  of  Tris- 
buffered  phenol  (Sigma)  was  added  and  the  suspension  mixed  for  5  min.  The  layers 
were  separated  by  centrifugation  at  19,000  xg  in  a  Biofuge  (Rotor  HFA  14.2)  for  15 
min  and  the  aqueous  phase  removed  into  a  fresh  microfuge  tube.  The  phenol  extraction 
was  repeated  if  necessary.  An  ethanol  precipitation  was  then  performed  using  0.1 
volume  of  3M  sodium  acetate  (pH  5.3)  and  2  volumes  of  ethanol  100%.  The  DNA 
usually  precipitated  and  could  be  spooled  out  using  a  sterile  Pasteur  pipette  or, 
alternatively  was  centrifuged  at  15,000  xg  for  15  min  in  a  Biofuge  (Rotor  HFA  14.2). 
The  DNA  was  then  resuspended  in  100  gl  of  50  mM  Tris,  1  mM  EDTA  (pH  7.5)  and 
left  overnight  at  4°C.  To  the  solution,  20  µg  of  RNAse  (Sigma)  was  added  and  the 
mixture  incubated  at  37°C  for  2  h.  The  DNA  was  then  extracted  with  chloroform:  iso- 
amyl  alcohol  (24:  1,  Sigma)  as  for  the  phenol  extraction.  The  DNA  was  precipitated  as 
before  and  resuspended  in  300  µl  of  sterile  water. 
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2.2.2  Plasmid  purification 
Plasmid  DNA  was  extracted  using  the  QlAprep  Miniprep  purification  system 
(Qiagen,  West  Sussex,  UK).  Briefly,  5  ml  of  overnight  E.  coil  was  centrifuged  at  10,000 
xg  for  10  min  (Biofuge,  Rotor:  HFA  14.2).  The  resultant  bacterial  pellet  was 
resuspended  in  250.  tl  of  Buffer  P1  and  lysed  using  250  µl  of  Buffer  P2  (alkali-detergent 
solution)  for  5  min  at  room  temperature.  The  macromolecules  were  then  precipitated 
using  350  µl  of  Buffer  N3  (chaotropic  solution)  and  then  centrifuged  at  15,000  xg  for  10 
min  (Biofuge,  Rotor:  HFA  14.2).  The  supernate  was  added  to  a  QlAprep®  column  and 
centrifuged  at  10,000  xg  for  1  min.  The  flow-through  was  discarded  and  the  column 
was  then  washed  with  500  µl  of  Buffer  PB  (trace  nuclease  removal)  and  centrifuged  at 
10,000  xg  for  1  min.  The  flow-through  was  again  discarded  and  the  final  wash  was 
performed  with  750  µl  of  Buffer  PE  (containing  ethanol)  with  a  further  centrifugation, 
as  described  previously.  An  additional  centrifugation  was  performed  following  flow- 
through  removal  to  ensure  thorough  removal  of  ethanol.  Finally,  the  DNA  was  eluted 
by  centrifugation  after  addition  of  40-80  µl  of  sterile  distilled  water  (preheated  to  65°C). 
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Table  4:  Plasmids  used  or  created  during  this  study 
Materials  and  Methods 
Plasmid  Name  Comments 
pGemT(30)  Amplicon  MR30  AT  cloned  into  plasmid  pGEMT 
pCRII(640)  EcoRI  subclone  of  pGemT(30)  (640  bp  fragment) 
pGem(PEB1)  5.2  Kb  Nod  fragment  (PEB1)  subcloned  from  cosmid  3 
Cosmid  3  B.  pertussis  genomic  cosmid  which  hybridised  to  P640 
pCRII(640)  EcoRI  subclone  of  pGemT(30)  (640  bp  fragment) 
pCRII(PCT1)  Prn  C-terminus  encoding  DNA  (PCT1)  AT  cloned  into 
pCRII 
pCRII(BCT1)  BrkA  C-terminus  encoding  DNA  (BCT1)  AT  cloned  into 
pCRII 
pCRII(TCT1)  Tcf  C-terminus  encoding  DNA  (TCT1)  AT  cloned  into 
pCRII 
pCRII(Bp5CT1)  Bap-5  C-terminus  encoding  DNA  (Bp5CT1)  AT  cloned 
into  pCRII 
pET  ll  a(B  CT  1)  B  CT  1  cloned  into  pet  IIa:  expression  construct  for  BrkA 
C-terminus 
pET33b(PCT1)  PCT1  cloned  into  pet33b:  expression  construct  for  Prn  C- 
terminus 
pET33b(TCT1)  TCT1  cloned  into  pet33b:  expression  construct  for  Tcf  C- 
terminus 
pET33b(Bp5CT1)  Bp5CT1  cloned  into  pet33b:  expression  construct  for  Bap- 
5  C-terminus 
pCRII(Bp5ATG1)  Bap-5  from  1st  potential  ATG  AT  cloned  into  pCRII 
pCRII(Bp5ATG2)  Bap-5  from  2nd  potential  ATG  AT  cloned  into  pCRII 
pCRII(Bp5ATG3)  Bap-5  from  3rd  potential  ATG  AT  cloned  into  pCRII 
pCRII(Bp5ATG4)  Bap-5  from  4th  potential  ATG  AT  cloned  into  pCRII 
pQE-60(Bp5ATG1)  Bp5ATG1  from  pCRII(Bp5ATG1)  cloned  into  pQE-60: 
expression  construct  of  Bap-5  (from  Ist  potential  ATG) 
pQE-60(Bp5ATG2)  Bp5ATG2  from  pCRII(Bp5ATG2)  cloned  into  pQE-60: 
expression  construct  of  Bap-5  (from  2nd  potential  ATG) 
pQE-60(Bp5ATG3)  Bp5ATG3  from  pCRII(Bp5ATG3)  cloned  into  pQE-60: 
expression  construct  of  Bap-5  (from  3rd  potential  ATG) 
pQE-60(Bp5ATG4)  Bp5ATG4  from  pCRII(Bp5ATG4)  cloned  into  pQE-60: 
expression  construct  of  Bap-5  (from  4th  potential  ATG) 
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Plasmid  Name  Comments 
pCRII(Kana)  Kanamycin  resistance  cassette  amplified  from  pUC4K  AT 
cloned  into  pCRII 
pGemT(Kana)  Kanamycin  resistance  cassette  amplified  from  pUC4K  AT 
cloned  into  pGemT 
pCR-Script(Bap-5Kr)  bap-5  disrupted  with  Kanamycin 
pCRII(PCTlink)  Pm  C-terminus  and  linker-encoding  DNA  (PCTlink)  AT 
cloned  into  pCRII 
pBAD/gIIIA(PCTlink)  PCTlink  from  pCRII(PCTlink)  cloned  into  pBAD/gIIIA: 
expression  construct  of  Prn  C-terminus  and  linker  fused  to 
a  signal  sequence 
pCRII(NTS)  Bap-5  specific  portion  (NTS)  AT  cloned  into  pCRII 
pQE-60(NTS)  Bap-5  specific  portion  (NTS)  cloned  into  pQE-60: 
expression  construct  of  NTS 
2.3  Agarose  gel  electrophoresis 
2.3.1  Sample  preparation 
The  sample  DNA  (5-30  µl)  was  mixed  with  6x  DNA  loading  buffer  (Appendix  I)  in  a 
vol:  vol  ratio  of  5:  1  prior  to  loading  into  the  wells.  Molecular  weight  markers  (1  Kb 
ladder,  Gibco  BRL,  UK)  were  utilised  according  to  manufacturer's  instructions. 
2.3.2  Gel  preparation 
Agarose  (type  II-A  medium  EEO,  Sigma)  was  suspended  in  0.5x  Tris-borate-EDTA 
(TBE)  buffer  (Appendix  I)  at  a  suitable  concentration  and  heated  until  the  agarose  was 
completely  dissolved.  The  solution  was  allowed  to  cool  (hand-hot)  and  ethidium 
bromide  (Bio-Rad,  UK)  was  added  to  a  final  concentration  of  0.5  µg/ml.  A  gel  tray  was 
prepared  by  taping  the  edges  with  adhesive  tape  and  the  gel  cast  to  the  desired 
thickness.  Upon  setting,  the  gel  was  immersed  in  0.5x  TBE  containing  ethidium 
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bromide  (0.5  tg/ml)  in  a  horizontal  submarine  electrophoresis  tank  (E-C  Apparatus 
Corporation,  USA). 
2.3.3  Electrophoresis 
A  powerpack  (model  SL3655,  Scotlab,  UK)  was  used  to  provide  a  constant  voltage 
corresponding  to  1-5  volts/cm.  Electrophoresis  was  carried  out  until  the  marker  dye 
migrated  an  appropriate  distance. 
2.3.4  Visualisation  of  DNA 
A  UV  transilluminator  (model  TM-40,  UVP  Inc.,  California,  USA)  was  used  to 
visualise  the  ethidium  bromide-stained  DNA.  Images  were  stored  electronically  as 
appropriate  using  the  Ultra  Violet  Products  Gel  Documentation  System-Image  Store 
5000,  version  7.2  (Ultra  Violet  Products,  Cambridge,  UK).  Images  were  printed  using  a 
video  graphic  printer  (model  UP-860,  Sony).  Where  appropriate,  photographs  were 
captured  with  Fotolook  (version  2.07.2  Agfa,  UK)  using  a  flatbed  scanner  (model 
Studioscan  Hsi, Agfa).  Electronic  images  were  edited  using  Adobe  Photoshop  3.0  and 
images  labelled  with  Microsoft  Powerpoint  4.0 
2.3.5  Gel  extraction  procedure 
DNA  was  purified  from  agarose  gels  using  the  Qiaex®II  purification  kit  (Qiagen) 
according  to  manufacturer's  instruction.  The  band  of  interest  was  excised  from  the  gel 
and  solubilised  in  Buffer  QX1  (usually  3  volumes  of  buffer  to  one  volume  of  gel).  Qiaex 
resin  (10-15  µl)  was  introduced  and  the  mixture  incubated  at  50°C  for  10  min. 
Following  centrifugation  for  1  min  at  10,000  xg  the  supernate  was  removed.  The  pellet 
was  then  washed  once  with  500  gl  of  Buffer  QX1  and  twice  with  500  gl  of  Buffer  PE, 
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with  centrifugation  as  before.  The  resin/DNA  pellet  was  air-dried,  5-25  Ri  of  sterile 
distilled  water  was  added  and,  after  incubation  for  5  min  at  50°C,  the  resin  was  removed 
by  centrifugation  as  before  and  the  eluted  DNA  was  retained. 
2.4  Estimation  of  DNA  concentration 
The  concentration  of  DNA  was  estimated  by  measuring  the  absorbance  at  260nm  in  a 
1  cm  quartz  cuvette  and  by  applying  the  equation: 
Concentration  of  DNA  (ng/µl)  = 
A260N￿  x  50  x  dilution  factor 
Alternatively,  band  intensity  of  a  sample  of  DNA  was  compared  with  those  of 
molecular  weight  standards  of  known  concentration  after  agarose  gel  electrophoresis. 
2.5  Concentration  of  DNA 
To  precipitate  and  concentrate  the  DNA,  3  volumes  of  ethanol  95%  (v/v)  and  0.1 
volume  of  3M  sodium  acetate  (pH  5.3)  was  added  to  the  sample  and  the  resultant  mix 
stored  at  either  -20°C  overnight  or  at  -80°C  for  30  min  depending  on  the  time  available. 
The  sample  was  then  centrifuged  at  19,000  xg  (Biofuge,  Rotor:  HFA  14.2)  for  15  min 
and  the  supernate  discarded.  The  DNA  pellet  was  then  washed  with  cold  ethanol  70% 
(v/v)  and  dried  at  room  temperature  for  10-15  min.  The  DNA  was  resuspended  in  an 
appropriate  volume  of  sterile  distilled  water  and  if  necessary  heated  to  65°C  for  30  min 
to  aid  dissolving. 
2.6  Restriction  enzyme  reactions 
All  reactions  were  performed  according  to  manufacturers'  instructions  (Gibco  BRL, 
New  England  Biolabs  or  Promega)  with  the  exception  of  Promega  universal  reaction 
buffer  occasionally  replacing  the  suggested  buffers  for  simultaneous  digestions  with 
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more  than  one  restriction  enzyme.  Total  reaction  volumes  of  30  µl  and  50  µl  were 
commonly  used.  Where  appropriate,  the  enzymes  were  heat  inactivated  (65°C  for  15 
min)  and  the  DNA  was  purified  using  the  Qiaex®II  kit,  often  in  conjunction  with 
agarose  gel  electrophoresis  if  isolation  of  a  single  restriction  product  was  desirable. 
2.7  Polymerase  chain  reaction 
Optimisation  of  the  PCR  conditions,  where  necessary,  was  performed  according  to  the 
orthogonal  array  method  described  by  Cobb  et  al.  (1994).  The  annealing  and  elongation 
thermal  parameters  were  then  varied  to  obtain  optimal  conditions.  A  Hybaid  thermal 
cycler  (model:  Touchdown,  Hybaid  Ltd,  Middlesex,  UK)  was  used  for  all  reactions. 
The  products  of  the  PCR  were  stored  at  -20°C  or  used  immediately. 
2.7.1  Primers 
During  primer  design,  care  was  taken  to  avoid  potential  internal  secondary  structure  and 
where  possible  a  GC  clamp  was  engineered  at  the  3'  end  of  the  primer.  Additionally, 
for  PCR,  primers  were  checked  so  as  to  avoid  overlap  and  possible  dimerisation, 
potential  for  secondary  structure  and  for  compatible  Tm  values.  Tm  values  were 
calculated  according  to  the  equation: 
Tm(°C)  =  4(G  +  C)  +  2(A  +  T)  -  5°C 
Primers  (50  nmol,  desalted  and  deprotected)  were  obtained  from  Gibco  BRL  (Paisley, 
UK)  and  resuspended  in  sterile  distilled  water  to  give  final  concentrations  of  50  pmol/µl 
or  0.5  pmol/µl  for  PCR  and  automated  sequencing  respectively.  Table  5  shows  the 
primers  used  in  this  study. 
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2.7.2  HotStarTagTM  method 
Hot-start  PCR  was  performed  according  to  the  HotStarTaqTM  PCR  kit  (Qiagen) 
according  to  manufacturer's  instruction.  The  following  mastermix  was  prepared  in  a  thin 
walled  0.5  ml  tube  immediately  before  use  (per  reaction): 
lOX  PCR  Buffer  (containing  15  mM  MgC12)  10  t1 
dNTP  mix  (10  mM  of  each)  2µl 
5'  primer  (50  pmol/µl)  1  µl 
3'  primer  (50  pmol/µl)  1  µl 
HotstarTaq  DNA  Polymerase  0.5  µl 
Template  DNA  <1  µg 
Distilled  water  Variable 
Total  volume  100  µl 
In  addition  to  the  above  components,  Q-Solution  was  often  added.  Q-solution  changes 
the  melting  behaviour  of  the  DNA  and  is  particularly  useful  when  amplifying  GC  rich 
templates.  Q-solution  was  supplied  at  5x  concentration  and  the  volume  of  distilled 
water  adjusted  accordingly. 
The  following  thermocycling  parameters  were  used: 
Initial  activation  step:  15  min  95°C 
30  Cycles  of 
Denaturation:  45  s  95°C 
Annealing:  45  s  50-68°C 
Approximately  5°C  below  T.  of  primers 
Extension:  1  min  72°C 
For  PCR  products  longer  than  1  Kb  the  extension  time  was  increased  by  1  min  per  Kb 
DNA 
Final  extension  step  of  72°C  for  15  min. 
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2.7.3  ExpandTM  high  fidelity  PCR  system 
Two  mastermixes  were  prepared  according  to  the  manufacturer's  instruction 
(Boehringer  Mannheim,  Germany).  A  total  volume  of  100  µl  was  routinely  used 
regardless  of  the  predicted  amplimer  size. 
Mastermix  1: 
dNTP  mix  (10mM)  4  µ1 
Upstream  primer  (50pmol/µl)  1  µl 
Downstream  primer  (50pmol/µl)  1  µl 
Template  DNA  variable 
dH2O  variable 
Total  volume  50  µl 
Mastermix  2: 
10X  Expand"  High  Fidelity  buffer  10  µl 
(containing  15mM  MgC12) 
Expand""  High  Fidelity  PCR  0.75  µl  (2.6U) 
System  enzyme  mix 
dH2O  39.25 
Total  volume  50  µl 
The  above  mastermixes  were  combined  in  a  0.5  ml  thin  walled  tube  and  thermal  cycling 
was  performed  as  described  by  the  manufacturer  except  that  targets  larger  than  1  Kb 
were  amplified  using  an  extension  temperature  of  68°C  and  no  initial  activation  step  was 
performed. 
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2.8  Universal  GenomeWalkerTM  procedure 
Libraries  were  constructed  according  to  the  Universal  GenomeWalkerTM  kit  user  manual 
(Clontech,  USA),  except  that  digested  genomic  DNA  was  purified  according  to  the 
Qiaex®II  method  in  place  of  the  suggested  phenol-chloroform  extraction. 
2.8.1  Preparation  of  genomic  DNA 
Chromosomal  DNA  was  extracted  from  B.  pertussis  (strain  Taberman)  according  to 
section  2.2.1  and  five  restriction  digests  (with  Dral,  EcoRV,  PvuII,  Scal  and  Stul)  were 
set  up  seperately  using  the  following  protocol: 
Genomic  DNA  (0.1  µg/µl)  25  µl 
Restriction  enzyme  (10  U/µl)  8  µl 
Restriction  enzyme  buffer  10  µl 
Deionised  distilled  H2O  57  µl 
The  above  were  mixed  gently  and  incubated  at  37°C  for  2  h.  The  reactions  were 
vortexed  at  slow  speed  for  5-10  s  and  returned  to  37°C  for  16-18  h.  Agarose  gel 
electrophoresis  was  performed  to  examine  5  µl  of  each  reaction  for  complete  digestion. 
The  remaining  DNA  then  was  purified  using  the  Qiaex®II  method  (section)  and 
resuspended  in  20  µl  of  TE. 
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2.8.2  Ligation  of  genomic  DNA  to  GenomeWalker  adaptors 
From  each  tube  of  purified,  digested  DNA  4  µl  was  added  to  the  following  reaction: 
GenomeWalker  Adaptor  (25  µM)  1.9  µl 
5x  ligation  buffer  1.6  µl 
T4  DNA  ligase  (1  U/µl)  0.5  µl 
The  above  reaction  was  incubated  at  16°C  overnight.  The  reactions  were  stopped  by 
incubation  at  70°C  for  5  min  with  72  µl  of  TE  and  the  tubes  vortexed  at  slow  speed  for 
15  s. 
2.8.3  PCR-based  DNA  walking  in  GenomeWalker  libraries 
2.8.3.1  Primary  PCR 
A  nested  PCR  was  performed  in  a  0.5  ml  thin-walled  tube  using  the  two  gene  specific 
primers,  GSP  1  and  GSP2  (table  5  and  figure  8)  and  two  adaptor  specific  primers,  AP  1 
and  AP2  (table  5).  A  primary  PCR  mastermix  was  prepared  (per  reaction): 
µl 
Deionised  water  37.8 
l  OX  Tth  PCR  reaction  buffer  5 
dNTP  (10  mM  each)  1 
Mg(acetate)  (25  mM)  2.2 
AP  1  (10  µM)  1 
GSP1  (10µM)  1 
Advantage  Tth  Polymerase  Mix  (50X)  1 
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To  each  reaction  1  µl  of  each  GenomeWalker  DNA  library  was  added  and  the  following 
thermocycling  parameters  used: 
STAGE  17  cycles: 
94°C  25  s 
72°C  3  min 
STAGE  2  32  cycles: 
94°C  25  s 
67°C  3  min 
STAGE  31  cycle: 
67°C  7  min 
2.8.3.2  Secondary  PCR 
The  secondary  PCR  was  performed  under  the  same  conditions  as  the  primary  PCR  with 
the  following  exceptions:  The  template  for  amplification  was  1  µl  of  the  primary  PCR 
reaction  mixture.  Primers  AP2  and  GSP2  were  used  (in  the  place  of  AP1  and  GSP1). 
Stage  2  was  replaced  with  20  cycles  of  94°C  for  25  s  and  67°C  for  3  min. 
From  each  reaction,  8  µl  was  analysed  by  agarose  gel  electrophoresis. 
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2.9  Cloning 
2.9.1  PCR  product  cloning 
2.9.1.1  Cloning  into  pCR®2.1-TOPO 
PCR  products  were  routinely  cloned  using  the  pCR®2.1-TOPO  vector  (also  referred  to 
as  pCRII  in  future  chapters)  included  in  the  TOPO  TA  cloning  kit  (Invitrogen,  The 
Netherlands).  Amplicons  of  interest  were  excised  following  agarose  gel  analysis  and 
DNA  extracted  using  the  Qiaex®II  kit.  The  DNA  was  resuspended  to  a  concentration 
of  approximately  50  ng/µl.  Ligation  of  the  PCR  product  into  pCR®2.1-TOPO  was 
performed  according  to  the  manufacturer's  instructions.  Briefly,  4  µl  of  cleaned  PCR 
product  was  mixed  gently  with  1  µl  of  TOPO  mix  (containing  topoisomerase,  prepared 
pCR®2.1-TOPO  and  ligation  buffer).  After  incubation  for  5  min  at  room  temperature, 
the  mixture  was  put  onto  ice.  Immediately,  one  vial  of  TOP  10F  One  ShotTM 
competent  cells  were  thawed  gently  on  ice  and  2  µl  of  mercaptoethanol  (0.5  M)  was 
added.  To  the  cells,  2  µl  of  the  ligation  mix  was  added  with  gentle  mixing.  After 
incubation  on  ice  for  30  min,  the  cells  were  then  heat-shocked  at  42°C  for  30  s  and 
returned  onto  ice  for  2  min.  SOC  medium  (250  µl;  Appendix  I)  was  added  and  the  cells 
shaken  at  37°C  for  2  h.  Recombinants  were  selected  according  to  section  2.10.3. 
2.9.1.2  Cloning  into  pCR-SCRIPTTM 
Cloning  was  performed  using  the  pCR-SCRIPTTM  cloning  kit  (Stratagene,  Cambridge, 
UK)  according  to  the  manufacturer's  instructions.  This  procedure  involves  blunt 
cloning  of  the  `polished'  PCR  product  into  a  predigested  Srfl  vector  site.  The  ligation 
occurs  in  the  presence  of  Srfl  which  reduces  the  frequency  of  vector  self-self  ligations. 
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PCR  products  were  electrophoresed  in  agarose  gel,  purified  by  gel  extraction  (Qiaex®II) 
and  then  `polished'  to  generate  blunt  ends.  The  following  were  assembled,  in  order,  in  a 
0.5  ml  tube  and  incubated  at  72°C  for  30  min: 
RI 
PCR  product  10 
10  mM  dNTP  mix  (2.5  mM  each)  1 
10X  polishing  buffer  1.3 
Pfu  DNA  polymerase  (0.5  U)  1 
The  `polished'  PCR  product  was  then  added  to  the  ligation  reaction  containing  the 
following: 
t1 
pCR-ScriptTM  Amp  SK(+)  cloning  vector  (10  ng/µl)  1 
PCR-Script  I  OX  reaction  buffer  1 
ATP(10  mM)  0.5 
Polished  PCR  product  2-4 
Srfl  (5  U/µl)  1 
T4  DNA  ligase  (4  U/µl)  1 
The  ligation  mix  was  mixed  gently  and  incubated  at  room  temperature  for  1  h,  then 
incubated  at  65°C  for  10  min,  transformed  into  E.  coli  and  a  blue-white  screen  was 
performed  (section  2.10.3). 
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2.9.2  Standard  cloning  protocol 
2.9.2.1  DNA  preparation 
Vector  and  insert  DNA  were  subjected  to  restriction  endonuclease  digestion  to  obtain 
complimentary  cohesive  overhangs  and  the  resultant  fragments  were  gel  purified.  DNA 
concentrations  were  estimated  according  to  section  2.4  and  ratios  determined  as  follows: 
100  ng  vector  X  ?  Kb  Insert  =?  ng  insert  DNA  to  every  100  ng  vector  for  a  1:  1  ratio 
?  Kb  vector 
Insert:  Vector  ratios  of  1:  1  and  3:  1  were  commonly  used. 
2.9.2.2  Ligation  strategies 
Ligation  reactions  were  performed  in  a  total  volume  of  10  µl  using  3  units  of  T4  DNA 
ligase  (Promega,  USA)  and  Promega  ligase  buffer.  After  incubation  at  16°C  for  18  h  the 
reactions  were  transferred  to  4°C  for  2  h.  The  ligase  was  inactivated  by  heating  to  70°C 
for  10  min  and  the  products  stored  at  -20°C  until  use. 
2.9.2.3  Ligation  ExpressTM  Kit 
The  ligation  was  performed  according  to  the  manufacturer's  instructions  (Clontech). 
Compatible  vector  and  insert  termini  were  prepared  and  ratios  calculated  as  described 
previously  (section  2.9.2.1).  Approximately  300  ng  of  total  DNA  was  used  per  reaction 
(maximum  volume  of  DNA  solution  was  7  µl).  To  the  DNA  10  µl  of  plasmid  ligation 
buffer,  1.2  µl  of  ATP  (10  mM)  and  1  µl  of  T4  DNA  ligase  (100  U)  were  added.  The 
total  volume  was  13.2-20  µl.  After  thorough  mixing  the  reaction  was  incubated  for  30 
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min  at  16°C.  To  this,  1  µl  of  glycogen  (20  µg),  85  µl  of  distilled  water  and  250  µl  of 
ethanol  100%  were  added.  The  DNA  was  precipitated  using  a  dry  ice/ethanol  bath  for 
30-60  min  and  the  DNA  recovered  by  centrifuging  at  19,000  xg  in  a  Biofuge  (Rotor 
HFA  14.2).  After  careful  removal  of  the  supernate  the  pellet  was  briefly  air-dried  and  a 
wash  in  ethanol  70%  (v/v)  was  performed  to  remove  salts.  The  DNA  was  resuspended 
in  5  µl  of  distilled  water  and  stored  at  -20°C. 
2.10  Standard  transformation 
2.10.1  Preparation  of  electroporation-competent  cells 
An  overnight  culture  of  E.  coli  was  diluted  1  in  100  in  500  ml  of  LB  in  a  2-L  dimpled 
flask.  The  flask  was  shaken  vigorously  at  37°C  until  an  OD%600nm  of  0.6-1.0  was 
obtained.  The  flask  was  then  chilled  on  ice  and  cells  harvested  at  5,000  xg  for  15  min  in 
a  Sorvall  superspeed  (rotor  GS-3) 
. 
The  resultant  bacterial  pellet  was  resuspended  in 
500  ml  of  cold  sterile  distilled  water  and  centrifuged  as  described  previously.  The  cell 
pellet  was  then  resuspended  in  250  ml  of  cold  sterile  water,  centrifuged  as  before  and 
resuspended  in  10  ml  of  cold  sterile  glycerol  10%  (v/v).  Following  a  final  centrifugation 
the  cells  were  resuspended  in  1.5  ml  of  cold  sterile  glycerol  10%  (v/v)  and  100  tl 
aliquots  were  snap  frozen  in  liquid  nitrogen.  Cells  remained  cold  (on  ice)  at  all  times 
during  the  procedure  and  were  stored  at  -70°C. 
2.10.2  Electroporation  procedure 
Prior  to  electroporation,  a  0.2  cm  electroporation  cuvette  (Flowgen,  UK))  and  the  safety 
chamber  were  chilled  at  -20°C.  To  the  cold  cuvette,  1-5  µl  of  DNA  (ligation  mix  or 
plasmid  preparation)  and  40  µl  of  competent  cells  were  added.  The  mixture  was  shaken 
to  the  bottom  of  the  cuvette  and  a  Bio-Rad  Gene  Pulser  (model  1652078,  Bio-Rad 
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laboratories,  UK)  set  at  2.5  KV,  25  RFD  was  connected  to  a  Bio-Rad  pulse  controller 
(model  1652098)  set  to  200  Q.  The  cells  were  pulsed  once  to  give  a  time  constant  of  4- 
5  msec.  Immediately  following  electroporation,  1  ml  of  prewarmed  SOC  medium  was 
added  and  the  cells  incubated  at  37°C  without  shaking  for  1  h. 
2.10.3  Blue-white  screening  of  recombinants 
Following  incubation  of  the  transformed  cells  in  SOC,  80  µl  was  spread  onto  pre- 
warmed  LB  agar  plates  containing  appropriate  antibiotics,  2  µg/ml  of  isopropyl  ß-D- 
thiogalactopyranoside  (IPTG)  (Sigma)  and  40  µg/ml  of  5-bromo-4  chloro-3-indolyl-ß- 
D-galactodisase  (X-GAL)  (Sigma).  To  allow  recovery  of  recombinants  from  low 
efficiency  transformations,  the  remaining  SOC  was  centrifuged  and  the  cell  pellet  was 
resuspended  into  150  tl  of  SOC  and  spread  onto  another  plate.  The  plates  were  then 
incubated  at  37°C  overnight.  Resultant  white  colonies  (potentially  containing  insert), 
due  to  disruption  of  vector  encoded  ß-galactosidase,  were  cultured  and  plasmid  DNA 
prepared  according  to  section  2.2.2.  Plasmid  DNA  was  analysed  by  endonuclease 
digestion  (section  2.6)  for  the  presence  of  an  insert. 
2.11  Southern  blotting 
The  composition  of  all  solutions  is  described  in  Appendix  I.  Unless  otherwise  stated  all 
reagents  were  supplied  by  Boehringer  Mannheim.  The  samples  to  be  analysed  were 
electrophoresed  on  an  ethidium  bromide-stained  agarose  gel.  The  gel  was  then  floated  in 
denaturing  solution  for  45  min,  followed  by  soaking  for  30  min  in  neutralising  solution. 
The  gel  was  then  blotted  overnight  by  capillary  action  onto  nylon  membrane  (Hybond 
N+,  Amersham  Pharmacia  Biotech,  UK).  After  blotting  overnight,  the  nylon  membrane 
was  removed  and  the  DNA  was  crosslinked  to  the  membrane  using  a  UV  crosslinker 
(Spectrolinker  XL-1000,  Spectroline,  New  York,  USA).  The  membrane  was  then 
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prehybridised  for  a  minimum  of  4h  in  a  rolling  hybridisation  oven  (model  HB-1D, 
Techne,  Cambridge,  UK)  with  at  least  20  ml  of  prehydridising  solution.  The 
temperature  of  the  oven  was  set  within  the  range  50°C  and  68°C  depending  on  the 
desired  specificity.  This  temperature  was  maintained  for  the  subsequent  hybridisation 
and  washing  steps  (see  below). 
2.11.1  Preparation  of  digoxigenin-labelled  probes 
Template  DNA  was  excised  from  an  agarose  gel  with  a  sterile  scalpel.  Extraction  was 
done  by  the  Qiaex®II  method  and  the  concentration  of  DNA  estimated  as  described  in 
section  2.4.  The  random  priming  method  was  utilised  as  described  in  The  DIG  System 
User's  Guide  for  Filter  Hybridisation  (Boehringer  Mannheim).  Briefly,  approximately 
1  µg  of  template  DNA  was  diluted  in  distilled  water  to  a  total  volume  of  15  µl.  The 
DNA  was  denatured  in  a  boiling  water  bath  for  10  min  followed  by  immediate  chilling 
on  ice.  Hexanucleotide  mixture  (10x)  and  dNTP  labelling  mixture  (10x),  2  µl  of  each, 
were  added  to  the  tube  on  ice.  To  the  reaction,  1  µl  of  labelling-grade  Klenow  DNA 
polymerase  was  added  to  a  final  concentration  of  100  U/ml.  After  brief  centrifugation, 
the  reaction  was  incubated  overnight  at  37°C,  then  terminated  by  adding  2  µl  of  EDTA 
(200  mM,  pH  8).  The  contents  of  the  labelling  tube  were  then  added  to  8  ml  of 
prehybridisation  solution  and  stored  at  -20°C.  Denaturation  of  the  probe  was 
performed  for  10  min  in  a  boiling  water  bath  followed  by  immediate  chilling  on  ice. 
2.11.2  Probe  hybridisation 
The  prehybridising  solution  was  discarded  and  the  denatured  probe  immediately  added 
to  the  roller  tube.  Hybridisation  was  performed  for  a  minimum  of  8  h.  The  membrane 
was  washed  at  the  hybridisation  temperature  for  2x  15  min  in  50  ml  of  washing  buffer  1 
followed  by  2x  15  min  washes  in  50  ml  washing  buffer  2. 
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2.11.3  Chemiluminescence  detection 
Detection  was  performed  according  to  the  protocol  described  in  The  DIG  system 
User's  Guide  for  Filter  Hybridisation  (Boehringer  Mannheim).  The  washed  membrane 
was  equilibrated  for  1-5  min  in  wash  buffer.  Antibody  blocking  solution  was  then 
incubated  with  the  membrane  for  30  min.  The  antibody  (anti-DIG  conjugated  to 
alkaline  phosphatase)  was  then  diluted  to  1  in  10,000  in  the  antibody  blocking  buffer 
and  the  membrane  was  then  incubated  for  30  min  in  at  least  20  ml  of  antibody  solution. 
The  membrane  was  then  washed  for  2x  15  min  in  washing  buffer  and  then  equilibrated 
in  detection  buffer  for  5  min.  The  alkaline  phosphatase  substrate  used  (CSPD®)  was 
diluted  to  1  in  100  min  detection  buffer  and  this  was  dripped  onto  the  membrane  prior 
to  sealing  within  a  plastic  sheet,  for  5  min.  The  excess  substrate  was  removed  using  a 
damp  paper  towel  on  the  top  plastic  surface.  The  plastic  was  heat  sealed  and  then 
incubated  at  37°C  for  15-45  min.  The  membrane  was  then  exposed  to  photosensitive 
film  (Kodak,  UK)  for  up  to  24  h,  although  1-4  h  was  usually  sufficient.  After  exposure 
the  autoradiograph  was  immersed  in  developing  solution  (LX24,  Kodak,  UK)  with 
agitation  for  3  min.  The  film  was  then  rinsed  in  water  and  fixed,  with  agitation,  in  Unifix 
(Kodak,  UK)  for  15  min. 
2.12  Automated  DNA  sequencing 
2.12.1  Preparation  of  sequencing  reactions 
Plasmid  and  cosmid  DNA  were  purified  using  the  QIAprep  Miniprep  purification 
system  (section  2.2.2)  and  reaction  mixtures  were  assembled  in  thin-walled  0.5  ml  tubes. 
Terminator  Ready  Reaction  Mix  (Perkin-Elmer,  UK):  8  tl 
Double  Stranded  DNA:  250-500  ng 
Primer  3.2  pmol 
Distilled  water  variable 
Final  Reaction  Volume  20  gl 
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Where  necessary,  5%  DMSO  was  included  for  GC-rich  templates. 
2.12.2  Cycle  sequencing 
The  above  reaction  mixture  was  placed  into  a  thermal  cycler  and  the  following 
parameters  used: 
30  cycles  of 
96°C  30s 
60°C  4  min 
2.12.3  Purification  of  extension  products 
Fluorescently-labelled  extension  products  were  recovered  by  adding  50  µl  of  ethanol 
95%  (v/v)  and  2  µl  of  2M  sodium  acetate  (pH  4.6).  The  tubes  were  mixed  by  hand  and 
incubated  on  ice  for  15  min.  The  tubes  were  then  centrifuged  at  19,000  xg  for  15  min 
using  a  Biofuge  (Rotor  HFA  14.2).  The  ethanol  was  aspirated  and  the  pellet  washed 
with  250  µl  of  ethanol  70%  (v/v)  without  centrfugation.  The  pellet  was  then  dried  at 
room  temperature  for  15  min  and  stored  at  -20°C. 
2.12.4  Running  the  sequencing  gel 
An  Applied  Biosystems  377  or  373  stretch  automated  sequencing  machine  (Perkin 
Elmer,  UK)  was  used  for  all  sequencing  reactions.  The  sequencing  service  at  the 
Molecular  Biology  Support  Unit  (MBSU)  at  the  University  of  Glasgow  performed  the 
gel  run  and  results  were  posted  electronically.  Briefly,  the  dried  pellet  was  resuspended 
by  vortexing  in  4  µl  of  loading  solution  (Perkin-Elmer)  containing  deionised  formamide 
and  50  mM  EDTA  in  the  ratio  5:  1.  The  samples  were  then  heated  to  90°C  for  2  min 
and  placed  on  ice  until  ready  to  load.  A  standard  4.5%  (w/v)  acrylamide  (19:  1 
acrylamide:  bis  acrylamide)  gel  was  used  for  all  reactions.  Occasionally,  primers  and 
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templates  were  posted  to  the  Protein  and  Nucleic  Acid  Chemistry  Laboratory 
(PNACL)  at  the  University  of  Leicester  and  the  reactions  performed  on  site.  Again  the 
results  were  posted  electronically  in  the  form  of  ABI  electropherograms. 
2.13  Analysis  of  sequence 
2.13.1  ABI  PrismTMEdit  View 
ABI  PrismTM  Edit  View  was  used  to  check  the  parameters  used  for  the  gel  run,  to  allow 
the  signal  strengths  to  be  evaluated  and  also  to  allow  the  quality  of  the  sequence  data  to 
be  verified  manually. 
2.13.2  Seqman  II 
Contiguous  sequences  were  generated  using  Seqman  II  (DNASTARTM,  UK).  The  ABI 
electropherograms  were  loaded  into  the  program,  filtered  to  remove  any  low  quality  data 
and  then  assembled  to  generate  a  consensus  sequence.  Finally  any  anomalies  were 
rectified  by  evaluation  of  the  trace  data. 
2.13.3  Genejockey  II 
Genejockey  II  sequence  processor  (Biosoft,  Cambridge,  UK)  was  used  for  a  wide 
variety  of  purposes.  For  example,  nucleotide  sequences  (not  trace  data)  were  aligned, 
translated  or  restriction  sites  identified.  Peptide  sequences  were  also  analysed  as 
appropriate.  For  example,  peptide  plots  could  be  derived  and  amino  acid  sequences 
compared. 
63 Blackburn  P.  E.  Materials  and  Methods 
2.13.4  Internet  tools 
2.13.4.1  National  Center  for  Biotechnology  Information  (NCBI) 
Query  sequences  were  routinely  compared  to  those  at  the  NCBI 
(http:  /  /www.  ncbi.  nlm.  nih.  gov/)  using  the  Basic  Local  Alignment  Tool  (BLAST) 
search  engines.  Sequences  of  interest  were  downloaded  and  manipulated  as  Genejockey 
II  files. 
2.13.4.2  B.  pertussis  genomic  databases  and  tools 
Query  sequences  were  compared  to  the  incomplete  B.  pertussis  genome  database  at: 
(http:  //www.  sanger.  ac.  uk/projects/B_pertussis). 
Contigs  were  searched  using  the  Alpha-powered  BLAST  search  engine  using  the 
TBLASTN  blast  executable at: 
(http:  //www.  sanger.  ac.  uk/Projects/B-pertussis/blast_server.  shtm1). 
Contigs  of  interest  were  downloaded  and  manipulated  as  Genejockey  files. 
The  PEDANT  web  site  was  also  used  to  identify  and  further  characterise  B.  pertussis 
genes.  A  list  of  predicted  open  reading  frames  (ORFs)  can  be  found  at: 
http:  //pedant.  mips.  biochem.  mpg.  de/cgi- 
bin/p2/wwwfly.  pl?  set=Bpertussis&page=index 
All  predicted  membrane  protein  ORFs  were  identified  using  PIR  (protein  function 
identification)  keywords  and  selecting  the  membrane  protein  hyperlink. 
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2.14  Protein  analysis 
Unless  otherwise  stated,  the  composition  of  all  reagents  and  buffers  can  be  found  in 
Appendix  I. 
2.14.1  Fractionation  of  bacterial  cells 
Bacteria  were  harvested  from  500  ml  of  broth  culture  at  5,000  xg  for  15  min  in  a 
Sorvall  superspeed  centrifuge  (rotor  GS-3).  A  suspension  of  pelleted  bacteria  was  made 
in  50  ml  of  envelope  buffer  (10  mM  sodium  phosphate,  pH  7.2).  The  cells  were 
disrupted  using  a  mechanical  cell  disrupter  (One  Shot,  Constant  Systems,  Warwick, 
UK)  set  to  15  Kpsi.  The  resultant  lysate  was  centrifuged  at  2500  xg  for  5  min  in  a 
Sorvall  superspeed  centrifuge  (rotor  SS34)  to  pellet  large  debris,  unbroken  cells  and 
insoluble  material.  The  supernate  was  centrifuged  in  a  Sorvall  ultracentrifuge  (OTD- 
COMBI)  at  100,000  xg  for  45  min.  The  resulting  supernate  contained  the  soluble 
content  of  the  cytoplasm  and  periplasm.  The  pellet  obtained  from  this  centrifugation, 
which  contained  cell  envelopes,  was  rinsed  in  envelope  buffer  and  the  tubes  dried  upside 
down  on  tissue  paper  for  10  min.  It  was  then  resuspended  in  0.5  ml  of  envelope  buffer 
containing  sodium  N-laurlylsarcosinate  (sarcosyl)  0.5%  (w/v)  and  then  mixed  by 
vortexing  every  5  min  for  30  min  to  differentially  solubilise  the  cytoplasmic  membrane 
proteins.  A  further  centrifugation  was  performed  as  described  previously.  The  final 
supernate  contained  the  inner  membrane  proteins  and  the  final  pellet  (outer  membrane) 
was  resuspended  in  0.5  ml  envelope  buffer  containing  sarcosyl  0.5%  (w/v)  which  could 
be  solubilised  in  protein  loading  dye  (section  2.15.8). 
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2.15  Expression  of  recombinant  proteins 
2.15.1  Expression  of  IPTG-induced  recombinant  proteins 
An  overnight  culture  of  E.  coli  strains  containing  expression  constructs  (Tables  4  and  6), 
was  diluted  1  in  100  in  2L  of  2X  YT  or  LB  containing  appropriate  antibiotics.  The 
culture  was  then  shaken  vigorously  at  37°C  until  an  OD%650nm  of  0.5-0.8  was 
obtained.  IPTG  was  then  added  to  a  concentration  of  1  mM  and  the  culture  again 
shaken  at  37°C  for  5  h.  Cells  were  harvested  at  5,000  xg  for  15  min  in  a  Sorvall 
superspeed  centrifuge  (rotor  GS-3). 
2.15.2  Expression  of  proteins  in  pBAD/gIII 
An  overnight  culture  of  E.  coli  strain  LMG194  containing  pBAD(PCT1)  (Table  4),  was 
diluted  1  in  100  into  2L  of  minimal  medium  containing  0.2%  (w/v)  glucose  and  100 
µg/ml  ampicillin.  The  culture  was  shaken  vigorously  at  37°C  to  an  OD?.  650nm  of 
approximately  0.5.  L-arabinose  was  added  to  the  flask  to  a  final  concentration  of  0.02% 
(w/v)  and  the  culture  returned  to  37°C  with  vigorous  shaking  for  3  h.  Cells  were 
harvested  at  5,000  xg  for  15  min  in  a  Sorvall  Superspeed  centrifuge  (rotor  GS-3). 
2.15.3  Urea  extraction  of  inclusion  bodies 
After  expression  of  recombinant  protein  as  described  above,  the  entire  culture  was 
centrifuged  at  5,000  xg  for  15  min  in  a  Sorvall  Superspeed  centrifuge  (rotor  GS-3)  The 
cell  pellet  was  resuspended  in  20  ml  of  Buffer  A  (Appendix  I).  The  cell  suspension  was 
disrupted  using  a  One-Shot  cell  disrupter  and  the  resultant  lysate  was  centrifuged  at 
17,000  xg  in  a  Sorvall  Superspeed  centrifuge  (rotor  SS34)  for  30  min  to  allow  inclusion 
bodies  to  be  pelleted.  Such  pellets  were  resuspended  in  10  ml  of  Buffer  B  (Appendix  I) 
and  inclusion  bodies  solubilised,  with  tube  rotation,  for  24  h  or  until  the  suspension 
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cleared.  A  final  ultracentrifugation  step  of  100,000  xg  for  3h  was  performed  and  the 
supernate,  containing  urea-soluble  protein,  was  retained  and  stored  at  -20°C. 
2.15.4  Large-scale  affinity  purification 
An  8m1  Omni  column  (Omnitech,  Cambridge,  UK)  containing  8  ml  of  Nickel-agarose 
(Qiagen)  was  attached  to  an  automated  Fast  Protein  Liquid  Chromatography  (FPLC) 
apparatus  (Controller  LCC501,  Pharmacia  biotech)  and  equilibrated  with  Buffer  B  at  1 
ml/min  for  1  h.  A  supercoil  was  then  used  to  load  8  ml  of  urea-soluble  fraction  (section 
2.15.3)  onto  the  column.  Buffer  B  was  used  to  wash  non-his-tagged  proteins  from  the 
column  until  the  spectrophotometer  (A280nm)  detected  no  proteins  in  the  flow-through. 
The  column  was  washed  with  Buffer  C,  followed  by  Buffers  D  and  E  (Appendix  I). 
Each  buffer  was  pumped  through  the  column  until  no  further  protein  was  detected  on 
the  spectrophotometer.  Proteins  represented  by  sharp  peaks  were  collected  into 
separate  containers.  All  fractions  were  retained  and  analysed  by  SDS-PAGE. 
2.15.5  Small-scale  affinity  purification 
Purification  was  performed  according  to  the  Ni-NTA  spin  kit  (Qiagen),  and  the  method 
was  adapted  from  that  described  in  the  manufacturer's  handbook.  Briefly,  a  Ni-NTA 
column  was  equilibrated  with  600  gl  of  Buffer  B  by  centrifugation  at  700  xg  for  2  min 
and  discarding  the  flow  through.  To  the  column,  600  gl  of  urea-soluble  protein  was 
added  and  centrifugation  performed  as  before.  The  column  was  then  washed  three  times 
with  600  gl  of  Buffer  C.  The  protein  was  eluted  twice  in  200  µl  of  Buffer  E  and  the 
eluates  combined. 
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2.15.6  Dialysis 
Dialysis  tubing  with  a  molecular  weight  cut-off  of  12-14  KDa  was  stored  in  ethanol 
100%  and  boiled  in  distilled  water  immediately  before  use.  The  sample  was  loaded  into 
the  tubing,  which  was  sealed  with  mediclips  and  placed  into  1000  volumes  of  dialysis 
buffer  (phosphate-buffered  saline  [PBS]  or  1M  urea  in  PBS).  The  dialysis  was 
performed  overnight  with  stirring  at  4°C. 
2.15.7  Protein  quantification 
The  Pierce  protein  estimation  kit  (Pierce,  USA)  provided  a  colourimetric  method  for 
estimating  protein  concentration,  according  to  the  microtiter  plate  protocol.  Briefly, 
Reagent  A  and  Reagent  B  were  combined  at  a  50:  1  ratio  to  prepare  Working  Reagent. 
Bovine  Serum  Albumin  (BSA)  (Sigma)  and  urea-extracted  test  proteins  were  diluted 
appropriately  (range  10-2000  µg/ml)  and  10  tl  was  added  to  the  microtitre  plate  wells. 
To  each  well  of  a  microtiter  plate  200  µl  of  Working  Reagent  was  added  and  the  plate 
incubated  at  37°C  for  30  min.  The  absorbance  at  562  nm  was  determined  with  a 
microtiter  plate  reader  and  protein  concentrations  estimated  from  a  standard  curve. 
2.15.8  Sample  preparation  for  electrophoresis 
The  sample  was  made  up  to  a  total  volume  of  50  µl  and  10  µl  6x  protein  loading  dye 
(Appendix  I)  was  added.  Samples  were  stored  at  -20°C  until  loading.  Immediately 
before  use,  samples  were  boiled  in  a  water  bath  for  10  min.  A  10  KDa  protein  ladder 
(Gibco  BRL)  was  used  according  to  the  manufacturer's  instructions. 
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2.15.9  SDS-PAGE 
Sodium  dodecyl  sulphate  polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was 
performed  according  to  the  method  of  Laemmli  (1970)  in  a  vertical  electrophoresis  gel 
tank  (model  SE600,  Hoefer  Scientific  Instruments,  California,  USA).  The  composition 
of  all  solutions  can  be  found  in  Appendix  I.  Glass  plates  were  assembled  according  to 
the  manufacturer's  instructions.  Resolving  gels,  containing  7.5-14%  acrylamide,  were 
poured  between  the  assembled  plates  until  the  gel  was  4cm  below  the  top  of  the  plates 
and  ethanol  100%  was  used  as  an  overlay.  The  gel  remained  undisturbed  for 
approximately  1h  at  room  temperature  until  set.  The  ethanol  was  poured  off  and  the 
gel  surface  washed  with  distilled  water.  A  stacking  gel  containing  6%  acrylamide  was 
poured  onto  the  polymerised  separating  gel  and  a  comb  was  placed  into  the  gel  solution. 
Again  the  gel  was  left  for  approximately  1h  at  room  temperature  and  the  comb 
removed.  The  wells  were  immediately  filled  with  lx  electrode  buffer  and  assembled  into 
the  electrophoresis  gel  tank.  The  lower  buffer  reservoir  was  stirred  with  a  magnetic 
stirrer  during  vertical  gel  electrophoresis.  The  gel  was  run  at  20  mA  until  the  gel  entered 
the  separating  (lower)  gel  when  the  current  was  increased  to  30  mA.  The  gel  was 
removed  when  the  tracker  dye  reached  the  bottom  of  the  separating  gel  (approximately 
3  h).  The  gel  was  removed  from  the  plates  and  stained  or  blotted  as  appropriate.  For 
staining  Coomassie  blue  stain  (Appendix  I)  was  utilised,  for  a  minimum  of  2h  on  a 
rotating  platform.  The  stain  was  then  replaced  with  destain  solution  until  the 
background  was  decolourised. 
2.16  Western  blots 
2.16.1  Blotting  protocol 
After  SDS-PAGE,  proteins  were  transferred  to  immobilising  nitrocellulose  membrane 
(Hybond-C,  Amersham  Pharmacia  Biotech)  according  to  the  method  described  by 
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Towbin  et  al.  (1979).  Briefly,  the  stacking  gel  was  removed  and  the  separating  gel 
soaked  in  electroblotting  buffer  (Appendix  I)  for  5  min.  The  blot  was  then  assembled 
and  placed  in  electroblotting  apparatus  (Trans-Blot  Cell,  Bio-Rad,  USA)  containing 
electroblotting  buffer  with  magnetic  stirring. 
2.16.2  Development  of  blots 
After  transfer  onto  the  membrane,  proteins  were  visualised  by  staining  in  Ponceau  S 
solution  (Sigma)  for  5  min.  Background  was  removed  by  destaining  in  water  for  2  min 
and  the  position  of  the  molecular  weight  markers  marked  with  indelible  ink.  The 
membrane  was  then  destained  in  PBS  for  10  min  and  incubated  in  blocking  buffer 
(Appendix  I)  for  1h  at  room  temperature  with  gentle  agitation.  Primary  antibody  was 
diluted  appropriately  in  blocking  buffer  and  incubated  with  the  membrane  for  1h  at 
room  temperature.  The  membrane  was  then  washed  for  15  min  in  2  changes  of  PBS  at 
room  temperature.  Horse  radish  peroxidase-conjugated  secondary  antibody  (anti-mouse 
or  anti-rabbit  as  appropriate,  Scottish  Antibody  Production  Unit,  UK)  was  then  diluted 
1  in  1000,  added  to  the  membrane  and  incubated  for  1h  at  room  temperature.  Again  the 
membrane  was  washed  for  2x  15  minutes  in  PBS  at  room  temperature.  The  membrane 
was  then  immersed  in  freshly  prepared  3,3'diaminobenzidine  (DAB)  (Sigma)  solution 
for  approximately  2  min  and  the  staining  reaction  stopped  by  washing  in  distilled  water. 
2.17  RNA  analysis 
2.17.1  Extraction  of  total  RNA  from  B.  pertussis 
B.  pertussis  cells  were  harvested  from  mid-log  phase  culture  in  CL  medium  by 
centrifugation  at  8,000  xg  for  15  min  in  a  Sorvall  superspeed  (rotor  GS-3).  Guanidine 
thiocyanate  (Sigma),  10  volumes,  were  added  to  1  volume  of  bacterial  pellet  and  the 
bacteria  resuspended  by  vortexing.  The  cells  were  lysed  with  a  mechanical  cell 
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disrupter.  The  lysed  cells  were  then  added  to  an  equal  volume  of  acid  phenol  (Tris- 
buffered,  pH  4.5,  Sigma)  and  heated  to  60°C  for  10  min.  The  reaction  mixture  was 
cooled  to  room  temperature  and  0.5  volumes  of  chloroform  was  added.  The  mixture 
was  then  shaken  vigourously  by  hand  for  2-3  min  and  centrifuged  for  15  min  at  12,000  x 
g  at  4°C  (megafuge,  Rotor:  HFA  14.2).  The  aqueous  phase  was  then  removed,  added  to 
an  equal  volume  of  isopropanol  and  left  at  room  temperature  for  10  min.  The  RNA  was 
pelleted  by  centrifugation  as  previously  described  and  washed  with  ethanol  70%  (v/v). 
The  RNA  was  then  resuspended  in  DEPC-treated  water  (Appendix  I)  and  heated  to 
70°C  for  10  min  to  aid  solubilisation  of  the  RNA.  The  RNA  was  then  stored  at  -70°C 
until  used. 
2.17.2  Reverse  transcription-PCR 
Reverse  transciption-PCR  (RT-PCR)  was  performed  using  the  Access  Kit  (Promega, 
UK)  according  to  the  manufacturers'  instructions  using  a  single  tube  reaction.  The 
following  components  were  assembled  in  a  thin-walled  0.5  ml  tube,  on  ice. 
RI 
Nuclease  free  water  30 
AMV/Tf  5x  reaction  buffer  10 
dNTP  Mix  (10  mM  each  dNTP)  1 
Primer  1  (50  pmol/ml)  1 
Primer  2  (50  pmol/ml)  1 
25mM  MgSO4  2 
AMV  reverse  transcriptase  1 
Tfl  DNA  polymerase  (5  u/µl)  1 
RNA  sample  (0.25  mg/µl)  3 
Final  volume  50 
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The  above  reaction  was  thermocycled  as  follows: 
First  Strand  cDNA  Synthesis 
1  cycle  48°C  45  min 
1  cycle  94°C  2  min 
Second  Strand  cDNA  Synthesis  and  PCR  Amplification 
40  cycles  94°C  30  s 
55°C  1  min 
68°C  1  min 
1  cycle  68°C  7  min 
The  products  were  analysed  by  agarose  gel  electrophoresis  according  to  section  2.3 
2.18  In  vivo  tests 
2.18.1  Preparation  of  antigens 
Crude  urea  extracts  or  His-purified  preparations  were  dialysed  into  1M  urea  (all 
carboxy  terminal  portions)  or  PBS  (all  other  recombinant  proteins).  These  test  antigens 
were  diluted  to  75  µg/ml  in  PBS  containing  1.5  mg/ml  alhydrogel.  Purified  P.  69  antigen 
(Smithkline  Beecham,  batch  PAC  031)  was  also  diluted  to  75  µg/ml  in  PBS/alhydrogel. 
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2.18.2  Active  immunisation 
Randomised  groups  of  male  CD1  mice  (Harlan  Olac,  Bicester,  Oxfordshire,  UK)  aged  3- 
4  weeks,  were  injected  subcutaneously,  under  light  halothane  anaesthesia,  with  15  µg  of 
test  antigen  per  mouse.  One  group  of  mice  was  vaccinated  with  1/10th  human  dose  of  a 
tricomponent  acellular  vaccine  (P.  69,  FHA,  PT)  obtained  from  Smithkline  Beecham 
(Batch  DPSK  315A2).  Another  group  of  mice  received  only  alhydrogel  in  PBS  and  a 
further  control  group  was  left  unvaccinated.  For  each  test  group,  a  second  dose,  as 
above,  was  administered  after  a  two  week  interval.  The  weight  of  the  mice  was  recorded 
prior  to  the  vaccinations  and  at  intervals  afterwards  to  check  for  toxicity  of  the  antigen 
preparation.  The  group  size  in  each  instance  was  5  mice. 
2.18.3  Mouse  intranasal  challenge 
B.  pertussis  18-323  or  Taberman  was  grown  as  a  lawn  on  BG  plates  in  a  humidified  box 
at  37°C  for  24  h.  The  resultant  growth  was  suspended  in  1%  casamino  acids  solution 
(Appendix  I)  and  adjusted  to  10  opacity  units  (approx  2x  109  cfu/ml)  by  comparison 
with  the  5t'  International  Reference  of  Opacity  (Perkins  et  al.,  1973).  The  challenge 
suspension  of  2x107  cfu/ml  was  prepared  by  diluting  1  in  100  in  1%  casamino  acids  and 
a  sublethal  dose  of  1x106  cfu/mouse  (50  µl)  was  instilled  intranasally  under  light 
halothane  anaesthesia  at  seven  days  after  the  second  vaccination.  One  control  group 
was  challenged  with  casamino  acids  only.  The  weight  of  the  mice  was  recorded  prior  to 
challenge  and  at  intervals  up  to  seven  days  post-challenge.  The  mice  were  sacrificed 
using  a  carbon  dioxide  chamber  and  the  lungs  removed  aspetically.  The  lungs  were  then 
homogenised  in  10  ml  of  1%  casamino  acids  using  a  sterile  homogeniser  (Silverson 
machines,  UK).  The  samples,  0.1  ml  of  both  neat  and  a1  in  100  dilution,  were  cultured 
on  BG  agar  at  37°C  in  a  humidified  box.  Colonies  were  counted  after  72  h. 
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2.18.4  Statistical  analysis  of  lung  count  data 
The  number  of  colony  forming  units  per  lung  was  extrapolated  from  the  colony  counts 
obtained  on  BG  agar  plates.  Nominal  values  of  20  and  107  were  given  to  counts  outside 
the  detection  limits  <100  and  >3x106  respectively.  The  loglo  counts  were  calculated  and 
analysed  using  Minitab  statistical  analysis  package  (version  12).  Analysis  included 
calculation  of  the  means  and  95%  confidence  limits,  one-  and  two-way  analysis  of 
variance  and  Tukey's  pairwise  comparisons. 
2.18.5  Antibody  production 
Groups  of  5  mice  were  injected  twice  subcutaneously  as  detailed  in  section  2.18.2.  The 
groups  of  mice  which  had  not  been  challenged  were  sacrificed  one  week  after  the  second 
vaccination  and  exsanguinated.  The  blood  was  allowed  to  clot  at  37°C  for  1h  and  was 
then  removed  from  the  side  of  the  collection  tube  and  placed  at  4°C  overnight.  The  sera 
were  cleared  by  centrifugation  at  4,000  xg  for  10  min  in  a  Biofuge  (Rotor  HFA  14.2) 
and  stored  at  -20°C  in  200  tl  aliquots. 
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3.1  Discovery  of  a  prn-like  sequence 
Prior  to  this  project  being  undertaken,  Roberts  et  al.  had  identified  an  840  bp  amplicon, 
designated  MR30,  obtained  when  primers  were  directed  to  the  3'  C-terminal  encoding 
domain  of  pertactin  on  B.  pertussis  (strain  BBC29)  genomic  DNA  (M.  Roberts, 
personal  communication).  The  MR30  amplicon  was  then  cloned  into  pGEMT  to 
generate  pGemT(30).  The  cloned  MR30  amplicon  had  previously  been  found  to  have  a 
restriction  pattern  different  to  that  predicted  for  prn.  Specifically,  MR30  contained  an 
EcoRI  site  which  was  not  predicted  for  prn.  pGEMT(30)  had  been  digested  with  EcoRI 
and  a  resultant  640  bp  fragment  was  subcloned  to  produce  pCRII(640).  Partial  manual 
sequencing  had  confirmed  that  the  MR30  sequence  was  different,  yet  similar,  to  prn 
(GenBank  accession  number  J04560)  and  may  represent  part  of  a  similar  gene  (Castro, 
Coote,  Parton;  unpublished  observation).  Plasmids  pGemT(30)  and  pCRII(640)  were 
provided  at  the  start  of  the  project  and  some  preliminary  manual  sequencing  data  was 
also  available. 
3.1.1  Sequencing  of  MR30 
Automated  sequencing  was  performed  on  pGemT(30)  and  pCRII(640)  using  vector 
directed  primers  M13FOR  and  M13REV  (Table  5).  As  the  average  read  length  was 
approximately  300  bp  per  reaction  at  this  time,  both  plasmids  were  sequenced  in  both 
directions  to  allow  overlapping  sequence  to  be  obtained.  The  resultant  sequences 
derived  from  the  electropherograms  were  assembled  to  generate  a  contiguous  sequence 
using  Seqman  II  (DNASTARTM).  Each  sequencing  reaction  was  performed  in  duplicate 
and  the  electropherograms  were  edited  manually  prior  to  assembly.  The  contig  was 
assembled  according  to  Figure  4.  Alignment  of  the  MR30  consensus  sequence  with  the 
predicted  prn  amplicon  using  GeneJockey  II  can  be  seen  in  Figure  5.  The  MR30 
amplicon  sequence  was  56%  identical  to  the  pm  3'  DNA  (when  the  primer  site  was 
disregarded).  The  sequence  obtained  for  MR30  was  compared  to  those  available  at 
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Genbank  using  BLASTn  and  at  the  time  (1997)  did  not  correspond  with  previously 
published  sequences.  It  was  assumed  that  the  MR30  sequence  was  part  of  a  gene  with 
similarity  to,  but  distinct  from,  prn. 
The  remainder  of  the  potential  open  reading  frame  was  then  investigated.  The  MR30 
sequence  had  not  been  amplified  using  high  fidelity  DNA  polymerase  and  this  sequence 
had  therefore  to  be  confirmed  using  unamplified  DNA.  The  sequences  that  the  primers 
annealed  to  during  the  PCR,  would  be  similar,  but  not  necessarily  identical,  to  prn. 
76 Figure  4:  A  schematic  overview  of  the  strategy  used  to  obtain  the  sequence  of  the 
MR30  amplicon.  The  sequence  names  are  given  at  the  left  of  the  arrows  in  the  box. 
FOR  sequences  were  obtained  with  the  M13FOR  and  REV  sequences  were  obtained 
with  M13  REV.  Each  arrow  represents  the  results  of  one  sequencing  reaction. Blackburn  P.  E. 
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3.1.2  Screening  a  cosmid  library  using  P640 
The  pCRII(640)  subclone  was  cut  using  EcoRI  to  generate  a  640  bp  fragment  which 
was  then  used  as  a  template  for  production  of  a  digoxigenin-labelled  Southern  blot 
probe,  P640,  to  enable  screening  of  a  B.  pertussis  (Taberman)  genomic  cosmid  library 
prepared  previously  (Brownlie  et  al.  1986).  Cosmid  DNA  was  extracted  from  each  of 
the  five  hundred  clones  in  the  library  by  pooling  5  overnight  cultures  (1  ml  of  LB 
containing  10  mg/ml  tetracycline)  prior  to  cosmid  extraction.  Dot  blots  were  performed 
at  high  stringency  (68°C)  with  the  P640  probe.  Cosmids  from  the  pools  that  hybridised 
to  P640  were  then  analysed  individually.  Subsequent  Southern  blots  revealed  many 
false  positive  hybridisation.  Ultimately  one  clone,  labelled  cosmid  3,  which  was 
positive  with  P640  was  selected  for  further  analysis. 
3.1.3  Subcloning  of  cosmid  3 
To  obtain  large  amounts  of  cosmid  3  for  further  analysis,  plasmid  DNA  was  prepared 
from  200  ml  of  an  overnight  culture  of  the  E.  coli  clone  containing  cosmid  3.  Cosmid  3 
DNA  was  then  cut  with  several  different  restriction  enzymes  and  the  fragments  probed 
in  Southern  blots  using  probe  P640  to  identify  positive  fragments.  These  fragments 
were  then  subcloned  to  provide  suitable  DNA  to  allow  confirmation  of  the  MR30 
sequence  and  flanking  sequences.  The  restriction  enzyme  pattern  of  cosmid  3  can  be 
seen  in  Figure  6a.  A  Southern  blot  of  the  gel  shown  in  Figure  6a  hybridised  with  probe 
P640  is  seen  in  Figure  6b.  The  probe  hybridised  to  bands  of  5.2  Kb  and  9.3  Kb 
following  incubation  of  cosmid  3  with  Notl  and  MIO. 
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respectively.  The  lanes  containing  DNA  treated  with  Apal  and  Xhol  restrictions  also 
contained  bands  which  hybridised  with  P640,  although  the  size  of  these  fragments  was 
not  determined. 
The  5.2  Kb  Notl  fragment  that  was  positive  by  Southern  blot  (lane  1,  Figure  6a)  was 
excised  and  gel  purified  and  named  "PEB  P.  A  1:  1  and  3:  1  ratio  of  insert  :  vector  was 
used  to  ligate  the  fragment  into  the  Nod  site  of  pGEM5Zf  using  the  standard  ligation 
protocol.  The  ligation  mixes  were  introduced  into  E.  coli  strain  JM109  cells  by 
electroporation  and  a  blue-white  screen  performed.  The  3:  1  ratio  resulted  in  55  blue 
colonies  and  11  white  colonies.  The  1:  1  ratio  gave  80  blue  colonies  and  4  white  colonies. 
Ten  white  colonies  were  selected  and  their  plasmids  extracted.  The  plasmids  were 
checked  for  the  presence  of  an  insert  by  redigestion  with  Notl.  The  PEB1  insert  was 
confirmed  by  hybridisation  to  P640.  One  clone  was  then  selected  for  further  analysis 
and  named  "pGEM(PEB  1)". 
3.1.4  Sequencing  of  pGEM(PEB1) 
At  the  time  of  this  study,  the  B.  pertussis  genome  sequence  was  not  available  and 
automated  sequencing  was  less  routine  and  of  less  effectiveness  compared  to  modem 
technology.  As  a  result,  and  combined  with  the  GC-rich  nature  of  the  template,  the 
sequencing  was  laborious  and  time  consuming. 
Initially,  primers  PEBIFOR17  and  PEBIREV4  were  designed,  based  on  the  MR30 
sequence.  Vector  (pGEM5Zf)-directed  primers  M13FOR  and  M13REV  were  also  used 
for  sequencing.  Automated  sequences  were  obtained  and  new  primers  were  designed  for 
a  gene  walking  strategy.  The  nucleotide  sequence  of  the  oligonucleotides  used  are  shown 
in  Table  5.  Approximately  100  bp  of  overlapping  sequence  was  generated  between 
individual  sequence  reads  to  allow  contigs  to  be  assembled  using  Seqman  II. 
82 Figure  7:  A  overview  of  the  gene  walking  strategy  used  to  generate  the  consensus 
sequence  of  PEB  1.  The  names  of  the  primers  are  listed  at  the  left  of  each  sequencing 
reaction.  The  numbers  in  the  brackets  are  the  range  of  sequence  which  was  of  medium 
quality  according  to  Seqman  II.  Each  arrow  represents  a  sequencing  reaction,  the  solid 
arrows  are  forward  reactions  and  the  dashed  arrows  are  reverse  reactions. Blackburn  P.  E.  Results 
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Problems  were  encountered  with  some  of  the  sequencing  reactions  which  resulted  in 
very  low  sequence  quality,  which  was  probably  due  to  the  very  high  GC  content  of  the 
template  DNA.  Such  difficulties  were  overcome  either  by  redesigning  the  primers, 
adding  DMSO  (final  concentration  5%  v/v)  or  increasing  the  denaturing  time  to  40  s. 
The  majority  of  the  pGEM(PEB1)  insert  was  sequenced  in  duplicate  using  both  DNA 
strands.  The  gene  walking  strategy  used  to  generate  the  contig  is  depicted  in  fig  7.  The 
edited  consensus  sequence  was  edited  by  manual  inspection  of  electropherograms  and  is 
shown  in  appendix  II. 
3.1.5  Analysis  of  pGEM(PEB1)  sequence 
The  5.2  Kb  PEB  I  consensus  sequence  was  compared  to  other  sequences  in  GenBank 
using  the  BLASTn  search  engine.  Such  analysis  revealed  that  the  sequence  had  not  been 
published  but  confirmed  that  it  was  similar  to  those  of  prn,  brkA  and  tcf.  In  addition  to 
sequence  corresponding  to  MR30,  the  pGEM(PEB  I)  insert  also  contained  some  cosmid 
sequence.  The  B.  pertussis  genomic  library  had  been  constructed  using  partial  EcoRI 
chromosomal  digests  to  generate  cosmid  inserts  of  approximately  50  Kb.  Such  digests 
appear  to  have  cleaved  the  EcoRI  site  (position  646,  Figure  5)  within  the  proposed  ORF 
and  therefore  cosmid  3  appeared  not  to  contain  the  complete  3'  region.  As  can  be  see  in 
the  alignment  with  the  3'  region  of  the  pertactin  gene  and  MR30  (Figure  5),  it  seemed 
likely  that  the  new  gene  sequence  was  not  complete  and  approximately  200  bases  were 
absent  downstream  from  the  EcoRI  site  at  position  646.  It  was  important  to  confirm 
the  MR30  sequence  that  was  missing  from  the  cosmid  insert  using  unamplified  DNA 
and  to  obtain  the  sequence  that  the  3'  primer  had  annealed  to  during  this  amplification. 
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3.1.6  Retrieval  of  the  3'  sequence  of  MR30 
3.1.6.1  Rescreening  of  cosmid  library 
The  B.  pertussis  genome  library  was  again  screened,  this  time  with  a  200  bp  probe 
(P200)  which  was  prepared  from  the  smaller  EcoRI  fragment  of  pGEMT(30)  (Figure  4). 
Almost  every  cosmid  pool  tested  appeared  positive  when  this  probe  was  used.  Such 
background  was  probably  due  to  the  size  and  GC  content  of  this  region.  Thus,  it  was 
not  possible  to  identify  a  cosmid  that  genuinely  contained  the  sequence  of  interest. 
3.1.6.2  pUC-ligated  single  specific  primer-PCR 
Chromosomal  B.  pertussis  (Taberman)  DNA  (0.5  µg)  was  digested  with  either  PstI, 
ApaI,  XhoI,  Hindu  !  or  NdeI  and  ligated  to  pUC  18  (0.75  µg,  predigested  with 
appropriate  enzyme)  to  form  five  gene  libraries  to  serve  as  templates  for  SSP-PCR. 
Primer  combinations  M13FOR/PEBIFOR16  and  M13REV/PEBIFOR16  (Table  5  and 
Figure  7)  were  used  with  an  annealing  temperature  of  53°C.  The  Hind!!!  library  SSP- 
PCR  produced  two  bands  for  both  primer  sets.  This  suggested  that  target  DNA  had 
been  cloned  into  pUC  18  in  both  directions.  These  bands  were  cloned  into  pCRII  and 
their  sequences  determined.  It  appeared  that  the  primer  PEBIFOR16  was  annealing  to 
two  positions  within  one  Hindu  fragment.  Unfortunately,  the  sequences  obtained  were 
not  similar  to  that  obtained  from  MR30  and  it  was  not  possible  to  obtain  an  amplicon 
that  contained  the  sequence  of  interest. 
3.1.6.3  GenomeWalkerTM  SSP-PCR 
The  GenomeWalker  libraries  were  prepared  as  represented  schematically  in  Figure  8 
using  B.  pertussis  strain  Taberman  genomic  DNA.  Nested  SSP-PCR  was  performed  on 
the  gene  libraries  DL1-DL5  according  to  section  2.7.2.  Figure  9  shows  the  results  of  the 
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secondary  PCR  on  the  libraries.  The  fragment  from  the  PvuII  derived  library  (DL3)  of 
approximately  850  bp  (lane3)  was  purified  and  ligated  into  pCRII-TOPO.  This  ligation 
mix  was  then  transformed  into  E.  coli  strain  TOP  10  and  a  blue-white  screen  performed. 
The  2.2  Kb  fragment  from  the  Dral  library  (DL2)  (lane2)  was  cloned  in  the  same  way. 
Plasmids  were  prepared  from  putative  recombinants  (white  colonies)  and  analysed  by 
EcoRl  digestion  to  confirm  the  presence  of  the  EcoRI  restriction  site  within  the  3' 
moiety  of  the  gene.  Figure  10  shows  the  result  of  this  digestion.  Lanes  1,2,6  and  8  all 
have  a  restriction  enzyme  pattern  consistent  with  that  predicted  i.  e.  the  insert  bands  add 
up  to  approximately  2.2  Kb  or  850  bp  as  appropriate.  Lanes  3,4,5  and  7  exhibit 
unexpected  restriction  patterns  for  reasons  unknown.  The  plasmids  analysed  in  lanes  1 
and  6,  named  pCRII(DL2a)  and  pCRII(DL3b)  respectively,  were  chosen  for  sequence 
analysis. 
3.1.6.3.1  Sequence  analysis  of  pCRII(DL2a)  and  pCRII(DL3b) 
Primers  GSP2  and  PEBIFOR17  (Table  5)  were  used  to  determine  the  sequence  of  the 
pCRII(DL2a)  and  pCRII(DL3b)  inserts.  The  consensus  sequence  derived  from  both 
inserts  had  identity  to  that  obtained  from  pGEM(PEB1)  over  381  nucleotides  (bases 
1960-2341,  Figure  5).  In  addition  to  this  overlap,  a  further  383  bases  were  obtained 
(position  2342-2725,  Figure  5)  which  provided  the  3'  sequence  absent  from  the 
subcloned  cosmid.  It  also  confirmed  the  fidelity  of  the  sequence  of  the  MR30  amplicon 
obtained  by  PCR  (100%  identity)  and  ascertained  the  actual  sequence  that  the  3'  primer 
had  annealed  to  during  the  PCR  amplification  that  produced  MR30. 
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Figure  8:  A  schematic  representation  of  the  GenomeWalker  method  used  to  obtain  the 
sequence  of  the  3'  end  of  MR30.  See  section  2.8  for  a  more  detailed  description  of  the 
method. 
87 Figure  9:  The  amplicons  obtained  from  GenomeWalkerTM  secondary  SSP  -  PCR 
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88 Figure  10:  EcoRI  digests  of  pCRII  constructs  containing  SSP-PCR  amplicons.  Note 
that  the  vector  contains  flanking  EcoRI  sites. 
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3.1.7  Identification  of  the  open  reading  frame  (bap-5) 
The  predicted  open  reading  frame  of  the  pertactin-like  sequence  is  shown  in  Figure  12. 
In  view  of  its  sequence  similarity  to  prn  and  genes  encoding  the  three  other  proteins 
now  recognised  as  belonging  to  the  autotransporter  protein  family  (BrkA,  Tcf  and 
Vag8),  the  sequence  was  designated  bap-5  (Bordetella  autotransporter  protein  D.  The 
ORF  was  predicted  using  amino  acid  homology  with  Prn  and  BrkA,  which  begins  at  the 
serine  residue  encoded  at  nucleotide  position  300  (Figure  12).  This  implies  that  the 
methionine  upstream  from  this  sequence  (nucleotide  position  261)  may  be  the 
translational  start.  The  presence  of  upstream  stop  codons  in  this  reading  frame 
(positions  43,103  and  114)  also  infers  that  the  open  reading  frame  begins  at  this  point. 
The  sequence  obtained  was  examined  for  open  reading  frames  by  using  the  TESTCODE 
and  CODONPREFERENCE  programmes  of  the  Genetics  Computer  Group  (1991). 
These  programmes  predicted  that  the  first  methionine  (position  261,  Figure  12)  is  the 
most  likely  translational  start  codon.  The  results  of  this  analysis  can  be  seen  in  Figures 
I  Ia  and  11b.  However  a  more  recent  software  package,  GLIMMER,  suggested  a  GTG 
start  codon  may  be  the  translational  start  (position  168,  Figure  12)(results  not  shown). 
The  true  start  however  could  be  identified  by  N-terminal  sequencing  of  the  native  Bap-5 
protein.  However,  this  may  be  difficult  if  Bap-5  encodes  a  signal  sequence  which  is 
readily  cleaved.  This  could  be  determined  by  cloning  and  expressing  different  fragments 
of  bap-5. 
There  are,  however,  alternative  potential  start  sites  (Figure  12)  and  it  would  require 
extensive  investigation  to  ascertain  the  true  ATG  translational  start  codon.  There  are  no 
translational  stop  codons  within  this  open  reading  frame  until  position  2538.  This  is  at 
a  position  consistent  with  previously  characterised  B.  pertussis  autotransporters  as  it  is 
immediately  preceded  by  a  consensus  outer-membrane  localisation  motif.  A  potential 
transcriptional  terminator  was  identified  in  the  form  of  mRNA  secondary  hairpin 
structure  which  formed  downstream  of  the  predicted  ORF  (Figure  13). 
90 Figure  11a:  The  output  from  CODONPREFERENCE.  The  nucleotide  sequence 
shown  in  Figure  12  was  analysed.  The  second  reading  frame,  which  begins  at  position 
261,  is  not  interupted  by  stop  codons  and  the  third  position  GC  bias  increases 
significantly  in  this  reading  frame.  A  B.  pertussis  codon  frequency  table  was  used  for 
this  analysis. Blackburn  P.  E. 
SPTB  D!  )  LOTjTSOd  pIT41 
0 
0 
ý 
0 
0 
0 
0 
0 
ý 
0 
0 
0 
C 
0 
ý 
0 
C  ý 
0  .  In 
0 
0S 
0  It' 
0 
Results 
!  ^ 
111ý 
=  ýý 
'ý'  }I 
llr:  l  -  , 
rý 
"  -  e 
- 
- 
= 
I 
` 
r 
I 
ý^I 
I 
Lý 
" 
"ý'I 
- 
I` 
1  R 
=  I  'r 
L 
-  - 
ý  =  I°-  Y 
ý- 
- 
ý 
II  -- 
`I 
ti  I 
lI  `^ 
i  ý" 
Iý% 
^1 
- 
- 
I  -  ý 
I1 
I  =ý 
ý 
- 
Iaý 
I  1ý 
1 
_ 
I 
rý 
ýL  I 
`li 
1ý 
_  'ý  ^  I  " 
ý 
S 
- 
` 
= 
I< 
I 
'  -  ý 
ýr 
(  ý 
, 
- 
_ r  - -  r 
'! 
I 
ý`  - 
TI  I  l  ` 
- 
-  -"Lý 
"tt  ýý 
+  " 
Z 
-_ 
. 
fýI 
- 
ý,  _ 
0  in  o  in 
0 
0 
C 
.  -.  .ro0 
0  ý 
0 
0 
C 
..  00 
aocaia3aid  Lopoo 
O  ýn  o  ýn 
0 
0 
0 
. 
..  oö 
0 
0 
n 
O 
O 
g 
ý 
C 
91 Figure  11b:  The  output  from  TESTCODE.  The  nucleotide  sequence  shown  in  Figure 
12  was  analysed.  A  measure  of  the  non-randomness  of  the  composition  of  every  third 
base  is  shown  against  the  nucleotide  position.  There  is  a  significant  rise  in  the  non- 
randomness  of  the  3rd  position  after  position  261  (figure  12). Blackburn  P.  E.  Results 
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92 Figure  12:  The  nucleotide  sequence  of  bap-5  and  the  predicted  open  reading  frame 
(underlined).  The  four  potential  methionine  start  codons  are  coloured  red.  The  RGD 
potential  integrin-binding  site,  and  SGSG  glycosaminoglycan  binding  motif  are 
highlighted  in  yellow  boxes.  The  putative  proteolytic  processing  site  and  the  outer 
membrane  localisation  sequence  were  determined  by  comparison  with  Pm,  BrkA  and 
Tcf  sequences  and  are  also  highlighted  in  yellow.  The  sequence  representing  the 
predicted  Rho  -  independent  secondary  structure  is  shown  in  grey.  The  Bap-5  specific 
region,  designated  NTS,  expressed  for  use  in  mouse  protection  tests  is  coloured  green. Blackburn  P.  E.  Results 
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TGGGCGAGTTGCGGCTCGATCCCGGCGCGGGCGGCZTCTGGGGGCGCACGTTCGCCCAGAAGCAGCAGCTCGACAACA 
GEL  RLDPGAGGFWGRTFAR0LDNR 
1800  1810  1820  1830  1840  1850  1860  1870 
11111111 
AGGCTGC'ýCCGACGCTTCGACCAGAAGGTGTACGGT'rPCGAGCTGGGGGCCGACCATGCCATCGCAGGACAGCAAGGGC 
AGRRFD0RVYGFELGADHAIAG00GR 
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1880  1890  1900  1910  1920  1930  1940  1950 
11111111 
GCTGGCACGTGGGCGGCCTGCTGGGCTATACCCGCGCAAGGCGCAGCTTCATCGATGACGGCGCCGGGCATACCGACA 
WHVGGLLGYTRARRSFIDDGAGHTDS 
1960  1970  1980  1990  2000  2010  2020 
IIIIIIi  GCGCGCATATCGGGGCCTACGCGGCGTACGTGGCGGACAACGGCTTCTATTTCGATTCGACCCTGCGCGCCAGCCGCT 
AHIGAYAAYVADNGFYFDSTLRASRF 
2030  2040  2050  2060  2070  2080  2090  2100 
11111111 
TCGAGAACGACTTCACGGTAACGGCCACCGACGCCGTTTCCGTACGGGGCAAGTACCGGGCCAATGGGGTAGGCGCCA 
ENDFTVTATDAVSVRGRYRANGVGAT 
2110  2120  2130  2140  2150  2160  2170  2180 
11111111 
CCTTGGAGGCCGGCAAACGTTT('ACGTTGCACGACGGCTGGTTCGTCGAACCTC'.  AGTCCGAGGTGTCGCTGTTCCATG 
LEAGRRFTLHDGWFVEP0SEVSLFHA 
2190  2200  2210  2220  2230  2240  2250  2260 
11111111 
CCAGCGGCGGAACCTACCGTGCCGCGAACAACCTGTCGGTCAAGGACGAAGGCGGCACCTCCGCCGTGCTGCGCCTGG 
SGGTYRAANNLSVRDEGGTSAVLRLG 
2270  2280  2290  2300  2310  2320  2330  2340 
11111111 
GCTTGGCGGCCGGGCGACGCATCGACC'IGGGC.  AAGGACCGCGTGATCCAGCCCTATGCCACCCTGAGCTGGCIG('.  AGG 
LAAGRRIDLGRDRV10PYATLSWL0E 
2350  2360  2370  2380  2390  2400  2410 
1111111 
AATTCAAAGGCGTCACGACCGTTCGCACCAACGGGTACGGGCTGCGCACCGACCTGAGCGGTGGCCGGGCTGAATTGG 
FRGVTTVRTNGYGLRTDLSGGRAELA 
2420  2430  2440  2450  2460  2470  2480  2490 
11111111 
CGCTGGGCCTGGCCGCCGCGTTGGGGCGCGGCCACCAGCTCTACACTTCGTACGAGTACGCCAAGGGCAACAAGCTGA 
LGLAAALGRGH0LYTSYEYARGNRLT 
2500  2510  2520  2530  2540  2550  2560  2570 
IIiIIiII  CCTTGCCTTGGACGTTCCACCTGGGCTATCGCTACACCTGGTAGCGGCGCATCGCAACAACGGGGTCATCGCGACCCC 
LPWTFHLGYRYT  WI  "RRIATTGSSRPR 
2580  2590  2600  2610  2620  2630  2640  2650 
111111(1 
GTTG'PTGGATTCCCGGACCGCGCTGCGGTCAGACCAGCCCGGGCCGTCGACCACGCGTGCCCTATAGTAAGGGCGAAT 
CCIPGPRCGQTSPGRRPRVPYSRGEF 
2660  2670  2680  2690  2700  2710  2720 
IIIIIII  TCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCGCCCTATAGTGATAG 
CRYPSHWRPLEHASRGPNSPYSD 
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DNA 
2540  2550  2560  2570  2580  2590 
11(1 
Coding  Strand....  TAGCGGCGCATCGCAACAACGGGGTCATCGCGACCCCGTTGTTGCATTCCCGGAC 
Template  Strand....  ATCGCCGCGTAGCGTTGTTGCCCCAGTAGCGCTGGGGCAACAACGTAAGGGCCTG 
RNA 
C 
UG 
AC 
C  "G 
UA 
G  "C 
G  "C 
GC 
GC 
CG 
AU 
A  "U 
C  "G 
AU 
A  "U 
STOP  CýG 
5......  =CGGCGCAUCG 
OCAUUCCCGGAC.....  3' 
TRANSCRIPTION 
Figure  13:  The  hairpin  structure  predicted  to  occur  downstream  from  the  putative 
Bap-5  open  reading  frame 
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The  sequence  was  submitted  to  GenBank  on  the  11/08/1998  as  a  "putative 
autotransporter  protein  of  B.  pertussis".  The  Accession  number  for  this  submission  is 
AF081494. 
3.1.8  Sequence  analysis  of  Bap-5 
As  can  be  seen  in  Figure  14,  the  deduced  amino  acid  sequence  for  the  Bap-5  C-terminus 
is  very  similar  to  that  described  for  pertactin  and  the  other,  recently  identified, 
B.  pertussis  autotransporters.  This  alignment  strongly  suggests  that  the  putative  Bap-5 
protein  should  be  included  in  the  autotransporter  family.  Motifs  of  interest  were 
identified  using  Genejockey  II  and  are  highlighted  in  Figure  12.  These  include:  A 
potential  integrin  binding  motif  (RGD,  position  944-952),  a  glycosaminoglycan  binding 
site  (SGSG  position  1347-1358),  a  proteolytic  processing  site  (ALSKRLGEL,  position 
1700-1727)  and  an  outer  membrane  localisation  signal  (FHLGYRYRW,  position  2510- 
2537).  No  signal  sequence  or  upstream  regulatory  elements  (eg.  ribosome  binding  site  or 
promotor  sequences)  were  identified  in  the  bap-5  sequence  presented  in  Figure  12.  No 
other  potential  open  reading  frames  were  identified  on  the  PEB  1  fragment.  The 
predicted  Mw  of  Bap-5  is  79.5  KDa.  If  processed  at  the  putative  cleavage  site,  the 
resultant  mature  N-terminus  is  predicted  to  be  49  KDa  and  the  C-terminus  30  KDa. 
The  N-terminus  and  C-terminus  of  Bap-5  were  compared  with  sequences  stored  in 
GenBank.  In  addition  to  the  bordetellae  autotransporters,  Bap-5  also  exhibits  similarity 
to  autotransporters  in  other  bacterial  genera  such  as  the  IgA  protease  of  N.  gonorrhoeae 
(results  not  shown).  A  more  detailed  analysis  of  the  similarity  between  the  B.  pertussis 
autotransporters  can  be  seen  in  Figure  15.  Bap-5  has  highest  similarity  to  the  amino  and 
carboxy-terminal  domains  of  Prn.  Such  similarities  with  Pm  are  higher  than  those  seen 
with  the  other  autotransporter  proteins  tested.  Figure  14  shows  the  alignment  between 
the  B.  pertussis  autotransporter  C-terminal  domains. 
97 Figure  14:  Alignment  of  the  C-terminal  amino  acid  sequences  of  Prn,  BrkA,  Tcf  and 
Vag-8  with  that  predicted  for  Bap-5.  Amino  acids  coloured  red  are  identical  at  this 
position.  Amino  acids  coloured  green  have  similar  properties  to  others  at  this  position. 
Note  that,  in  many  instances,  the  remaining  amino  acids  in  black  are  identical  or  similar, 
at  a  given  position,  in  at  least  two  members  of  this  family. Blackburn  P.  E. 
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Figure  15:  A  matrix  to  demonstrate  amino  acid  similarities  between  the  the  B.  pertussis 
autotransporter  domains  described  to  date.  The  N-termini  (N)  and  C-termini  (C)  have 
been  compared  separately  to  highlight  the  extent  of  the  C-terminus  homology.  The  C- 
terminal  and  N-terminal  domains  were  chosen  on  the  basis  of  known  or  putative 
cleavage  sites.  All  similarities  were  determined  by  BLASTp  analysis  and  are  displayed 
as  the  %  positive  (identical  and  similar)  amino  acids  /  extent  of  the  overlap.  The  extent 
of  the  overlap  is  the  window  of  amino  acids  which  have  been  analysed.  NS  represents 
no  significant  similarity. 
Bap-5:  GenBank  Acc.  No.  AF081494 
Prn:  GenBank  Acc.  No.  AJ006152 
BrkA:  GenBank  Acc.  No.  U12276 
Tcf:  GenBank  Acc.  No.  U  16754 
Vag8:  GenBank  Acc.  No.  U90124 
Bap-5  Prn  BrkA  Tcf  Vag8 
Bap-5  N:  100  N:  45  N:  41  N:  NS  N:  40 
480  503  483  497 
C:  100  C:  72  C:  62  C:  66  C:  57 
279  279  279  279  265 
Prn  N:  45  N:  100  N:  41  N:  NS  N:  37 
503  631  636  668 
C:  72  C:  100  C:  67  C:  Z  C:  58 
279  279  279  279  265 
BrkA  N:  41  N:  41  N:  100  N:  NS  N:  40 
483  636  731  584 
C:  62  C:  67  C:  100  C:  58  C:  56 
279  279  279  279  266 
Tcf  N:  NS  N:  NS  N:  NS  N:  100  N:  NS 
393 
C:  66  C:  Z  C:  58  C:  100  C:  55 
279  279  279  279  279 
Vag8  N:  40  N:  37  N:  40  N:  NS  N:  100 
497  665  584  665 
C:  57  C:  58  C:  56  C:  55  C:  100 
265  265  266  279  279 
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3.1.9  Identification  of  bap-5  in  Bordetella  genomes 
The  digoxigenin-labelled  Southern  blot  probe  P640  (section  3.1.2)  was  used  to  detect 
sequences  in  the  genomes  of  other  Bordetella  species  which  may  be  homologous  to  bap- 
5.  Initial  problems  with  high  background  were  overcome  by  preheating  the  wash  buffers 
and  by  reducing  the  probe  concentration.  Figure  16  shows  the  result  of  the  Southern 
blot  analysis  of  Bordetella  chromosomal  DNA  with  P640.  Strong  positive  signals  were 
seen  in  lanes  1-6  which  implies  hybridisation  to  the  genomes  of  B.  pertussis  (strains 
Taberman,  BBC29,  BBC30  and  BP2041),  B.  bronchiseptica  and  B.  parapertussis.  No 
signal  was  detected  with  B.  avium.  In  B.  pertussis  DNA,  the  size  of  the  positive  EcoRI 
fragment  was  approximately  1.2  Kb.  This  was  smaller  than  the  positive  band  detected 
from  EcoRI  digests  of  B.  bronchiseptica  and  B.  parapertussis  (approximately  2.6  Kb). 
The  presence  of  the  same  sized  bands  in  the  B.  pertussis  strains  BBC30  (prn)  and 
BP2041  (brkA")  provides  evidence  that  the  probe  640  is  not  hybridising  to  the  prn  and 
brkA  genes. 
100 Figure  16a:  Bordetella  genomic  DNAs  digested  with  EcoRI  and  analysed  by  agarose 
gel  electrophoresis. 
Kb:  1  Kb  ladder 
Lane  1:  B.  pertussis  Taberman  (wild  type) 
Lane  2:  B.  pertussis  BBC29  (wild  type) 
Lane  3:  B.  pertussis  BBC30  (prn  deletion  of  BBC29) 
Lane  4:  B.  pertussis  2041  (brkA  deletion) 
Lane  5:  B.  bronchiseptica  214  (wild  type) 
Lane  6:  B.  parapertussis  5952  (wild  type) 
Lane  7:  B.  avium  4480  (wild  type) 
Figure  16b:  Southern  blot  of  bordetella  genomic  DNAs  (figure  16a)  with  probe  P640. Blackburn  P.  E. 
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3.1.10  Expression  of  bap-5  in  B.  pertussis 
To  analyse  the  expression  of  bap-5,  RT-PCR  and  Western  blotting  was  performed  on 
RNA  and  outer  membrane  preparations  of  B.  pertussis  strains  Taberman  (wild  type) 
and  BP347  (Bvg').  RT-PCR  was  performed  using  the  primers  NTSFOR  and  NTSREV 
(Table  5)  and  an  amplicon  was  obtained  on  several  occasions.  This  procedure  was  not 
highly  reproducible,  presumably  due  to  the  instability  of  prokaryotic  RNA  preparations 
(section  2.17.1).  Figure  17  shows  the  amplicon  obtained  from  the  RNA  template  from 
strain  Taberman.  This  product  was  of  predicted  size  (450  bp)  and  was  not  present  in 
the  sample  with  no  reverse  transcriptase  which  implies  that  the  template  was 
transcribed  from  RNA.  Also,  no  amplicon  was  obtained  from  the  Bvg  mutant  BP347 
which  suggests  that  the  transcription  of  this  gene  is  Bvg-regulated  (like  Prn,  section 
1.3.1).  The  Western  blot  was  performed  using  pooled  mouse  antisera  which  had  been 
raised  to  the  whole  Bap-5  protein  (sections  3.2  and  2.18.5)  and  reacted  with  an  outer 
membrane  preparation  of  B.  pertussis  strain  Taberman  at  65  KDa,  38  KDa  and  30  KDa 
(Figure  18).  The  predicted  size  for  unprocessed  Bap-5  is  79.5  KDa  and  the  processed 
forms  are  predicted  to  be  49  and  30.5  KDa  for  the  N  and  C-termini  respectively. 
Therefore,  the  30  KDa  reaction  could  represent  the  C-terminal  domain  and  the  65  KDa 
could  be  either  the  N-terminal  portion  migrating  at  higher  Mw  (as  with  P.  69)  or  an 
unprocessed  form  which  is  either  migrating  at  lower  Mw,  or  translation  has  occured 
from  a  site  different  to  that  predicted.  No  reaction  was  seen  with  the  avirulent  (Bvg') 
mutant,  BP347. 
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bp  1  2  3 
103 Figure  18:  Western  blot  of  outer-membrane  preparations  using  anti-whole  Bap-5  sera. 
Arrows  highlight  the  strongest  reactions  with  the  antibody.  Non-specific  reactions  are 
evident  in  lane  3  and  are  of  lower  intensity  than  the  proposed  reactions. 
Lane  1:  E.  coli  outer  membrane  preparation  (negative  control) 
Lane  2:  B.  pertussis  strain  Taberman  (wild  type)  outer-membrane  preparation 
Lane  3:  B.  pertussis  strain  BP347  (Bvg)  outer-membrane  preparation Blackburn  P.  E.  Results 
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3.2  Recombinant  expression  of  domains  from  B.  pertussis 
autotransporter  proteins 
The  intention  was  to  directionally  ligate  autotransporter-encoding  DNA  fragments  into 
pETlla,  pET33b  (Novagen)  or  pQE-60  (Qiagen)  for  high  level  expression  in  E.  coll. 
Such  material  would  then  be  purified  and  used  in  acellular  vaccine  formulations  for 
mouse  protection  tests  and  for  structural  analysis,  including  X-ray  crystallography. 
The  true  translational  start  codon  of  bap-5  was  not  known,  therefore  to  allow 
recombinant  expression  of  the  whole  Bap-5  protein,  constructs  were  created  using  each 
of  the  four  ATG  codons  at  the  5'  end  of  the  putative  open  reading  frame  (section  3.1.7). 
Only  the  construct  expressing  Bap-5  from  the  first  methionine  was  used  in  further 
experiments.  The  rationale  for  this  was  that  all  the  potential  start  codons  were  in  the 
same  reading  frame  and,  even  if  the  incorrect  start  site  was  chosen,  the  resultant  protein 
would  still  contain  the  complete  Bap-5  amino  acid  sequence.  Plasmids  expressing  the  C- 
terminal  portions  of  Bap-5,  BrkA,  Prn  and  Tcf  were  also  created.  In  addition,  a  Bap-5 
specific  N-terminal  domain,  designated  NTS,  which  bears  less  similarity  with  the  other 
known  B.  pertussis  autotransporters,  was  expressed  and  purified.  The  NTS  sequence  is 
highlighted  in  green  in  Figure  12 
3.2.1  Creation  of  expression  constructs 
All  the  expression  systems  were  produced  according  to  the  schematic  overview 
presented  in  Figure  19,  with  the  850  bp  C-terminus  of  pertactin  used  as  an  example. 
3.2.1.1  Amplification  of  sequences  encoding  autotransporter  domains 
The  sequences  of  all  primers  used  are  given  in  Table  5.  For  the  entire  predicted  Bap-5 
open  reading  frame,  primers  were  designed  to  all  4  potential  start  codons  and  to  the 
predicted  3'  TGA  stop  codon  (position  2537,  Figure  12).  Primers  were  also  designed  to 
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amplify  the  DNA  encoding  the  C-terminal  regions  of  Bap-5,  Prn,  BrkA  and  Tcf  based 
on.  published  sequences. 
For  amplification  of  DNA  encoding  the  C-terminal  domains,  an  ATG  start  codon  was 
engineered  into  the  5'  end  of  the  artificial  open  reading  frame  to  permit  translation. 
Restriction  sites  were  incorporated  into  the  primers  to  allow  directional  cloning  into  the 
expression  vector  (Table  6).  Care  was  taken  during  primer  design  to  ensure  that  the 
correct  reading  frame  would  be  maintained.  The  template  used  for  each  amplification 
was  B.  pertussis  (Taberman)  genomic  DNA.  High  fidelity  amplification  of  bap-5,  from 
all  4  potential  start  codons  was  obtained,  (two  shown  in  Figure  20b).  In  addition,  a 
region  of  Bap-5,  NTS,  which  had  least  homology  to  other  described  autotransporters 
was  also  amplified  to  allow  expression  of  a  Bap-5  specific  peptide  for  antibody 
production  (Figure  20a). 
106 Figure  19:  A  schematic  overview  of  the  methods  used  to  create  protein  expression 
constructs. 
Figure  19a:  PCR  amplification  of  DNA  encoding  the  pertactin  C-terminus  (850  bp, 
see  arrow)  according  to  Taguchi  optimisation  methods  (Cobb  and  Clarkson  1994).  See 
Table  5  for  primers  used.  Note  that  in  addition  to  the  major  product  of  predicted  size, 
non-specific  amplification  products  are  evident  in  lane  9  at  approximately  1.6  Kb  and 
2.7  Kb.  All  reactions  were  carried  out  in  a  50  µl  volume  with  5%  DMSO,  3U  Taq 
polymerase  (Promega),  lx  reaction  buffer  (Promega).  The  template  DNA  was  from 
B.  pertussis  strain  Taberman.  The  variables  are  given  in  brackets  and  represent  the  final 
reaction  conditions. 
Kb:  1  Kb  ladder 
Lane  1:  Products  from  tube  1: 
(0.5  pM  each  primer;  50  ng  template;  1  mM  MgC12;  0.1  mM  each  dNTP) 
Lane  2:  Products  from  tube  2 
(0.5  pM  each  primer;  150  ng  template;  2  mM  MgCI2;  0.2  mM  each  dNTP) 
Lane  3:  Products  from  tube  3 
(0.5  pM  each  primer;  300  ng  template;  3  mM  MgC12;  0.3  mM  each  dNTP) 
Lane  4:  Products  from  tube  4 
(1  pM  each  primer;  50  ng  template;  2  mM  MgCl2;  0.3  mM  each  dNTP) 
Lane  5:  Products  from  tube  5 
(1  pM  each  primer;  150  ng  template;  2  mM  MgC12;  0.1  mM  each  dNTP) 
Lane  6:  Products  from  tube  6 
(1  pM  each  primer;  300  ng  template;  1  mM  MgCl2;  0.2  mM  each  dNTP) 
Lane  7:  Products  from  tube  7 
(1.5  pM  each  primer;  50  ng  template;  2  mM  MgCl2;  0.3  mM  each  dNTP) 
Lane  8:  Products  from  tube  8 
(1.5  pM  each  primer;  100  ng  template;  1  mM  MgCl2;  0.3  mM  each  dNTP) 
Lane  9:  Products  from  tube  9 
(1.5  pM  each  primer;  300  ng  template;  2  mM  MgCl2;  0.1  mM  each  dNTP) 
Lane  10:  Template-free  control  (otherwise  equivalent  to  tube  5) 
Figure  19b:  Restriction  digest  of  the  insert  encoding  the  pertactin  C-terminus  from 
pCRII  using  BspHJ  and  BamHI.  This  DNA  (at  850  bp,  see  arrow)  was  gel  purified  and 
ligated  into  the  overexpression  vector  pET33b  (Ncol  and  BamHI  sites). 
KB:  1  Kb  ladder 
Lane  1:  Restriction  of  pertactin  C-terminus  encoding  DNA  from  pCRII Blackburn  P.  E.  Results 
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107 Figure  20a:  Amplification  of  DNA  that  encodes  a  specific  portion  of  the  Bap-5  N- 
terminus  (NTS) 
Kb:  1  Kb  ladder 
Lane  1:  Template-free  negative  control 
Lane2:  Amplification  of  NTS-encoding  DNA  (450  bp) 
Figure  20b:  Amplification  of  bap-5: 
Kb:  1  Kb  ladder 
Lane  1:  Amplification  of  bap-5  from  the  1st  ATG  (position  261,  Figure  12). 
Lane  2:  Amplification  of  bap-5  from  the  2nd  ATG  (position  336,  Figure  12) 
Lane  3:  Template-free  negative  control  with  primers  designed  for  amplification 
from  the  first  ATG  of  bap-5. Blackburn  P.  E.  Results 
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Attempts  to  amplify  the  C-terminus  encoding  regions  of  Prn,  BrkA  and  Tcf  with  proof- 
reading  DNA  polymerase  were  not  successful,  probably  due  to  the  high  GC  content  of 
the  template  sequence.  Use  of  an  orthogonal  array  optimisation  procedure  described  by 
Cobb  and  Clarkson  (1994)  enabled  optimisation  of  these  reactions  and  the  results  of  the 
Prn  C-terminus  encoding  amplification  can  be  seen  in  Figure  19a.  The  pattern  produced 
by  this  array  was  the  same  for  each  C-terminus  encoding  fragment  amplified,  i.  e.  with 
prn  lanes  5,7  and  9  produced  a  band  of  the  expected  size  (850  bp).  The  product  from 
lane  5  was  chosen  on  this  occasion.  The  Bap-5  C-terminus-encoding  amplicon  was 
amplified  later  in  the  project  using  HotStarTagTM  DNA  polymerase  (section  2.7.2) 
which  was  not  available  previously. 
3.2.1.2  Cloning  of  expression  amplicons  into  pCRII 
To  propagate  the  DNA  of  interest  in  a  form  that  could  be  easily  prepared  and  restricted, 
the  amplicons  were  gel  purified,  AT-cloned  into  pCRII-TOPO  and  transformed  into 
E.  coli  strain  TOPIOF'.  Plasmids  were  purified  from  10  resultant  white  colonies  and 
analysed  for  presence  of  an  insert  of  correct  size  by  EcoRI  restriction  analysis.  The 
sequences of  the  cloned  amplicons  were  confirmed  by  automated  sequencing  using 
primers  M13FOR  and  M13REV  (Table  5).  The  bap-5  amplicons  were  also  sequenced 
using  M13FOR,  M13REV,  PEBIREV4,  PEBREV5  and  PEBIFOR12.  Fewer  primers 
were  needed  to  cover  the  whole  bap-5  amplicon  than  previously  required  as  sequencing 
reactions  were  performed  at  the  Protein  and  Nucleic  Acid  Chemistry  Laboratory 
(PNACL)  at  the  University  of  Leicester.  Read  lengths  from  PNACL  were  longer  than 
those  previously  obtained  from  the  MBSU  at  the  University  of  Glasgow.  However,  the 
sequences  were  confirmed  as  identical  to  those  obtained  from  previous  work  or  those 
available  at  GenBank  (accession  numbers:  J04560  [prn],  U12276  [brkA]  and  U16454 
[tcf]).  From  the  clones  analysed,  the  fidelity  of  the  non-proofreading  Taq  polymerase 
used  was  excellent.  The  constructs  containing  correct  insert  were  named  pCRII(PCT1), 
pCRII(TCF1),  pCRII(BRKA1),  pCRII(Bp5CT1),  pCRII(Bap5M1),  pCRII(Bap5M2), 
pCRII(Bap5M3),  pCRII(Bap5M4)  and  pCRII(NTS)  (Table  6). 
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3.2.1.3  Cloning  of  expression  fragments  into  overexpression  vectors 
Initially,  pETI  la  was  used  to  clone  the  DNA  encoding  the  BrkA  C-terminus.  However, 
problems  were  encountered  when  trying  to  ligate  other  fragments  into  this  vector.  It 
was  also  realised  that  a  vector  encoding  an  Histidine6  tag  (N-terminal  for  pET33b;  C- 
terminal  for  pQE-60)  to  aid  purification  would  be  advantageous.  The  DNA  encoding 
the  Pm  and  BrkA  C-terminal  fragments  were  ligated  into  pET33b  for  this  reason. 
Again,  technical  problems  with  the  vector  pET33b  led  to  use  of  another  readily  available 
Histidine6  tag-encoding  vector,  pQE-60,  for  cloning  of  the  Bap-5  fragments.  Therefore, 
all  constructs  with  the  exception  of  pET1la(BrkA)  encoded  a  His6  tag.  The  cloned 
amplicons  were  subjected  to  restriction  digestion  according  to  Table  6.  The  restricted 
fragments  were  then  separated  by  agarose  gel  electrophoresis  and  the  bands  of  correct 
size  purified  (Figure  19b).  The  expression  vectors,  pET-1  la,  pET-33b  or  pQE-60,  were 
digested  with  either  NdeI/BamHI,  BspHI/BamHI  or  NcoI/Bg1II  as  appropriate  (Table  6) 
and  gel  purified.  Ligations  were  performed  according  to  section  2.9.2  and  the  products 
were  transformed  into  either  BL21(DE3)  or  M15p(Rep4)  E.  coli  strains  as  appropriate 
(Table  3).  The  resultant  colonies  were  checked  for  presence  of  an  insert  of  correct  size 
with  the  enzymes  used  to  generate  the  cohesive  termini  prior  to  ligation.  Those 
containing  an  insert  of  correct  size  were  subjected  to  expression  analysis. 
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Table  6:  Primers  and  restriction  sites  used  to  generate  expression  constructs. 
Results 
Constructs  Insert  and  primers  used  for  Enzyme  sites  in 
amplificationt  primers  used  for 
cloning  into 
expression  vector* 
pCRII(BCT),  BrkA  C-terminus  DNA,  brkACT  NdeI,  BamHI 
pETIIa(BCT)  BRKAC-TERMS'  and  BRKA3' 
pCRII(PCT),  Pm  C-terminus  DNA,  prnCT  BspHI,  BamHI 
pET33b(PCT)  PRNC-TERM5'  and  PRN3' 
pCRII(TCT),  Tcf  C-terminus  DNA,  tcfCT  NcoI,  BamHI 
pET33b(TCT)  TCFC-TERM5'  and  TCF3' 
pCRII(TTS),  Specific  Bap-5  portion,  nts  NcoI,  BglII 
pQE-60  (NTS)  NTSFOR  and  NTSREV 
Bap-5  from  the  4  potential  start  codons  BspHI,  Bg1II 
pCRII(Bap5M1), 
pQE-60(BapM  1)  NTMI  and  BAP-5CTERM3' 
pCRII(Bap5M2), 
pQE-60(BapM2)  NTM2  and  BAP-5CTERM3' 
pCRII(Bap5M3), 
pQE-60(BapM3)  NTM3  and  BAP-5CTERM3' 
pCRII(Bap5M4), 
pQE-60(BapM4)  NTM4  and  BAP-5CTERM3' 
pCRII(BPSCT),  Bap-5  C-terminus  DNA,  Bap-5CT  NcoI,  Bg1II 
pQE-60(BP5CT)  BAP-5CTERM5'  and  BAP- 
5CTERM3' 
'See  Table  5  for  primer  sequences.  *BspHI  generates  cohesive  overhangs  that  are 
compatible  with  Ncol.  This  site  was  used  in  place  of  Ncol  in  primers  that  amplified  a 
sequence  containing  Ncol. 
111 Blackburn  P.  E.  Results 
3.2.2  Expression  of  recombinant  autotransporter  domains 
The  amount  of  protein  expressed  as  a  proportion  of  whole-cell  protein  (the  expression 
level)  was  found  to  be  comparable  regardless  of  IPTG  concentration  in  the  range  0.2-1.5 
mM  (see  Figure  21).  The  expression  levels  in  both  2xYT  and  LB  media  were 
comparable  for  all  systems  tested,  although  2xYT  enabled  greater  E.  coli  cell  density  and 
therefore  more  recombinant  protein  per  unit  volume  of  culture  (data  not  shown).  A  final 
concentration  of  0.2  mM  IPTG  was  therefore  used  to  induce  expression  of  all  proteins. 
In  all  cases,  protein  expression  was  tightly  regulated  and  was  not  detectable  from 
uninduced  cultures  in  either  Coomassie-blue  stained  gels  or,  where  performed, 
immunoblots  with  anti-His6  antibodies  (Figure  28).  The  expression  of  Bap-5  from 
clones  pQE-60(BapMI)  and  pQE-60(BapM2)  can  be  seen  in  Figure  22.  The  predicted 
molecular  weight  of  Bap-5  (from  the  1st  ATG)  is  79.5  KDa,  and  bands  can  be  seen  at 
80,50  and  28  KDa.  These  bands  may  represent  an  unprocessed  form  of  Bap-5  (80 
KDa)  and  a  processed  form  consisting  of  a  C-terminus  (30  KDa)  and  a  mature  N- 
terminal  band  (50  KDa). 
The  pertactin  C-terminus  protein  expressed  from  3  clones  containing  pET33b(PCT)  at 
different  IPTG  concentrations  was  noted  previously  (Figure  21).  The  C-terminal 
portions  of  BrkA,  Tcf  and  Bap-5  were  expressed  at  approximately  the  same  level  as  the 
Pm  C-terminus  and  the  apparent  molecular  weights  were  approximately  30  KDa  in  all 
cases,  as  predicted.  The  clone  pET33b(NTS)  expressing  the  specific  N-terminal  portion 
of  Bap-5  had  a  predicted  Mw  of  16.5  KDa  and  reproducibly  produced  proteins  of  size 
16.5  KDa  and  14  KDa.  The  14KDa  protein  is  probably  due  to  proteolytic  cleavage  of 
the  16.5KDa  protein  (Figure  23).  An  insert-free  control  was  also  induced  under  the 
same  conditions  as  the  recombinant  strains  and  showed  no  apparent  change  in  whole-cell 
protein  profile  following  induction  (lanes  10-12,  Figure  21). 
112 Figure  21:  Whole-cell  lysates  of  BL21(DE3)  E.  coli  expressing  the  C-terminus  of 
pertactin  under  different  ITPG  conditions  (pET33b  used).  Cultures  were  grown  in  1L 
of  2xYT  and  were  induced  at  OD600  of  0.4.  Note  that  the  amount  of  protein  loaded  onto 
the  gel  was  not  normalised. 
KDa:  10  KDa  ladder 
Lane  1:  pET33b(PCT)  immediately  prior  to  induction  (Time  0  h) 
Lane  2:  pET33b(PCT)  without  induction  of  recombinant  expression  (Time 5  h) 
Lane  3:  pET33b(PCT)  with  0.2  mM  IPTG  induction  (Time 5  h) 
Lane  4:  pET33b(PCT)  immediately  prior  to  induction  (Time  0  h) 
Lane  5:  pET33b(PCT)  without  induction  of  recombinant  expression  (Time 5  h) 
Lane  6:  pET33b(PCT)  with  0.75  mM  IPTG  induction  (Time 5  h) 
Lane  7:  pET33b(PCT)  immediately  prior  to  induction  (Time  0  h) 
Lane  8:  pET33b(PCT)  without  induction  of  recombinant  expression  (Time 5  h) 
Lane  9:  pET33b(PCT)  with  1.5  mM  IPTG  induction  (Time 5  h) 
Lane  10:  pET33b(No  Insert)  immediately  prior  to  induction  (Time  0  h) 
Lane  11:  pET33b(No  Insert)  without  induction  of  recombinant  expression  (5  h) 
Lane  12:  pET33b(No  Insert)  with  1.5  mM  IPTG  induction  (5  h) Blackburn  P.  E.  Results 
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113 Figure  22:  Whole-cell  lysates  of  E.  coli  strain  M15p(Rep4)  containing  Bap-5 
expression  constructs  (pQE-60  used).  Note  the  bands  of  apparent  molecular  weight  80 
KDa,  50  KDa  and  28  KDa  (marked  with  arrows)  in  lanes  2  and  4. 
KDa:  10  KDa  ladder 
Lane  1:  pQE-60(Bap-5M1)  without  induction  of  recombinant  protein  (Time  5  h) 
Lane  2:  pQE-60(Bap-5M1)  with  0.2  mM  IPTG  induction  (Time  5  h) 
Lane  3:  pQE-60(Bap-5M2)  without  induction  of  recombinant  protein  (Time  5  h) 
Lane  4:  pQE-60(Bap-5M2)  with  0.2  mM  IPTG  induction  (Time  5  h) Blackburn  P.  E. 
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114 Figure  23:  Whole-cell  lysates  of  E.  coli  strain  M15p(Rep4)  containing  an  NTS 
expression  contruct  (pQE-60  used).  Note  the  presence  of  bands  with  apparent 
molecular  weights  of  16.5  KDa  and  14.5  KDa  in  lane  2  (see  arrows). 
KDa:  10  KDa  ladder 
Lane  1:  pQE-60(NTS)  without  induction  of  recombinant  protein  (Time  5  h) 
Lane  2:  pQE-60(NTS)  with  0.2  mM  IPTG  induction  (Time  5  h) Blackburn  P.  E.  Results 
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3.2.3  Purification  of  recombinant  autotransporter  domains 
3.2.3.1  Partial  purification  by  urea  extraction 
Results 
To  partially  purify  the  recombinant  proteins,  the  urea  soluble  fraction  was  prepared 
according  to  section  2.15.3.  All  recombinant  proteins  used  in  this  study  could  be 
extracted  as  insoluble  protein,  probably  as  inclusion  bodies,  which  could  then  be 
solubilised  in  8M  urea.  All  recombinant  proteins  could  be  purified  to  approximately 
95%  purity  (assessed  by  SDS-PAGE)  by  extracting  the  inclusion  bodies  and  solubilising 
them  in  8M  urea.  Figures  24a  and  24b  show  the  urea  extracts  of  the  various 
recombinant  proteins.  This  provided  semi-purified  denatured  recombinant  proteins 
which  were  dialysed  into  either  1M  urea  in  PBS  or  PBS  alone  or  subjected  to  Ni-NTA 
affinity  purification  as  appropriate  (sections  2.15.4,2.15.5).  Inclusion  bodies  are 
generally  more  stable  against  proteolysis  and  all  proteins  should  be  able  to  be  stored  in 
urea  at  -20°C  for  at  least  18  months  (Enfors  1992).  The  Bap-5  urea  extract  (Figure  24b) 
shows  Bap-5  at  an  apparent  Mw  of  90  KDa  (predicted  size  79.5  KDa).  This  size 
anomaly  was  reproduced  on  several  occasions  and  appeared  to  be  gel  specific  and 
occurred  irrespective  of  sample  preparation.  It  is  possible,  however,  that  the  excessive 
amount  of  protein  loaded  in  Figure  24b  made  the  Bap-5  protein  appear  larger. 
116 Figure  24a:  Whole-cell  lysates  and  urea-soluble  fraction  of  recombinant  E.  coli 
induced  with  0.2  mM  IPTG  to  express  Prn  (from  pET33b),  BrkA  (from  pET33b),  Tcf 
(from  pET33b)  and  Bap-5  C-terminal  domains  (from  pQE-60)  and  the  Bap-5  specific 
domain  (NTS))  (from  pQE-60).  The  major  bands  represent  the  recombinant  domains. 
Lane  1:  Whole-cell  lysate  of  E.  coli  expressing  PCT 
Lane  2:  Urea  soluble  fraction  of  E.  coli  expressing  PCT 
Lane  3:  Whole-cell  lysate  of  E.  coli  expressing  TCT 
Lane  4:  Urea  soluble  fraction  of  E.  coli  expressing  TCT 
Lane  5:  Whole-cell  lysate  of  E.  coli  expressing  BCT 
Lane  6:  Urea  soluble  fraction  of  E.  coli  expressing  BCT 
Lane  7:  Whole-cell  lysate  of  E.  coli  expressing  Bap-5CT 
Lane  8:  Urea  soluble  fraction  of  E.  coli  expressing  Bap-5CT 
Lane  9:  Whole-cell  lysate  of  E.  coli  expressing  NTS 
Lane  10:  Urea  soluble  fraction  of  E.  coli  expressing  NTS 
Figure  24b:  Urea-soluble  fraction  of  E.  coli  strain  M15p(Rep4)  containing  pQE- 
60(Bap-5M1)  and  expressing  Bap-5  from  the  Ist  potential  start  codon  can  be  seen  in 
lane  1. Blackburn  P.  E. 
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3.2.3.2  Purification  by  affinity  chromatography 
To  further  purify  the  recombinant  His6-tagged  autotransporter  domains,  the  pH- 
dependent  interaction  between  the  His6  tags  and  Ni-NTA  was  utilised.  Recombinant 
proteins  bound  to  the  column  and  were  then  washed  and  eluted  using  a  pH  gradient 
containing  8M  urea.  The  optimal  elution  pH  for  all  proteins  tested  was  pH  4.5.  All  C- 
terminal  domains  and  the  NTS  domain  were  purified  by  this  affinity  method  using  either 
FPLC  or  using  Ni-NTA  microspin  columns  depending  on  the  scale  of  the  preparation. 
For  unknown  reasons,  in  a  preliminary  experiment,  whole  Bap-5  was  not  purified  by 
this  technique  and  appeared  not  to  bind  to  the  Ni-NTA  resin.  However,  an  anti-His6 
immunoblot  was  not  performed  to  investigate  this  further  as  the  urea  extract  was 
considered  pure  enough  for  the  purposes  of  raising  antibodies  and  mouse  protection 
tests.  The  band  of  14  KDa  obtained  from  expression  of  NTS  did  not  bind  to  the  resin 
and  was  presumably,  therefore,  not  His6-tagged  (Figure  27).  This  assumption  was 
confirmed,  as  shown  in  Figure  28,  as  the  lower  band  (14.5  KDa)  did  not  bind  anti-His6 
monoclonal  antibodies  during  Western  blotting,  whereas  the  larger  16.5  KDa  band  did 
bind  the  antibody.  Figure  25  shows  the  purification  of  the  Pm  C-terminus.  On  this 
occasion,  the  binding  capacity  of  the  Ni-NTA  has  been  exceeded  (see  major  protein  band 
in  lanes  2  and  3),  although  the  effectiveness  of  the  purification  was  not  reduced.  Only 
representative  fractions  are  shown  in  Figure  25.  Similar  profiles  were  obtained  for  the 
other  C-terminal  proteins. 
118 Figure  25:  FPLC  Purification  of  the  pertactin  C-terminus  using  Ni-NTA  affinity.  The 
binding  capacity  of  the  Ni-NTA  was  exceeded,  as  can  be  seen  by  the  presence  of  protein 
of  apparent  Mw  32  KDa  in  the  flow-through.  Also,  more  protein  could  potentially 
have  been  eluted  in  Buffer  E,  as  the  recombinant  protein  is  still  bound  to  the  column  and 
is  present  the  Buffer  F  eluate. 
KDa:  10  KDa  ladder 
Lane  1:  Urea  extract  of  pertactin  C-terminus  loaded  onto  column 
Lane  2:  Buffer  B,  first  flow  through 
(8 M  urea,  0.1  M  sodium  phosphate,  0.01  M  Tris,  pH  8.0) 
Lane  3:  Buffer  C,  eluate  1 
(8 M  urea,  0.1  M  sodium  phosphate,  0.01  M  Tris  HC1,  pH  6.3) 
Lane  4:  Buffer  C,  eluate  2 
Lane  5:  Buffer  D,  eluate  1 
(8 M  urea,  0.1  M  sodium  phosphate,  0.01  M  Tris  HCI,  pH  5.9) 
Lane  6:  Buffer  E,  eluate  1 
(8 M  urea,  0.1  M  sodium  phosphate,  0.01  M  Tris  HCI,  pH  4.5) 
Lane  7:  Buffer  F,  eluate  1 
(6  M  guanidine  hydrochloride,  0.2  M  acetic  acid) 
Lane  8:  Buffer  F,  eluate  2 Blackburn  P.  E.  Results 
KDa  12345678 
60 
50 
40 
30 
20 
10 
119 Figure  26:  Purification  of  the  Bap-5  C-terminus  using  Ni-NTA  microspin  columns. 
KDa:  10  KDa  ladder 
Lane  1:  Urea  extract  of  pertactin  C-terminus  as  loaded  onto  column 
Lane  2:  Buffer  C,  eluate  1 
(8 M  urea,  0.1  M  sodium  phosphate,  0.01  M  Tris  Hcl,  pH  6.3) 
Lane  3:  Buffer  C,  eluate  2 
(8 M  urea,  0.1M  sodium  phosphate,  0.01M  Tris  Hcl,  pH  6.3) 
Lane  4:  Buffer  C,  eluate  3 
(8  M  urea,  0.1M  sodium  phosphate,  0.01M  Tris  Hcl,  pH  6.3) 
Lane  5:  Buffer  E,  eluate  1 
(8  M  urea,  O.  1M  sodium  phosphate,  0.01M  Tris,  pH  4.5) 
Lane  6:  Buffer  E,  eluate  2 
(8 M  urea,  O.  1M  sodium  phosphate,  0.01M  Tris,  pH  4.5) Blackburn  Y.  E. 
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120 Figure  27:  Purification  of  the  Bap-5-specific  NTS  domain  by  FPLC  Ni-NTA  affinity 
chromatography  (solid  arrow,  lane  8).  The  14.5  KDa  band  is  present  in  Lane  1  and  does 
not,  therefore,  appear  to  bind  to  the  resin  (dashed  arrrow).  This  suggests  that  this 
protein  is  not  His6-tagged. 
KDa:  10  KDa  Protein  Ladder 
Lane  1:  Buffer  B,  first  flow  through 
Lane  2:  Buffer  B,  second  flow  through 
Lane  3:  Buffer  B,  third  flow  through 
Lane  4:  Buffer  C,  eluate  2 
Lane  5:  Buffer  C,  eluate  3 
Lane  6:  Buffer  D,  eluate  2 
Lane  7:  Buffer  E,  eluate  1 
Lane  8:  Buffer  E,  eluate  2 
Lane  9:  Buffer  E,  eluate  3 
Lane  10:  Gap-no  sample  loaded 
Lane  11:  Urea  extract  of  NTS  loaded  onto  column Blackburn  P.  E. 
KDa  123456789  10  11 
50  Omw 
40  waw 
30  *,  *- 
20  ohlib 
10 
Results 
121 Blackburn  P.  E.  Results 
3.2.4  Immunoblotting  of  recombinant  domains  with  anti-His6  antibody 
To  confirm  that  a  His6  tag  was  present  on  the  predicted  recombinant  proteins  and  to 
confirm  the  lack  of  expression  in  non-induced  clones,  whole-cell  lysates  were 
immunoblotted  with  an  anti-His6  antibody.  As  predicted  from  the  construct  design,  the 
His6-tagged  C-terminal  domains  of  Prn  (30.6  KDa),  Tcf  (31.7  KDa)  and  Bap-5  (31.3 
KDa)  reacted  with  this  antibody  (lanes  2,4  and  8;  Figure  27).  Also  the  specific  N- 
terminus  portion  (NTS,  16.5  KDa)  reacted  with  the  antibody.  The  lower  band  of 
apparent  Mw  14.5  KDa  (lane  10,  Figure  27)  did  not  react  with  this  antibody.  The  C- 
terminus  of  BrkA  (lane  6)  was  not  His6-tagged  and  did  not  react  with  the  anti-His6 
antibody. 
122 Figure  28:  Immunoblot  of  induced  and  non-induced  whole-cell  lysates  using  anti-His6 
monoclonal  antibodies.  There  appears  to  be  some  degradation  of  the  recombinant 
proteins,  which  resulted  in  multiple  bands. 
KDa:  10  KDa  protein  ladder 
Lane  1:  Whole-cell  lysate  of  E.  coli  not  induced  to  express  PCT 
Lane  2:  Whole-cell  lysate  of  E.  coli  expressing  PCT 
Lane  3:  Whole-cell  lysate  of  E.  coli  not  induced  to  express  TCT 
Lane  4:  Whole-cell  lysate  of  E.  coli  expressing  TCT 
Lane  5:  Whole-cell  lysate  of  E.  coli  not  induced  to  express  BCT 
Lane  6:  Whole-cell  lysate  of  E.  coli  expressing  BCT 
Lane  7:  Whole-cell  lysate  of  E.  coli  not  induced  to  express  Bap-5CT 
Lane  8:  Whole-cell  lysate  of  E.  coli  expressing  Bap-5CT 
Lane  9:  Whole-cell  lysate  of  E.  coli  not  induced  to  express  NTS 
Lane  10:  Whole-cell  lysate  of  E.  coli  expressing  NTS Blackburn  P.  E.  Results 
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3.2.5  Immunoblotting  of  recombinant  domains  with  mAbs 
Monoclonal  antibodies  had  been  raised  previously  that  reacted  with  virulence  (Bvg)- 
regulated  28  KDa  and  30  KDa  bands  present  in  the  outer  membrane  of  B.  pertussis 
(Hertz  and  Parton,  unpublished).  These  bands  later  proved  to  be  the  processed  C- 
terminal  domains  of  BrkA  (Finn  and  Stevens,  1995)  and  Tcf  respectively  (Fernandez 
and  Weiss,  1994).  The  antibodies  were  used  to  confirm  the  presence  of  these 
recombinant  proteins  and  also  to  check  for  any  cross  reactivity  due  to  common  epitopes 
between  the  very  similar  C-terminal  domains  of  the  other  B.  pertussis  autotransporter 
proteins. 
Figure  29a  shows  the  Coomassie  blue-stained  samples  on  an  SDS-PAGE  gel  and  the 
differences  in  apparent  Mw  of  the  C-terminal  domains  Bap-5  (31.3  KDa),  Pm  (30.6 
KDa),  Tcf  (31.3  KDa)  and  BrkA  (30.4  KDa).  All  samples  were  urea  extracted  proteins 
(section  2.15.3)  and  were  loaded  in  duplicate  on  the  gel.  The  major  band  in  each  lane 
represents  the  recombinant  protein. 
Figure  29b  shows  an  immunoblot  of  the  reaction  between  the  samples  shown  in  Figure 
29a  and  mAb  49.3,  which  is  known  to  react  with  native  and  SDS-denatured  Tcf.  The 
recombinant  Tcf  C-terminus  was  found  to  react  with  this  antibody  but  cross  reaction 
with  the  other  recombinant  C-terminal  domains  did  not  occur.  This  was  confirmatory 
evidence  that  the  protein  in  lanes  5  and  6  represented  the  C-terminus  of  Tcf  and  that 
Bap-5  was  not  antigenically  closely  related  to  Tcf. 
Figure  29c  shows  an  immunoblot  with  mAb  149  and  the  C-terminus  extracts  decribed 
above.  This  antibody  also  reacts  with  native  Tcf  C-terminus  and  again  reacted  with  the 
recombinant  form.  Under  the  conditions  used,  there  also  appeared  to  be  some  very 
slight  cross  reactivity  with  Prn  C-terminus  and  the  C-terminus  of  Bap-5.  No  reaction 
was  evident  with  the  C-terminus  of  BrkA.  This  provides  further  evidence  that  the 
major  protein  in  lanes  5  and  6  represents  the  C-terminus  of  Tcf. 
124 Blackburn  P.  E.  Results 
Figure  29d  shows  an  immunoblot  between  the  aforementioned  recombinant  C-terminal 
domains  with  P.  28  mAb,  which  reacts  with  native  BrkA.  This  antibody  did  react 
strongly  with  the  recombinant  BrkA  and,  under  the  conditions  used,  also  reacted  very 
weakly  with  the  other  C-terminal  domains.  This  cross  reaction  may  be  non-specific  as 
many  other  bands,  presumably  E.  coli  proteins  that  are  present  in  the  extract,  also 
reacted  weakly  with  this  mAb.  The  results,  however,  indicated  that  the  major  band  in 
lanes  7  and  8  corresponds  to  the  the  BrkA  C-terminus  and  that  Bap-5  was  not 
immunologically  related  to  BrkA. 
125 Figure  29a:  SDS-PAGE  of  inclusion  bodies  containing  recombinant  C-terminal 
domains  solubilised  in  urea. 
KDa:  10  KDa  protein  ladder 
Lanes  1  and  2:  Bap-5  C-terminus 
Lanes  3  and  4:  Pm  C-terminus 
Lanes  5  and  6:  Tcf  C-terminus 
Lanes  7  and  8:  BrkA  C-terminus 
Figure  29b:  Immunoblot  of  fractions  shown  in  figure  29a  with  monclonal  antibody 
49.3  which  reacts  with  native  Tcf  C-terminus. 
KDa:  10  KDa  protein  ladder 
Lanes  1  and  2:  Bap-5  C-terminus 
Lanes  3  and  4:  Pertactin  C-terminus 
Lanes  5  and  6:  Tcf  C-terminus 
Lanes  7  and  8:  BrkA  C-terminus Blackburn  Y.  E. 
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126 Figure29c:  Immunoblot  of  fractions  shown  in  figure  29a  with  monclonal  antibody  149 
which  reacts  with  native  Tcf  C-terminus 
KDa:  10  KDa  protein  ladder 
Lanes  1  and  2:  Bap-5  C-terminus 
Lanes  3  and  4:  Pm  C-terminus 
Lanes  5  and  6:  Tcf  C-terminus 
Lanes  7  and  8:  BrkA  C-terminus 
Figure  29d:  Immunoblot  of  fractions  shown  in  figure  29a  with  monclonal  antibody 
P.  28  which  reacts  with  native  BrkA  C-terminus. 
KDa:  10  KDa  protein  ladder 
Lanes  1  and  2:  Bap-5  C-terminus 
Lanes  3  and  4:  Pertactin  C-terminus 
Lanes  5  and  6:  Tcf  C-terminus 
Lanes  7  and  8:  BrkA  C-terminus Blackburn  P.  E.  Results 
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3.3  Recombinant  expression  of  BADPCT 
Results 
The  aim  of  this  study  was  to  use  the  autotransporter  protein  system  to  create  a  vector 
that  would  enable  surface  location  and  potentially  surface  release  of  heterologous 
proteins  or  peptides.  Such  a  vector  would  be  self-replicative  and  sell-contained  and 
may  have  great  value  in  the  development  of  antigen  display  systems  for  use  in  vaccines 
and  may  also  be  useful  in  the  expression  of  proteins  which  are  toxic  for  the  host  cell. 
The  intention  was  to  promote  transport  of  such  recombinant  proteins  (passenger 
domains)  from  the  periplasm  to  the  cell  exterior  using  the  C-terminal  domain  of  pertactin 
and  to  incorporate  a  portion  upstream  from  the  C-terminus  (linker  region)  to  allow 
presentation  of  the  heterologous  protein  to  the  pore  and  to  allow  translocation  across 
the  outer  cell  membrane.  The  topology  of  this  heterologous  display  system  is  shown  in 
Figure  30. 
128 Figure  30:  Topology  of  BADPCT  heterologous  antigen  display.  The  signal  sequence 
is  removed  during  protein  export. Blackburn  P.  E. 
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3.3.1  Construction  of  a  heterologous  antigen  display  vector 
The  pBAD/gIII  vector  was  chosen  as  expression  is  tightly  regulated  by  an  arabinose 
promoter  (araB)  and  the  vector  encodes  a  gill  signal  sequence  which  is  capable  of 
transporting  proteins  via  the  Sec-dependent  pathway  into  the  periplasm.  An  outline  of 
the  methods  used  to  construct  the  vector  can  be  seen  in  Figure  31.  The  prn/linker  target 
sequence  was  deduced  from  analysis  of  the  prn  sequence  in  GenBank  (Accession  No. 
AJ04560).  The  sequence  was  amplified  from  B.  pertussis  Taberman  genomic  DNA 
using  primers  BADPCT5'  and  BADPCT3'  (Table  5)  and  HotstarTagTM  (section  2.7.2). 
The  linker  region,  including  the  PQP  repeats,  was  estimated  from  sequence  deposited  at 
GenBank  (nucleotide  position  1771  Acc  No.  AJ006152  encoding  AANGNGQ...  ). 
BadPCT3'  incorporated  the  translational  stop  codon  to  prevent  the  pBAD/gIII  vector- 
encoded  His6  tag  being  translated.  The  reaction  resulted  in  a  1.1  Kb  amplicon  (Figure 
31)  which  was  gel  purified  and  AT  cloned  into  pCRII-TOPO  according  to  section 
2.9.1.1.  The  insert  was  sequenced  using  primers  M13FOR,  M13REV  and  PRNC- 
TERM5'  (Table  5)  and  the  sequence  was  identical  to  that  predicted.  This  vector  was 
named  pCRII(PCTLINK).  The  pCRII(PCTLINK)  construct  was  digested  with  Sacl 
and  EcoRI  and  the  1.1  Kb  fragment  purified  following  agarose  gel  electrophoresis. 
pBAD/gIIIA  was  also  digested  with  these  enzymes  and  ligated  to  the  insert  according  to 
the  rapid  ligation  protocol  described  in  section  2.9.2.3.  The  reaction  was  transformed 
initially  into  E.  coli  strain  TOPIOF'  by  electroporation.  Plasmids  were  purified  from  20 
resultant  colonies  and  checked  for  the  presence  of  a  1.1  Kb  insert  by  double  digestion 
with  EcoRI  and  SacI.  One  such  clone  was  selected  for  expression  analysis  and  named 
pBAD/gIII(PCT1). 
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Figure  31:  A  schematic  overview  of  the  construction  of  pBAD/gIII(PCT  I).  Lane  I  is  a 
template-free  negative  control;  Lane  2  shows  the  amplicon  obtained. 
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3.3.2  Expression  of  BADPCT 
The  E.  coli  expression  strains  TOP10F'  and  LMG194  provided  by  the  manufacturer 
are  capable  of  transporting  arabinose  into  the  cell  yet  not  metabolising  it.  This  allows 
the  arabinose  level  within  the  cytoplasm  to  remain  constant.  E.  coli  strain  LMG194  is 
recommended,  as  expression  from  this  strain  can  be  repressed  further  by  the  addition  of 
glucose.  Attempts  to  optimise  the  expression  of  BADPCT  from  pBAD/gIII(PCT1)  in 
strain  TOP  10F'  failed  and  no  recombinant  proteins  were  detected  from  whole  cells  on 
Coomassie  blue-stained  SDS-PAGE.  Final  arabinose  concentrations  of  0.0002%, 
0.002%,  0.02%  and  0.2%  were  used,  as  recommended  by  the  manufacturer  (Invitrogen). 
Figure  32a  shows  the  lack  of  recombinant  protein  from  pBAD/gIII(PCT1)  in  TOP  I  OF'. 
The  plasmid  was  then  transformed  into  E.  coli  strain  LMG194  and  the  same 
optimisation  conditions  used.  The  results  of  this  optimisation  can  be  seen  in  Figure 
32b.  The  predicted  Mw  of  the  recombinant  protein  is  37  KDa.  Recombinant  protein 
appeared  to  be  present  at  apparent  Molecular  weights  of  43  KDa  and  also  at  29  KDa 
(see  arrows  in  Figure  32b).  This  discrepancy  may  be  due  to  the  high  proline  content  of 
the  linker  region,  which  is  thought  to  be  responsible  for  the  anomalous  migration  of 
P.  69.  For  comparison,  purified  His6-tagged  PCT  of  predicted  and  apparent  molecular 
weight  30.6  KDa  (section  3.2.3.2)  was  run  in  parallel  (lane  1).  Although  it  is  not 
apparent  from  Figure  32b,  the  optimum  arabinose  concentration  for  recombinant  protein 
expression  was  0.02%  (lane  4)  and  was  therefore  used  in  further  experiments.  The 
proteins  produced  were  named  BADPCTa  (43  KDa)  and  BADPCTb  (29  KDa). 
132 Figure32a:  SDS-PAGE  of  whole  cell  lysates  to  determine  expression  of  BADPCT 
from  E.  coli  strain  TOP1OF'  pBAD/gIII(PCTI)  under  the  conditions  used. 
KDa: 
Lane  1: 
Lane2: 
Lane3: 
Lane4: 
Lane5: 
Lane6: 
1  OKDa  protein  ladder 
Purified  PCT  (section  3.2.3.2) 
Not  induced 
Induced  with  0.0002%  L-arabinose 
Induced  with  0.002%  L-arabinose 
Induced  with  0.02%  L-arabinose 
Induced  with  0.2%  L-arabinose 
Figure32b:  SDS-PAGE  of  whole  cell  lysates  to  show  the  optimisation  of  BADPCT 
expression  from  E.  coli  strain  LMG194  pBAD/gIII(PCT1)  with  various  arabinose 
concentrations.  Arrows  show  protein  bands  at  43  KDa  and  29  KDa. 
KDa: 
Lane  1: 
Lane2: 
Lane3: 
Lane4: 
Lanes: 
10KDa  protein  ladder 
Purified  PCT 
Not  induced 
Induced  with  0.0002%  L-arabinose 
Induced  with  0.002%  L-arabinose 
Induced  with  0.02%  L-arabinose Blackburn  P.  E.  Results 
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3.3.3  Localisation  of  BADPCT 
3.3.3.1  Fractionation  of  E.  coli  strain  LMG194  containing  pBAD/g1IIA(PCTI) 
To  determine  the  cellular  location  of  the  BADPCTa  and  BADPCTb  recombinant 
proteins,  cells  were  fractionated  according  to  section  2.14.1  and  the  fractions  analysed 
by  SDS-PAGE.  All  fractions  can  be  seen  in  Figure  33.  As  a  negative  control,  strain 
LMG194  containing  pBAD/glIIA  with  no  insert  was  induced  and  fractionated.  Proteins 
BADPC'i  a  (43  KDa)  and  BADPCTb  (29  KDa)  can  be  seen  in  the  whole  cell  fraction, 
inclusion  bodies  and  outer-membrane  fractions  (lanes  2,4  and  10  respectively,  Figure 
33).  The  recombinant  proteins  appear  to  constitute  a  major  component  of  the  outer 
membrane  (approximately  25-30%). 
3.3.3.2  Immunoblot  of  LMG194  containing  pBAD/gIIIA(PCTI)  fractions 
The  cellular  fractions  (Figure  33)  were  blotted  with  a  mouse  monoclonal  antibody  BB05 
(kindly  provided  by  M.  Roberts)  which  reacts  with  the  linker  region  of  pertactin  (which 
is  rich  in  PQP  repeats).  As  can  be  seen  in  Figure  34,  the  antibody  reacted  with  proteins 
present  in  lanes  2,4  and  10  and  to  a  much  lesser  extent,  lane  8.  This  confirms  the 
presence  of  BADPCTa  in  the  whole  cell  fraction,  inclusion  bodies,  outer  membrane  and 
the  inner  membrane.  There  appears  to  be  less  recombinant  protein  in  the  inclusion 
bodies  and  the  inner  membrane  than  in  the  outer  membrane.  The  main  reacting  band  is  at 
43  KDa.  The  smaller  recombinant  band  of  an  apparent  Mw  of  29  KDa  in  SDS-PAGE 
(Figure  33)  does  not  react  with  BB05  and  presumably  does  not  contain  the  linker  region 
target.  There  appears  to  be  some  degradation  products  of  the  linker-containing  protein 
(BADPC"I'a)  which  is  detected  as  lower  molecular  weight  (<43  KDa)  bands  in  Figure 
34. 
134 Figure  33:  SDS-PAGE  to  show  fractionation  of  E.  coli  strain  LMG194  containing 
pBAD/gIII(PCT1)  or  pBAD/gIID(no  insert)  after  induction  with  0.02%  arabinose. 
Arrows  identify  bands  at  43  KDa  and  29  KDa. 
KDa:  10  KDa  protein  ladder 
Lane  1:  Whole-cell  lysate  pBAD/gIII(no  insert) 
Lane2:  Whole-cell  lysate  pBAD/gIII(PCT1) 
Lane3:  Inclusion-body  fraction  pBAD/gIII(no  insert) 
Lane4:  Inclusion-body  fraction  pBAD/gIII(PCT  1) 
Lanes:  Soluble  fraction  (cytoplasm  and  periplasm)  pBAD/gIII(no  insert) 
Lane6:  Soluble  fraction  (cytoplasm  and  periplasm)  pBAD/gIII(PCT1) 
Lane  7:  Inner-membrane  fraction  pBAD/gIII(no  insert) 
Lane  8:  Inner-membrane  fraction  pBAD/gIII(PCTI) 
Lane  9:  Outer-membrane  fraction  pBAD/gIII(no  insert) 
Lane  10:  Outer-membrane  fraction  pBAD/gIII(PCT1) Blackburn  P.  E.  Results 
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135 Figure  34:  Immunoblot  with  monoclonal  antibody  BB05  of  the  samples  described  in 
figure  33 
KDa:  10  KDa  protein  ladder 
Lane  1:  Whole-cell  lysate  pBAD/gIII(no  insert) 
Lane2:  Whole-cell  lysate  pBAD/gIII(PCT1) 
Lane3:  Inclusion-body  fraction  pBAD/gIII(no  insert) 
Lane4:  Inclusion-body  fraction  pBAD/gIII(PCT1) 
Lanes:  Soluble  fraction  (cytoplasm  and  periplasm)  pBAD/gIII(no  insert) 
Lane6:  Soluble  fraction  (cytoplasm  and  periplasm)  pBAD/gIII(PCT1) 
Lane  7:  Inner-membrane  fraction  pBAD/gIII(no  insert) 
Lane  8:  Inner-membrane  fraction  pBAD/gIII(PCT1) 
Lane  9:  Outer-membrane  fraction  pBAD/gIII(no  insert) 
Lane  10:  Outer-membrane  fraction  pBAD/gIII(PCT1) Blackburn  P.  E.  Results 
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3.3.4  Heat  modifiability  of  BADPCTa  and  BADPCTb 
The  native  C-terminal  domains  of  BrkA  and  Tcf  are  heat  modifiable  ie.  the  migration  of 
these  proteins  on  SDS-PAGE  depends  on  the  temperature  of  solubilisation  of  the 
sample  (R.  Parton,  personal  communication).  To  assesss  the  heat  modifiability  of  the 
recombinant  C-terminal  domains,  inclusion  bodies  were  resuspended  in  PBS  and  either 
boiled  for  10  min  or  were  maintained  at  room  temperature  prior  to  loading  onto  the  gel. 
The  migration  of  these  recombinant  proteins,  in  contrast  with  the  native  counterparts, 
was  not  affected  by  ommision  of  boiling  prior  to  gel  loading  (results  not  shown).  Outer- 
membrane  preparations  containing  BADPCTa  and  BADPCTb  were  also  tested  in  this 
way.  As  can  be  seen  in  Figure  35,  the  migration  of  the  43  KDa  protein  band 
(BADPCTa,  black  arrows)  appears  unaltered,  whereas  the  29  KDa  protein  band  is  heat 
modifiable  (BADPCTh,  dashed  arrows).  BADPCTh  migrates  at  an  apparent  Mw  of  26 
KDa  when  sample  solubilisation  is  at  room  temperature.  BADPCTb  migrates  more 
slowly  (approximately  30  KDa)  following  boiling  for  10  minutes  prior  to  gel  loading. 
The  major  E.  coli  bands  present  in  lanes  3-6  (grey  arrows)  are  also  heat  modifiable. 
137 Figure  35:  Heat  modifiability  of  BADPCTa  and  BADPCTb  (black  arrows  and  dashed 
arrows  respectively).  E.  coli  proteins  are  marked  with  grey  arrows. 
Lanes  1  and  2: 
Lanes  3  and  4: 
Outer-membrane  fraction  of  E.  coli  containing  pBAD/gIII(PCT1) 
without  boiling 
Outer-membrane  fraction  of  E.  coli  containing  pBAD/gIII(PCT1) 
with  boiling 
Lanes  5  and  6:  Outer-membrane  fraction  of  E.  coil  containing  pBAD/gIII(no 
insert)  with  boiling 
Lanes  7  and  8:  Outer-membrane  fraction  of  E.  coli  containing  pBAD/gIII(no 
insert)  without  boiling Blackburn  Y.  E.  Results 
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3.4  Construction  of  a  bap-5  mutant  of  B.  pertussis 
The  intention  was  to  disrupt  the  bap-5  open  reading  frame  with  a  kanamycin  cassette 
(KR).  This  mutant  would  be  of  great  value  in  assessing  the  function  of  the  Bap-5, 
perhaps  as  a  virulence  factor  in  a  number  of  in  vivo  and  in  vitro  assays  such  as  mouse 
respiratory  tract  colonisation  and  adhesion.  The  NcoI  site  within  Bap-5  was  considered 
to  be  a  suitable  site  for  insertion  of  KR  as  such  a  disruption  would  provide  flanking 
sequences of  1738  and  542  bp  and  only  one  NcoI  site  was  present  in  the  vector 
pCRII(Bp-5ATG1)  (Table  4).  The  flanking  sequences  should  have  been  adequate  for 
homologous  recombination  into  the  B.  pertussis  genome.  Unfortunately,  the  final  stages 
of  construction  of  this  mutant  were  not  completed,  due  to  technical  difficulties. 
Initially,  the  KR  cassette  from  pUC4K  was  excised  using  BamHI  and  the  resultant 
fragment  gel-purified  and  polished.  The  presence  of  an  Ncol  site  in  the  pCRII  vector 
sequence  meant  that  partial  digests  were  necessary,  with  serial  dilutions  of  Ncol  used  for 
Ih.  The  resultant  single  digest  products  (Figure  37)  were  gel-purified  and  made  blunt 
using  T4  DNA  polymerase.  Attempts  to  disrupt  the  cloned  bap-5  gene  with  KR  by 
ligation  of  the  BamHI  KR  fragment  at  the  NcoI  using  standard  and  rapid  ligation 
protocols  resulted  in  no  colonies  following  transformation  into  E.  coli  strain  JM109 
after  selection  on  media  containing  ampicillin  (encoded  by  pCRII  vector)  and  kanamycin 
(encoded  by  KR). 
An  alternative  strategy  was  attempted  which  would  allow  cohesive  ligation  of  KR  into 
bap-5.  This  is  outlined  in  Figure  36.  The  kanamycin  cassette  was  amplified  from 
pUC4K  using  primer  KANANCOI  (Table  5)  which  contained  an  NcoI  site  and  annealed 
to  2  sites  which  flank  the  kanamycin  cassette.  The  resultant  amplicon  was  cloned  into 
pGemT  and  pCRII-TOPO  to  generate  plasmids  pGemT(KANA)  and  pCRII(KANA) 
respectively.  Such  plasmids  will  enable  the  cloning  of  the  KR  cassette  into  a  greater 
variety  of  restriction  sites  and  should  be  a  useful  laboratory  resource. 
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Figure  36:  Construction  of  a  Bap-5  mutant  of  B.  pertussis 
Amplification  and  subcloning 
of  kanamycin  cassette 
to  allow  cohesive  ligation.  pGemT(KANA) 
and  pCRII(KANA)  generated 
* 
Subcloning  of  bap-5  into  pCR-Script  to  allow 
selection  of  kanamycin  insert 
and  subsequent  BgIII  ligation 
into  pSS1129 
II 
Ligation  of  kanamycin  cassette 
into  Ncol  site  of  bap-5 
....  ......................  L.............  ........  ....  Ligation  of  bap-5 
disrupted  with  Kr  into  = 
suicide  vector  pSS1  129 
..  _....................  ...........  _........... 
F 
Mating  of  pSS1129(bap-5K6  from 
=  E.  coli  strain  SMIOPIR 
into  B.  pertussis 
*Note:  Dashed  lines  respresent  the  uncompleted  stages  of  mutant  construction 
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To  enable  selection  for  kanamycin  resistance  within  the  disrupted  bap-5  gene,  bap-5 
was  cloned  into  pCR-Script  following  amplification  with  primers  BAP5MUT5'  and 
BAP5MUT3'  (Table  5).  These  primers  possessed  Bg1II  restriction  sites  to  enable 
subsequent  ligation  of  bap-5KR  into  the  Bg1II  site  of  the  suicide  vector  pSSI  129.  The 
PCR  was  performed  using  the  ExpandTM  high  fidelity  PCR  system  (section  2.7.3)  with 
pCRII(ATGI)  as  a  template.  The  resultant  amplicon  (approximately  3.7  Kb)  was  gel 
purified  and  ligated  into  pCR-Script  (section  2.9.1.2)  which  contains  no  NcoI  sites  and 
is  not  kanamycin  resistant.  Recombinant  clones  were  selected  using  LB  agar  containing 
both  ampicillin  and  kanamycin  and  were  checked  by  NcoI  analysis.  One  positive  clone 
was  selected  and  named  pCR-Script(ATGI). 
The  cloned  KR  cassette  in  pCRII(KANA)  was  digested  with  Ncol  and  the  1.3  Kb  insert 
(Figure  37a)  was  gel  purified,  ligated  into  the  NcoI  site  of  pCR-Script(ATG1)  using  the 
rapid  ligation  protocol  (section  2.9.2.3)  and  transformed  into  E.  coli  strain  JM109. 
Resultant  colonies  were  checked  for  presence  of  a  correct  size  insert  by  NcoI  restriction 
analysis  of  plasmids.  The  positive  selection  (kanamycin)  resulted  only  in  clones  that 
contained  the  kanamycin  cassette  inserted  into  bap-5.  Figure  37b  confirms  the  presence 
of  the  1.3  Kb  KR  cassette.  One  clone  was  chosen  and  called  pCR-Script(Bap-5  KR). 
Insertion  of  the  kanamycin  cassette  at  the  correct  site  was  confirmed  by  sequencing 
using  primers  PEB1FOR12  and  PEBIREV6  (Table  5). 
The  plasmid  pCR-Script  (Bap-5KR),  containing  bap-5  disrupted  with  KR  was  digested 
with  Bg1II  and  the  disrupted  bap-5  was  gel  purified.  The  suicide  vector  pSS  1129  was 
also  digested  with  Bg1II  and  gel  purified.  Attempts  were  made  to  ligate  the  bap-5KR 
into  pSS1129  using  both  standard  ligation  and  rapid  ligation  procedures.  The  reactions 
were  transformed  into  E.  coli  strain  TOP10F'  by  heat  shock,  or  E.  coli  strain  JM109  by 
electroporation.  Insert  :  vector  ratios  of  1:  1,3:  1,10:  1  and  15:  1  were  used.  Also,  the 
vector  was  dephosphorylated  in  an  attempt  to  increase  the  chance  of  insert 
incorporation.  In  addition,  an  insert-free  control  was  used  to  check  the  ability  of  the 
vector  to  self  ligate.  Selection  was  performed  on  LB  agar  containing  ampicillin  and 
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kanamycin  or  LB  agar  containing  ampicillin  alone  (insert-free  control)  and  resulted  in 
either  no  colonies  on  any  plates  or,  in  some  instances,  few  colonies  after  2  days  which 
later  proved  to  contain  a  plasmid  with  properties  different  to  those  expected/predicted. 
Despite  several  attempts,  ligation  of  the  disrupted  bap-5  gene  into  pSS  1129  was  not 
successful  and  for  unknown  reasons  it  was  not  possible  to  regenerate  pSS1129  by  self 
ligation  following  Bg1II  digestion.  If  the  above  cloning  experiment  had  worked,  the 
suicide  construct  could  then  have  been  mated  into  B.  pertussis  and  construction  of  the 
mutant  completed. 
142 Figure  37a:  Digestion  of  the  pGemT(KANA)  (lanes  1  and  2)  and  PCRII  (KANA) 
(lanes  3-  6)  with  NcoI  to  show  release  of  a  1.3  Kb  kanamycin  resistance  cassette  (KR) 
(arrows).  The  other  bands  are  vector  DNA.  pGemT  has  an  Ncol  site  which  is  also  cut 
(lanes  1  and  2). 
Figure  37b:  Digestion  of  pCR-Script(Bp-5  KD  with  Ncol  to  show  the  1.3  Kb  KR  is 
present  (arrow  against  lane  1).  The  5.5  Kb  band  is  the  vector  and  bap-5  sequences  and 
the  7.5  Kb  band  is  presumably  a  partially  cut  or  uncut  form  of  pCR-Script(Bp-5Ký. Blackburn  P.  E. 
Figure  37a 
Figure  371) 
Kb  I 
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3.5  Mouse  protection  tests  using  autotransporter  domains 
The  methods  used  for  the  mouse  protection  tests  are  described  in  section  2.18.  Briefly, 
two  doses  of  vaccine  (15µg  of  total  protein  per  dose  or  1/10th  human  dose  ACV)  were 
administered  subcutaneously  with  a  two  week  interval,  followed  one  week  later  by  a 
sublethal  intranasal  challenge  (of  1x106  cfu/mouse)  with  B.  pertussis  strain  Taberman  or 
18323.  Mouse  lungs  were  removed  seven  days  post  challenge  and  viable  counts  were 
obtained.  The  lung  count  data  can  be  found  in  Appendix  III.  Three  experiments  were 
performed,  R12,  R13  and  R14,  and  the  results  from  mice  given  acellular  vaccine  (ACV) 
containing  pertactin  (P69)  or  alhydrogel  (AL)  were  combined  and  analysed  in  a  separate 
experiment. 
3.5.1  Mouse  protection  test  R12 
This  experiment  was  designed  to  test  the  ability  of  Bap-5,  and  NTS  (Bap-5  specific 
portion),  as  urea-solubilised  inclusion  bodies,  to  protect  adult  mice  against  challenge 
with  either  of  two  B.  pertussis  strains  (Taberman  or  18-323).  Strain  Taberman  was  used 
as  this  strain  was  the  first  found  to  contain  the  bap-5  gene  (section  3.1).  Strain  18-323 
was  also  used  as  this  is  a  well-described,  mouse-virulent  strain.  As  a  positive  control  in 
this  experiment,  a  Smithkline  Beecham  acellular  vaccine  (ACV)  containing  P.  69,  FHA 
and  PTd  was  used  at  1/10th  human  dose.  Also  included  as  a  positive  control  was  a 
purified  pertactin  (P.  69)  preparation,  also  from  Smithkline  Beecham.  Negative  controls 
included  alhydrogel  (AL)  alone  and  E.  coli  crude  cell  lysate.  As  can  be  seen  in  Figure 
38a  and  Table  7a,  both  challenge  strains  behaved  in  a  similar  way,  in  terms  of  the  lung 
counts  of  mice  immunised  with  the  different  antigen  preparations.  No  interaction  was 
seen  between  the  challenge  strains  and  antigen  preparations  (confirmed  by  analysis  of 
variance  [ANOVA],  Table  7a  and  b).  Therefore  the  data  for  each  challenge  strain  was 
combined  to  increase  the  sample  size  and  analysed  as  one  experiment.  Figure  38b  and 
Table  7B2  gives  the  results  of  such  analysis. 
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Figure  38a:  Results  of  Experiment  R12:  Total  lung  counts  (login)  from  mice 
immunised  with  various  B.  pertussis  antigen  preparations  and  challenged  intranasally 
with  two  different  strains  (Taberman  and  18-323)  of  live  B.  pertussis.  Each  point 
represents  one  mouse.  Counts  of  <100  or  >3x106  were  given  notional  values  of  20  and 
107  respectively  and  plotted  as  open  symbols.  The  Minitab  `jitter'  option  was  applied  so 
as  to  spread  the  points  horizontally  to  avoid  coincidence. 
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Figure38b:  Boxplots  of  the  data  in  Figure  37a  (above)  with  the  results  of  the  two 
challenges  combined. 
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Table  7:  Expt.  R12:  Summary  of  the  statistical  analysis  of  the  data  in  Fig  38. 
Part  A.  Summarised  output  from  Minitab  of  the  two-way  analysis  of  variance  to 
examine  the  influence  of  Antigen  preparation  and  Challenge  strain  on  the  login  (Total 
mouse  lung  count). 
Source  of  variation  P-value  Interpretation 
Challenge  strain  0.915  Not  significant 
Antigen  preparation  0.000  Highly  significant 
Interaction  of  Challenge  0.500  Not  significant 
strain  and  Antigen  preparation 
Part  B.  Summarised  output  of  one-way  analysis  of  variance  and  Tukey  test,  from 
Minitab,  to  explore  the  differences  in  the  logo  (Total  mouse  lung  count)  associated  with 
the  different  antigen  preparations  (data  from  the  two  challenges  combined). 
B1.  Primary  output:  Antigen  preparation:  P=0.000  (Highly  significant) 
B2.  Basic  statistics  and  graphical  summary  (Mean  and  95%  confidence  intervals) 
Antigen  No.  Mean  StDev  Mean  loglo  count*  (and  95%  Cl) 
Preparation  obs. 
ACV  6  1.8465  0.6220 
P.  69  9  3.3096  1.1963 
Bap-5  (urea)  10  6.0220  0.5128 
NTS  9  6.1797  0.1379 
E.  coli  lysate  10  6.4999  0.5050 
AL  9  6.1959  0.5699 
(---*--) 
(--*-) 
(--*-) 
(--*-) 
(--*-) 
(--*--) 
Pooled  StDev  =  0.6652  --+---------+---------+---------+---- 
Scale  of  Mean  (logto  count)  -º  1.6  3.2  4.8  6.4 
(Table  continued  on  next  page) 
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Table  7.  (Continued) 
B3.  Tukey's  pairwise  comparisons  of  lung-count  means  (logio  values) 
The  table  shows  the  95%  confidence  intervals  for  (Column  antigen  mean  minus  Row 
antigen  mean}.  Significant  differences  in  counts  are  shown  in  bold. 
ACV  P.  69  Bap-5  NTS  E.  coli 
(urea)  lysate 
P.  69  -2.5042 
-0.4219 
Bap-5  -5.1956  -3.6201 
(urea)  -3.1554  -1.8047 
NTS  -5.3744  -3.8014  -1.0654 
-3.2921  -1.9389  0.7499 
E.  coli  -5.6735  -4.0980  -1.3614  -1.2278 
lysate  -3.6333  -2.2827  0.4055  0.5875 
AL  -5.3905  -3.8175  -1.0815  -0.9474  -0.6036 
-3.3082  -1.9550  0.7338  0.9151  1.2117 
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When  one  way  Anova  was  applied  to  the  combined  results,  highly  significant 
differences  between  the  antigen  preparations  were  apparent.  This  was  further  analysed 
using  the  Tukey  test  which  revealed  that  the  results  with  ACV  were  significantly 
different  from  those  with  all  of  the  other  antigen  preparations  Table  7B3.  Immunisation 
with  ACV  resulted  in  significantly  lower  lung  counts  and  therefore  better  protection. 
P.  69  was  significantly  different  from  both  ACV  and  the  other  antigen  preparations  and 
also  gave  significant  protection.  The  Bap-5  (urea)  and  NTS  antigen  preparations  were 
ineffective  immunogens  because  the  lung  counts  were  not  significantly  different  to  those 
obtained  with  alhydrogel  (AL). 
3.5.2  Mouse  protection  test  R13 
Only  strain  Taberman  was  used  for  this  experiment,  on  the  basis  of  the  results  from 
experiment  R12.  This  experiment  involved  using  the  urea-solubilised  C-terminal 
domains  of  pertactin  (PCT),  BrkA  (BCT),  Tcf  (TCT)  and  Bap-5  (Bap5CT).  The 
results  were  treated  as  in  R12  except  for  the  omission  of  the  challenge  differences.  ACV 
was  the  only  preparation  to  give  significant  protection  in  this  experiment  (Figure  39  and 
Table  8). 
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Figure  39a:  Results  of  Experiment  R13:  Total  lung  counts  (logio)  from  mice 
immunised  with  various  B.  pertussis  antigen  preparations  and  challenged  intranasally 
with  live  B.  pertussis  strain  Taberman.  Each  point  represents  one  mouse.  Counts  of 
<100  or  >3x106  were  given  notional  values  of  20  and  107  respectively  and  plotted  as 
open  symbols.  The  Minitab  `jitter'  option  was  applied  so  as  to  spread  the  points 
horizontally  to  avoid  coincidence. 
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Figure  39b:  Boxplots  of  the  above  data 
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Table  8:  Experiment  R13:  Summary  of  the  statistical  analysis  of  the  data  in  Fig  39. 
Output  of  one-way  analysis  of  variance  and  Tukey  test,  from  Minitab,  to  explore  the 
differences  in  the  logjo  (Total  mouse  lung  count)  associated  with  the  different  antigen 
preparations. 
1.  Primary  output  of  the  one-way  Anova:  Antigen  preparation:  P=0.000  (Highly 
significant) 
2.  Basic  statistics  and  graphical  summary  (Mean  and  95%  confidence  intervals) 
Antigen  No.  Mean  StDev  Mean  loglo  count  and  95%  Cl 
Preparation  obs. 
ACV  5  2.7169  1.9460  (----*----) 
PCT  4  6.8138  0.3724  (-----*-----) 
BCT  4  6.4582  0.4275  (-----*--:  --) 
TCT  5  6.1556  0.5619  (---+*-----) 
Bap5CT  5  6.3572  0.2145  (-----*----) 
AL  5  6.5873  0.5705  (----*-----) 
Pooled  StDev  =  0.9259---------+---------+---------+------- 
Scale  of  Mean  (loglo  count)  -º  3.2  4.8  6.4 
3.  Tukey's  pairwise  comparisons  of  lung-count  means  (logio  values) 
The  table  shows  the  95%  confidence  intervals  for  {Column  antigen  mean  minus  Row 
antigen  mean}.  Significant  differences  in  counts  are  shown  in  bold. 
ACV  PCT  BCT  TCT  Bap5CT 
PCT  -6.0338 
-2.1601 
BCT  -5.6782 
-1.8044 
TCT  -5.2648 
-1.6126 
Bap5CT  -5.4665 
-1.8142 
AL  -5.6966 
-2.0443 
-1.6860 
2.3973 
-1.2786  -1.6343 
2.5952  2.2395 
-1.4803  -1.8359  -2.0278 
2.3935  2.0379  1.6245 
-1.7104  -2.0660  -2.2579  -2.0562 
2.1634  1.8078  1.3944  1.5960 
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3.5.3  Mouse  protection  test  R14 
Results 
Again,  strain  Taberman  was  used  as  the  challenge  in  this  experiment  which  was  designed 
to  test  the  effect  of  urea  solubilisation  on  the  protective  capacity  of  Bap-5  and  P.  69. 
This  was  necessary  as  P.  69  was  present  as  a  non-denatured  protein  and  may  not  have 
been  a  suitable  comparison  to  urea  denatured  Bap-5.  P.  69  was  denatured  in  8M  urea 
and  Bap-5  was  either  urea-solubilised  as  before,  solubilised  in  PBS,  or  dialysed  from 
urea  into  PBS.  Analysis  was  performed  as  above  and  results  showed  that  the  ACV  was 
significantly  more  protective  than  other  antigen  preparations  with  the  exception  of  P.  69 
and  P.  69  (urea).  Urea  treatment  of  P.  69  did  not  appear  to  alter  its  ability  to  protect 
against  challenge  and  no  significant  difference  was  detected  between  the  Bap-5 
preparations.  The  results  of  this  analysis  can  be  seen  in  Figure  40  and  Table  9. 
3.5.4  Combination  and  analysis  of  data  obtained  with  acellular  vaccine,  pertactin 
and  alhydrogel 
Attention  was  directed  to  the  ACV,  P.  69  and  AL  which  had  been  tested  in  experiments 
R12,  R13  and  R14.  First  each  antigen  was  subjected  to  Anova  to  determine  whether 
there  were  significant  differences  between  the  results  obtained  from  each  experiment 
(Table  10a).  None  was  detected.  Therefore,  for  each  of  these  three  antigen 
preparations,  the  results  of  the  three  experiments  were  pooled  to  allow  antigen 
comparisons  based  on  all  the  data.  The  point  plots  and  boxplots  (Figures  41a  and  41b) 
suggested  that  protection  from  ACV  was  not  significantly  more  effective  than  P.  69  and 
both  gave  significantly  better  protection  than  AL  based  on  the  lung  count  data.  This 
was  confirmed  by  analysis  of  variance  and  the  Tukey  test  (Tables  IOB,  10B2  and 
1OB3). 
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Figure  40a:  Results  of  Experiment  R14:  Total  lung  counts  (logio)  from  mice  immunized 
with  various  B.  pertussis  antigen  preparations  and  challenged  intranasally  with  live 
B.  pertussis  strain  Taberman.  Each  point  represents  one  mouse.  Counts  of  <100  were 
given  notional  values  of  20  and  plotted  as  open  symbols.  The  Minitab  `jitter'  option  was 
applied  so  as  to  spread  the  points  horizontally  to  avoid  coincidence. 
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Table  9:  Experiment  R14.  Summarised  output  of  one-way  analysis  of  variance  and 
Tukey  test,  from  Minitab,  to  explore  the  differences  in  the  Loglo  (Total  mouse  lung 
count)  associated  with  the  different  antigen  preparations. 
1.  Primary  output  of  the  one-way  Anova:  Antigen  preparation:  P=0.001  (Highly 
significant) 
2.  Basic  statistics  and  graphical  summary  (Mean  and  95%  confidence  intervals) 
Antigen  No.  Mean  StDev  -Mean  loglo  count  and  95%  CI 
preparation  obs. 
ACV  5  3.634  2.133  (------*------) 
P.  69  5  4.612  2.146 
P.  69  (urea)  5  5.021  0.876 
Bap-5  (PBS)  5  6.617  0.413 
Bap-5  (urea)  5  6.520  0.435 
Bap-5  (dial)  5  6.522  0.190 
AL  5  6.170  0.669 
GP  5  6.650  0.633 
(------*------) 
(------*-=-----) 
(------*------) 
(-  -----*-------) 
(- 
(------*------) 
(------*-------) 
Pooled  StDev  =  1.182  ---+---------+---------+---------+--- 
Scale  of  Mean  (logio  count)  -º3.0  4.5  6.0  7.5 
3.  Tukey's  pairwise  comparisons  of  lung-count  means  (logio  values) 
The  table  shows  the  95%  confidence  intervals  for  (Column  antigen  mean  minus  Row 
antigen  mean).  Significant  differences  in  counts  are  shown  in  bold. 
ACV  P.  69  P.  69  Bap-5  Bap-5  Bap-5  AL 
(urea)  (PBS)  (urea)  (dial) 
P.  69  -3.399 
1.441 
P.  69  -3.807  -2.828 
(urea)  1.033  2.012 
Bap-5  -5.403  -4.425  -4.016 
(PBS)  -0.563  0.416  0.824 
Bap-5  -5.306  -4.327  -3.919  -2.323 
(urea)  -0.466  0.513  0.921  2.517 
Bap-5  -5.309  -4.330  -3.922  -2.325 
(dial)  -0.469  0.510  0.918  2.515 
-2.423 
2.418 
Al  -4.956  -3.977  -3.569  -1.973  -2.070  -2.068 
-0.116  0.863  1.271  2.867  2.770  2.773 
GP  -5.437  -4.458  -4.050  -2.454  -2.551  -2.548  -2.901 
-0.597  0.382  0.790  2.386  2.289  2.292  1.939 
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There  is  an  apparent  discrepancy:  R12  ACV  was  significantly  more  protective  than 
P.  69  and  the  same  was  apparent  in  R14.  However  when  the  data  from  R12,  R13  and 
R14  were  combined  there  was  no  significant  difference  between  them  (Table  l0A).  This 
is  because  of  statistical  fluctuations  in  the  data  being  affected  by  the  absence  of  P.  69  in 
experiment  R13. 
The  summary  statistics  for  the  two  protective  antigens  and  the  AL  control  were 
produced.  The  median  and  confidence  intervals  are  the  most  appropriate  way  to 
summarise  the  lung  counts  for  the  three  preparations  since  the  means  are  biased  by  the 
use  of  notional  values  (Table  10,  part  Q. 
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Figure  41a:  Combined  results  of  total  lung  counts  (loglo),  with  preparations  ACV,  P.  69 
and  AL,  from  Experiments  R12,  R13  and  R14.  Each  point  represents  one  mouse.  Counts  of 
<100  or  >3x106  were  given  notional  values  of  20  and  107  respectively  and  plotted  as  open 
symbols.  The  Minitab  `jitter'  option  was  applied  so  as  to  spread  the  points  horizontally  to 
avoid  coincidence. 
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Table  10:  Statistical  analysis  of  the  data  in  Fig  41. 
Part  A.  Summarized  output  from  Minitab  of  the  one-way  analysis  of  variance  to 
determine  whether,  with  each  antigen  preparation,  there  were  significant  differences 
between  experiments. 
Antigen  preparation  P-value  Interpretation 
ACV  0.238  Not  significant 
P.  69  0.164  Not  significant 
AL  0.547  Not  significant 
These  results  justified  the  combination  of  the  data  for  each  antigen  preparation,  across 
the  experiments,  to  give  the  point  plots  and  boxplots  in  Fig.  41. 
Part  B.  Analysis  of  variance  and  Tukey  test  on  the  three  antigen  preparations 
Bl.  Primary  output  of  the  one-way  Anova:  Antigen  preparation:  P=0.001  (Highly 
significant) 
B2.  Basic  statistics  and  graphical  summary  (Mean  and  95%  Confidence  intervals) 
Antigen  No.  Mean  StDev  Mean  loglo  count  and  95%  Cl 
preparation  obs. 
ACV  16  2.677  1.713  (----*---) 
P.  69  14  3.775  1.648  (----*----) 
AL  19  6.471  0.600 
(___*___) 
Pooled  StDev  =  1.366  ------+---------+---------+--------- 
Scale  of  Mean  (loglo  count)  -º3.0  4.5  6.0 
B3.  Tukey's  pairwise  comparisons  of  lung-count  means  (logio  values) 
The  table  shows  the  95%  Confidence  intervals  for  (Column  antigen  mean  minus  Row 
antigen  mean).  Significant  differences  in  mean  counts  are  shown  in  bold. 
ACV  P.  69  AL 
P.  69  -2.310 
0.114 
AL  -4.918  -3.863 
-2.670  -1.530 
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Part  C.  Summary  statistics:  Mean,  median,  SEM  and  confidence  intervals  (CI)  of 
Total  logbo  lung  counts  for  each  antigen  preparation,  combining  the  results  of  all  the 
experiments 
Antigen  No.  Mean  SEM  Median  95%  CI  of 
preparation  obs.  median 
ACV  16  2.677  0.428  1.739  1.301,4.696 
P.  69  14  3.775  0.441  3.763  2.672,5.023 
AL  19  6.471  0.138  6.531  5.985,7.000 
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4.1  Overview 
A  new  member  of  the  B.  pertussis  autotransporter  family  has  been  identified.  A  mis- 
primed  PCR  led  to  preliminary  data  which  suggested  the  presence  of  a  pertacin-like 
sequence  in  the  B.  pertussis  genome.  This  open  reading  frame  was  identified  using  a 
combination  of  library  screening  and  SSP-PCR  techniques.  Further  characterisation  of 
this  open  reading  frame  (bap-5)  implicated  the  encoded  protein  (named  Bap-5)  as  a 
virulence-regulated  outer-membrane  protein  which  appears  to  be  processed  in  a  similar 
manner  to  pertactin.  Motif  analysis  suggests  that  Bap-5  may  function  as  an  adhesin. 
Construction  of  a  bap-5  mutant  was  undertaken  but  the  final  stages  were  not  completed. 
Expression  constructs  were  created  for  Bap-5  and  also  the  C-terminal  domains  of  Prn, 
BrkA  and  Tcf  which  allowed  large  amounts  of  protein  to  be  expressed  and,  in  most 
cases,  purified.  The  expression  strains  created  will  provide  a  source  of  protein  which 
can  be  used  in  future  mouse  protection  trials.  Fusion  of  the  pertactin  C-terminus  and 
linker  region  to  a  signal  sequence allowed  this  domain  to  be  targeted  to  the  outer 
membrane.  This  construct  may  be  of  future  use  in  display  of  heterologous  proteins  on 
the  bacterial  surfaces. 
Preliminary  experiments  to  examine  the  protective  capacity  of  the  autotransporter 
domains  (C-terminal  domains  of  Prn,  Tcf,  BrkA  and  Bap-5)  in  addition  to  Bap-5  and  a 
specific  portion  of  Bap-5  showed  no  protection  in  a  murine  model  under  the  conditions 
tested. 
4.2  Autotransporter  characterisation 
During  the  course  of  this  study,  a  number  of  reports  appeared  in  the  scientific  literature 
indicating  that  autotransporter  proteins  are  present  in  a  wide  range  of  Gram-negative 
genera.  This  family  of  proteins  has  been  established  by  comparison  of  the  amino  acid 
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sequences  of  their  C-terminal  domains.  These  domains  are  thought  to  allow  self- 
promoted,  extracellular  secretion  by  forming  a  monomeric  ß-barrel.  The  most 
conserved  amino  acids  between  the  autotransporters  are  those  that  traverse  the  outer 
membrane,  as  proposed  by  hydrophobicity  and  amphipathicity  plots  (Loveless  and 
Saier  1997).  The  computer-based  predictions  for  ß-sheet  formation  are  reputed  to  be 
accurate,  although  prediction  of  the  number  of  sheets  formed  by  a  protein  is 
significantly  less  so  (Jose  et  al.  1995).  The  function  of  the  mature  N-terminal  domains 
is  varied  and  ranges  from  adhesion  to  proteolysis  (Table  2).  Recently,  the 
autotransporter  protein  family  has  been  reviewed,  a  signature  sequence  has  been 
assigned,  and  the  evolution  and  probable  structure  of  these  proteins  evaluated  (Loveless 
and  Saier  1997;  Henderson  et  al.  1998;  Holland  1998).  The  signature  sequence  suggested 
by  Loveless  and  Saier  (1997),  based  on  18  known  autotransporter  proteins  was: 
[SATQRGH]-[AKLTQNF]-[FGATL]-[GPDSNKI]-[KRHNDQS]-X3-[DPAQH]- 
[QNDWKYFIT]-[ASTQN]-[LIVFGAS]-[NQHEGAIF]-[LIVA]-[NGSK]-[LIVMFY]- 
[RKQSTG]-[LIFVYW]-[STAKRNV]-[FW] 
This  signature  sequence  is  proposed  to  form  the  final  beta  sheet  in  the  outer  membrane 
and  complete  the  predicted  beta  barrel.  This  sequence  has  also  been  implicated  in  outer 
membrane  targeting. 
The  emergence  of  whole  genome  sequencing  and  subsequent  analysis  (genomics)  has 
allowed  confirmation  of  the  autotransporter  sequences  and  has  allowed  identification  of 
further,  related  open  reading  frames  in  E.  coli  and,  more  recently,  B.  pertussis  and 
B.  bronchiseptica  (section  1.7).  The  autotransporter  secretion  pathway  has  been  named 
the  type  IV  secretion  pathway  (Finlay  and  Falkow  1997). 
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4.3  Characterisation  of  bap-5 
4.3.1  Sequence  analysis  of  bap-5 
4.3.1.1  Characterisation  of  the  MR30  amplicon  and  identification  of  cosmid  3 
As  described  in  section  3.1,  the  amplification  of  the  3'  end  of  bap-5  (MR30)  occurred 
due  to  mispriming  by  the  oligonucleotides  that  were  designed  to  anneal  to  part  of  the 
prn  3'  sequence.  The  sequence  of  MR30  obtained  was  similar  to,  but  different  from,  the 
predicted  prn  sequence  (Figure  5). 
From  my  investigation  of  the  genome  sequence,  it  is  now  apparent  that  the  B.  pertussis 
genome  contains  at  least  10  genes  which  may  be  classified  as  autotransporter  proteins 
on  the  basis  of  predicted  amino  acid  homology  (section  3.1.8).  It  is  perhaps  not 
surprising  that  the  MR30  amplicon  arose  from  a  genomic  template  containing  so  many 
similar  genes,  especially  as  the  primers  used  were  directed  towards  the  highly  conserved 
putative  processing  site  and  the  outer  membrane  localisation  signal  (Figure  3).  The  bap- 
5  sequence  (Figure  12)  revealed  that  the  MR30  primer  binding  sequences  were  very 
similar  to  those  of  pertactin. 
To  obtain  the  corresponding  gene  sequence  within  unamplified  DNA,  to  avoid  potential 
errors  caused  by  DNA  polymerase  activity  and  therefore  ensure  accuracy  of  the 
sequence,  a  cosmid  library  was  screened  using  part  of  the  MR30  amplicon  as  a  probe 
(P640)  (section  3.1.2).  One  cosmid,  cosmid  3,  contained  sequence  identical  to  the 
MR30  amplicon.  In  addition,  analysis  of  the  flanking  sequence  revealed  that  MR30  did 
represent  part  of  a  larger  putative  ORF.  Screening  of  a  cosmid  library  using  an  amplicon 
as  a  Southern  blot  probe  is  a  commonly  used  technique  to  aid  the  identification  of  genes. 
This  is  often  a  laborious  task  and  several  alternative  approaches  are  currently  available. 
In  the  case  of  B.  pertussis,  the  genome  sequence  alleviates  this  need.  In  instances  where 
160 Blackburn  P.  E.  Discussion 
the  genome  sequence  is  not  known,  other  approaches  are  now  more  favoured.  Perhaps 
the  most  convenient  is  the  use  of  an  adapter  tag  to  allow  the  construction  of  a  molecular 
library.  From  such  libraries,  target  genes  can  be  amplified  by  PCR  using  only  one  gene- 
specific  oligonucleotide  in  conjunction  with  an  adapter-targeted  primer.  If  a  project 
similar  to  the  one  described  was  approached  at  the  present  time,  such  an  approach 
would  prove  more  convenient. 
4.3.1.2  Obtaining  the  3'  sequence  of  bap-S 
Unfortunately,  the  cosmid  insert  did  not  contain  the  3'  end  of  the  putative  ORF  or 
encode  a  suitable  translational  stop  codon,  due  to  the  EcoPJ  site  (position  2341,  Figure 
5)  being  restricted  during  cosmid  library  construction.  To  obtain  the  3'  of  the  bap-5 
sequence  and  thus  complete  the  putative  open  reading  frame,  attempts  were  made  to  re- 
screen  the  cosmid  library  using  another  Southern  blot  probe,  P200,  which  was,  like  P640, 
derived  from  MR30  (Figure  4).  This  probe  proved  unsuitable  and  resulted  in  high 
background,  probably  due  to  non-specific  hybridisation.  This  was  possibly  due  to  the 
high  GC  content  of  this  region  (65%). 
Conventional  Single  Specific  Primer-PCR  (SSP-PCR)  was  also  attempted  using 
PEBIFOR16  with  M13FOR  or  M13REV  (Table  5).  Although,  on  several  occasions, 
the  pUC  ligated  B.  pertussis  DNA  resulted  in  plausible  amplicons,  the  resultant 
sequences  were  always  due  to  mispriming  of  the  specific  primer. 
GenomeWalkerTM  SSP-PCR  proved  to  be  an  effective  way  to  establish  the  sequence  at 
the  3'  end  of  the  putative  open  reading  frame.  Such  approaches  have  major  advantages 
over  conventional  techniques.  This  method  obviates  the  requirement  for  a  library  stored 
at  -80°C  in  E.  coli,  as  5  libraries  (in  microfuge  tubes)  are  stored  at  -20°C.  This  technique 
allows  rapid  identification  of  sequences  and  is  limited  only  by  PCR  elongation,  which  is 
in  turn  dependent  on  the  distance  between  the  restriction  sites  (adapter  location)  and 
the  target  site  of  the  gene-specific  primer.  Libraries  can  be  re-used  approximately  80 
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times  for  identification  of  different  flanking  sequences.  Resultant  amplicons  can  be 
conveniently  cloned  using  AT  cloning  techniques,  which  are  often  easier  than  cosmid 
subcloning. 
The  nucleotide  sequence  of  bap-5,  including  some  flanking  sequence,  and  the  predicted 
open  reading  frame  was  submitted  to  GenBank  on  the  11/08/1998  as  a  "putative 
autotransporter  protein  of  B.  pertussis"  (accession  number  AF081494). 
4.3.1.3  Detection  of  bap-5  in  the  genomes  of  bordetellae 
In  addition  to  Southern  blot  identification  of  bap-5  in  the  wild-type  B.  pertussis  genome 
of  strains  Taberman  and  BBC29  (Table  3),  it  was  also  possible  to  identify  related 
sequences,  that  hybridised  with  the  P640  probe  in  the  EcoRI  digested  genomes  of  B. 
bronchiseptica  and  also  B.  parapertussis  (Figure  16).  Such  bands  were  present  at  a 
different  size  in  these  species.  The  Pm  and  BrkA  mutants  (strains  BBC30,  a  derivative 
of  BBC29  wild  type,  and  BP2041,  respectively)  of  B.  pertussis  also  showed 
hybridisation  to  restriction  fragments  of  the  same  size  as  the  wild  type  strains.  The 
genes  that  are  mutated  in  these  strains  represent  the  sequences  with  most  similarity  to 
the  probe  and  it  was  considered  that  cross  reaction  to  these  genes  might  have  been 
possible.  The  results  suggested  that  the  target  DNA  was  not  within  prn  or  brkA  and 
represented  a  distinct  sequence.  The  presence  of  bap-5  in  the  genomes  of  B.  pertussis 
and  B.  bronchiseptica  has  since  been  confirmed  by  the  genome  sequencing  projects  (see 
Figure  42  for  B.  bronchiseptica  bap-5  homologue).  The  sequence  in  B.  pertussis  strain 
Tohama  reported  by  the  Sanger  Center  has  100%  nucleotide  identity  to  the  bap-5 
nucleotide  sequence  obtained  for  this  project  using  strain  Taberman  (BLAST  search 
performed  at  http:  //www.  sanger.  ac.  uk/Projects/B_pertussis).  The  fact  that  the  bap-5 
sequence  is  identical  in  two  B.  pertussis  isolates  suggests  functional  importance.  Also,  a 
gene  with  high  homology  to  Bap-5  has  been  identified  in  B.  bronchiseptica  strain  RB50, 
which  also  infers  commmon  functional  importance.  The  absence  of  a  reaction  of  P640 
to  the  B.  avium  genome  was  not  surprising,  as  many  other  virulence  factor  genes, 
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including  pertactin,  are  absent  from  this  species  and  the  envelope  profile  of  B.  avium  is 
distinctly  different  to  those  of  other  bordetellae  (Leyh  and  Griffith  1992). 
Bordetellae  harbour  redundant  genes,  such  as  the  flagellin  genes  in  B.  pertussis  and  B. 
parapertussis  and  the  brkA  gene  in  some  B.  bronchiseptica  strains  (Arico  and  Rappuoli 
1987;  Leigh  et  al.  1993;  Rambow  et  al.  1998).  The  brk  locus  has  been  identified  in  all 
Bordetella  species  except  B.  avium  and  is  expressed  by  all  B.  pertussis  tested  but  only 
by  some  B.  bronchiseptica  strains,  although  its  role  in  B.  bronchiseptica  is  unclear 
(Rambow  et  al.  1998).  Another  example  of  silent  genes  is  the  pertussis  toxin  (ptx) 
operon  which,  although  present  in  B.  bronchiseptica  and  B.  parapertussis,  is  not 
expressed.  This  is  due  to  altered,  defective,  promoter  sequences  which  prevent 
transcription  (Arico  and  Rappuoli  1987).  It  was  therefore  important  to  confirm  the 
expression  of  the  open  reading  frame  of  Bap-5  at  the  transcriptional  level  (by  RT-PCR, 
Figure  17)  and  also  at  the  translational  level  (by  Western  blotting,  Figure  18). 
From  the  data  presented  in  this  thesis  Bap-5  appears  to  be  a  protein  of  predicted 
molecular  weight  79.5  KDa,  and  transcription  is  Bvg-regulated.  The  protein  appears  to 
be  localised  in  the  outer  membrane  and  processed  to  fragments  of  apparent  molecular 
weight,  30  KDa,  and  65  KDa  on  SDS-PAGE  of  B.  pertussis  outer  membrane 
preparations.  The  30  KDa  band  is  consistent  with  that  predicted  for  the  C-terminal 
portion  of  Bap-5  and  it  is  feasible  that  the  65  KDa  band  represents  a  surface  associated 
N-terminal  portion  (predicted  size  49  KDa).  However,  size  estimation  of  the  N- 
terminus  from  SDS-PAGE  is  probably  inaccurate.  It  is  known  that  the  related  protein, 
P69,  migrates  anomolously  on  SDS-PAGE. 
4.4  Bap-5  as  an  autotransporter 
The  similarities  between  the  B.  pertussis  autotransporters  obtained  by  performing  a 
BLASTp  search  with  the  Bap-5  C-terminus  amino  acid  sequence  are  summarised  in 
Figure  14.  The  N-terminus  of  Bap-5  exhibits  some  sequence  similarity  to  other 
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described  B.  pertussis  autotransporters  but  not  Tcf  (Figure  15).  The  high  sequence 
similarity  between  the  Bap-5  C-terminus  and  other  known  autotransporters  (Figure  15) 
strongly  suggests  that,  on  the  basis  of  such  homology,  Bap-5  is  another  member  of  the 
autotransporter  family.  This  high  similarity  is  not  surprising  as  these  C-termini 
probably  function  to  form  a  ß-barrel  pore  and  allow  translocation  of  the  N-terminus  to 
the  cell  surface.  This  similarity  suggests  that  these  proteins  are  closely  related,  and 
probably  diverged  following  gene  duplication,  but  with  conservation  of  the  C-terminal 
encoding  regions.  It  is  interesting  to  note  the  lack  of  similarity  between  the  Tcf  N- 
terminus  and  the  other  B.  pertussis  autotransporters  (Figure  15).  The  N-terminal 
similarity  between  Prn,  BrkA,  Vag8  and  Bap-5  is  approximately  40%  whereas  the  Tcf 
N-terminus  possesses  no  significant  similarity.  This  may  imply  a  different  origin  for 
the  5'  of  the  gene  encoding  Tcf  and  have  implications  for  the  function  of  Tcf  compared 
to  the  other  B.  pertussis  autotransporter  proteins. 
The  role  of  the  more  highly  conserved  20  amino  acids  at  the  C-termini  of 
autotransporters  must  be  established.  It  has  been  suggested  for  IgA  protease  and 
AIDA-I  that  they  consitute  a  signal  of  outer  membrane  localisation  and  form  the  final  ß- 
sheet  in  the  outer  membrane  (Klauser  et  al.  1993;  Suhr  et  al.  1996).  Further  evidence  is 
provided  by  the  Hap  protein  of  H.  influenzae.  If  the  C-terminal  three  amino  acids  of  the 
outer  membrane  localisation  signal  are  mutated  or  removed,  the  protein  is  no  longer 
detected  in  the  outer  membrane  (Hendrixson  et  al.  1997). 
4.4.1  The  putative  functional  domains  and  motif  analysis  of  Bap-5 
The  N-terminus  of  Bap-5  exhibits  some  homology  to  Prn  and  BrkA  (Figure  15).  These 
proteins  all  act  as  adhesins  and  BrkA  also  confers  serum  resistance  to  B.  pertussis 
(Fernandez  and  Weiss  1994;  Finn  and  Stevens  1995;  Everest  et  al.  1996).  Several  motifs 
were  identified  in  the  predicted  amino  acid  sequence  of  Bap-5.  A  potential  integrin 
binding  motif,  arg-gly-asp  (RGD),  was  identified  within  the  N-terminus  of  Bap-5 
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(Figure  12).  Such  motifs  are  present  in  the  N-terminal  domains  of  Prn,  BrkA  and  Tcf. 
(Figure  3).  In  Prn,  the  role  of  the  RGD  in  adhesion  and  invasion  has  been  studied  using 
synthetic  RGD-containing  sequences  in  competitive  binding  experiments  with  HeLa 
cells.  The  results  suggested  that  RGD  in  pertactin  may  play  a  role  in  adhesion  and 
invasion  (Leininger  et  al.  1992).  Seemingly  contradictory  results  were  obtained  when  an 
RGD--)RGE  mutant  of  recombinant  pertactin  expressed  by  E.  coil  had  no  significant 
effect  on  adhesion  to  CHO  or  HepC  cells  (Everest  et  al.  1996).  The  position  of  the 
RGD  within  Bap-5  could  be  determined  from  structural  analysis.  Such  experiments 
would  be  useful  in  determining  a  role  for  the  RGD  motif  in  Bap-5. 
The  presence  of  a  glycosaminoglycan-binding  motif,  serine-glycine-serine-glycine 
(SGSG,  position  1346,  Figure  12),  provides  further  evidence  that  Bap-5  may  function  as 
an  adhesin  and  promote  binding  to  glycosaminoglycans  such  as  heparin.  Such  motifs 
(SGXG)  are  also  present  in  BrkA  and  Tcf  (Figure  3)  although  the  role  of  these  motifs  in 
these  proteins  has  still  to  be  established  experimentally.  In  addition, 
glycosaminoglycan-binding  motifs  have  also  been  implicated  in  mediating  resistance  to 
complement,  possibly  by  inhibiting  polymerisation  of  the  complement  component  C9 
in  a  manner  similar  to  that  suggested  for  the  Rck  protein  in  Salmonella  ryphimurium 
(Hefferman  et  al.  1992;  Hefferman  et  al.  1992;  Fernandez  and  Weiss  1994).  The  serum 
protein  vitronectin  also  has  a  glycosaminoglycan  binding  site  which  also  inhibits  C9 
polymerisation  (Millis  et  al.  1993).  Again,  the  role  of  this  motif  in  adhesion,  and 
possibly  complement  resistance  could  be  evaluated  using  synthetic  peptides  in 
competitive  binding  experiment  and  also  by  characterisation  of  a  Bap-5  mutant  lacking 
this  motif. 
A  N-terminal  leader  (signal)  sequence  was  not  identified  in  Bap-5  using  matrix 
prediction  methods  which  are  based  on  characterised  signal  sequences  (Perlman  and 
Halvorson  1983;  Von  Henge  1986).  Prn,  Tcf  and  Vag8  have  typical  signal  sequences  ie. 
those  predicted  to  target  the  protein  through  the  inner  membrane  by  the  Bordetella 
equivalent  of  the  Sec  pathway  (Charles  et  al.  1989;  Finn  and  Stevens  1995).  It  is  likely, 
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from  E.  coli  studies  of  autotransporters  that  the  cleavage  of  a  leader  sequence,  if  present, 
occurs  during  translocation  via  the  Sec-dependent  pathway,  or  equivalent.  This 
presumably  accounts  for  the  targetting  of  Prn,  Tcf  and  Vag8  to  and  across  the 
cytoplasmic  membrane.  In  the  case  of  BrkA,  and  possibly  Bap-5,  an  alternative 
pathway  must  be  utilised.  For  BrkA,  BrkB  appears  to  fulfil  this  role.  It  is  possible  that 
BrkB,  or  a  functionally-related  protein  may  be  responsible  for  the  translocation  of  Bap- 
5  across  the  cytoplasmic  membrane.  The  use  of  a  B.  pertussis  BrkB  mutant  to  study 
the  processing  and  export  of  Bap-5  (expression  and  cellular  localisation  studies)  may 
provide  evidence  for  the  secretion  pathway  used  by  Bap-5.  Alternatively,  the 
B.  pertussis  genome  sequence  may  aid  identification  of  factors  which  may  be  responsible 
for  the  export  of  Bap-5.  However,  BLAST  analysis  of  the  genome  database  revealed  no 
BrkB  homologues  (results  not  shown). 
Several  autotransporters,  such  as  SepA  and  AIDA-I,  appear  to  have  atypical,  longer 
signal  sequences  which  include  N-terminal  extension  sequences  (Benjelloun-Toulmi  et  al. 
1995).  It  has  been  suggested  that  such  large  atypical  signal  sequences  present  in 
autotransporters  could  be  acting  as  an  unfoldase  in  the  periplasm  (Holland  1998). 
Again,  no  such  signal  sequence  could  be  identified  within  Bap-5.  It  is  likely,  therefore, 
that  the  export  of  Bap-5  across  the  cytoplasmic  membrane  is  not  mediated  by  a  type  II 
pathway. 
4.4.2  Regulatory  sequences  adjacent  to  the  proposed  bap-5  open  reading  frame 
The  transcriptional  start  of  bap-5  was  not  determined  during  this  study.  Perhaps  this 
could  be  achieved  using  5'RACE  (rapid  amplification  of  5'  ends).  This  may  aid  the 
identification  of  the  regulatory  sequences  upstream  from  the  bap-5  ORF.  No  typical 
Shine-Dalgarno  sequence  (Shine  and  Dalgamo  1975)  was  identified  in  the  sequence  5'  to 
the  proposed  open  reading  frame.  Also,  no  BvgA  dimer  binding  site  was  identified, 
which  have  been  described  upstream  from  the  promoters  of  prn,  fha,  bvg,  ptx  and  cya 
and  takes  the  form  TTTC(C/T)TA  (Marques  and  Carbonetti,  1997;  Kinnear  et  al. 
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1999).  The  BvgA  dimer  is  thought  to  interact  with  RNA  polymerase  and  regulates 
transcription. 
Downstream  from  the  bap-5  proposed  open  reading  frame  there  is  a  sequence  which 
may  represent  a  rho-independent  terminator  (Figure  13).  There  is  also  a  putatitive  rho- 
independent  terminator  for  the  gene  encoding  P.  93  (Charles  et  al.  1989).  In  P93,  this 
secondary  structure  is  further  from  the  stop  codon  and  smaller  than  in  bap-5.  This 
potential  hairpin  structure  at  the  3'  end  of  the  mRNA  could  be  responsible  for  causing 
the  RNA  polymerase  to  pause  and  therefore  preventing  further  mRNA  synthesis 
(Stryer  1988). 
4.5  Identification  of  novel  B.  pertussis  autotransporter  proteins 
The  B.  pertussis  genome  sequence  (http:  //www.  sanger.  ac.  uk/Projects/B_pertussis)  was 
considered  almost  complete  at  the  time  of  this  analysis  (finishing/gap  closure  taking 
place).  However,  according  to  the  database,  this  sequence  may  contain  errors  and  vector 
sequences  and  is  not  contigous.  The  amino  acid  sequences  of  the  characterised 
B.  pertussis  C-terminal  domains  were  BLAST  searched  against  the  genome  data  to 
identify  potentially  novel  open  reading  frames  for  autotransporter  (C-terminal)  domains. 
The  resultant  coding  sequences,  and  flanking  sequences  were  then  analysed  using 
Genejockey  II.  The  first  methionine  following  an  in-frame  stop  codon  was  used  where 
appropriate.  Figure  43  shows  an  alignment  of  the  characterised  autotransporters  and  the 
novel  autotransporters  Bap-6  -  Bap-9  and  Phg.  Figure  44  shows  a  matrix  comparison  to 
highlight  gross  sequence  similarity  in  the  N  and  C-terminal  domains.  Phg  has  not  yet 
been  characterised,  but  has  been  deposited  in  GenBank  (accession  number  AJ009835)  as 
a  cold  shock  protein  of  B.  pertussis. 
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Several  similarities  can  be  identified  from  this  preliminary  information: 
Bap-6:  No  start  codon  was  identified  within  the  novel  N-  terminus  which  contains 
forty  four  RR  repeats.  The  significance  of  these  repeats  is  not  known.  Bap-6  also 
contains  an  RGD  motif. 
Bap-7:  No  start  codon  was  identified  within  the  N-terminus.  The  N-terminus  does 
have  some  homology  to  P.  69  and  contains  an  SGXG  motif. 
Bap-8:  No  ATG  start  codon  was  identified,  although  it  is  possible  that  a  GTG  start  is 
present.  The  N-terminus  has  some  homology  with  Tcf  and  P.  69  and  contains  two  PQP 
repeats. 
Bap-9:  No  ATG  start  codon  was  identified.  The  N-terminus  has  some  homology  with 
Tcf  and  AIDA-I  and  contains  an  RGD  and  a  SGXG  motif. 
The  reason  for  B.  pertussis  possessing  so  many  adhesins  with  similar  proposed 
mechanisms  of  binding,  such  as  those  mediated  by  RGD  and  SGXG,  is  not  clear.  It  has 
been  suggested  that  it  may  be  to  allow  "immune  exclusion"  by  allowing  the  cells  to  avoid 
the  effect  of  antibodies  to  specific  adhesins  which  would  prevent  adhesion  (Weiss, 
1997). 
168 Figure  42:  An  alignment  of  the  amino  acid  sequences  of  Bap-5  from  B.  pertussis  (top) 
and  B.  bronchiseptica  (bottom).  Dots  represent  amino  acid  identity,  lines  represent 
amino  acids  with  similar  properties. Blackburn  P.  E. 
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170 Figure  43:  An  alignment  of  the  characterised  autotransporters  with  those  predicted 
from  the  B.  pertussis  genome  sequence  during  the  course  of  this  study.  Red  amino  acids 
represent  identity  and  blue  repesent  similar  amino  acids. Blackburn  P.  E. 
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Tcf 
Bap-7 
Bap-8 
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91  100  110  120  130  140  150  160  170  180 
1  +-------+  +---------1 
MNMSLSRIVKRRPLRRTTLRMR-LGRLGRR---PRRHRDNNNQSIVKTGERQHGIHIQ6SDPGGVRTRSGTTIKVSGRQ--RQ 
GETRPPTLKDIHISVEHKNPMSKPRIGVR-VSGRGRRLTLRGSTIDRTEGGIPRVVRRGGTLELDGVTVRGGEGMEPMTVSDRGSRLSVR 
GHTGRGGRHPIHFQISRGRRLMLGLLDYRGRRRVTRRQRIDGGRRFLGDVRIRTTKRSEHGINYTGRTRE--VRYTGGTIRTSGNQ--RQ 
.............................  ........................................................ 
161  190  200  210  220  230  240  250  260  270 
11 
GILLENP-RRELQFRNGSVTSSGQLSDDGIRRFLGTVTVKRGKL-VRDHRTLRNVGD  IRLYVRGEQR 
GGYLGGE-RPGVGLYRRRQGGQRSIIDRTLQSILGPRLIRDGGSISVRGGSIDHDIIGPGFPPPPPPLPGRPLRRHPPLDRVRRVHRGQDG 
GLRVGTENRPDNTRLGRSVFLQNLIIETSGTGRLGVSVHEPQGGGGTRLSHSGTTVRTRGDDSFRLQLSGPRSR--TLNDVRLETRGQQR 
MCDTCRDDDGTSP 
Pq 
.......  .................................................................. 
Discussion 
.............. 
271  280  290  300  310  320  330  340  350  360 
1I 
QRSIRDSTL  QGRGGVQIERGRNVTVQRSRI-VDGGLHIGRLQSLQPED-LPPSRVVLRDTNVTRVPRSGRPRRVSVLGRSELTLD 
KVTLREVRLRRHGPQRTGVYRYNPGSEITLQGGTVSVQGDDGRGVVRGRGLLDRLPPGGTVRLDGTTVSTDGRNTDRVLVRGDRRRREVV 
PRVVLNQGRQLNRQGLVVQYNGRGYSRIHfNIDRGSFTLSGSDITRRGLEVRGIYVQEGNQGTLTGTRVTTQGDTRPRLQVEDRGTHVSNN 
SIRVQGGVVQGGNGRNNVRVVRTGSGKVRIEHRELLGRSGNYRTFGRQVDHKGGRILRHNTNILGSQGYRDGPYGGVVVTEDG--QVNLE 
HHIYGNhNRRTPCRGRVRRLRLR 
Bap-6  PYRQRGHDPDGRRRRRLRRRHGGFRRQQPVDQPRIDHDIGQRRRRHLGRQRRQYRDRGRQQRQHPHPGRQRRRHRHQRPGQPRPEQRRHH 
Phg 
Bap-9 
Consensus 
.........................................................................................  " 
361  370  380  390  400  410  420  430  440  450 
11 
Prn  GGHITGGR--RRGVRRNQGRVVHLQRRTIRRGDRLRGG-RYPGGRYPGGRVPGGFGPGGFGPVLDG--NYGVDVSGSSVELRQSIVERPE 
BrkR  NTVLRTRKSLRRGYSRQHGGRVTLRQTRIETRGRGREGISVLGFEPQSGSGPRSYDHQGGSITTTGNRRRGIRLTHGSHRLEGVRYRREG 
VaKB  GGRLSTSGRNSPRRNLLRGGSRQFRDTVLRTVGERSHGVDV-------flRHSEVELRHRQVRRDGQGRHGLVVTRSSRHYRRGSL-VES 
Bap-5  GRKVSRTGLGRRGLNLLGDKDTSPRRSLRNTDVHGEVRRIRLGFNGERNISGGSLSVEDGRYLTTLTPDRVEYYYDYRLSIIEHLPRDRPL 
Tcf  LLGRGHNTLSPPSRIüiLKLPSLLTDDELELYLPTGHSLEDFKRSLQESRPSRLRTPPSSSPPVRKPGPGSVRERPSGSGHKDNPSPPVYG 
Bap-7 
Bap-8 
Bap-6  RQRHRRQGRVSRRRQPRGQRTGQRRHHPCRRR000RHIRPRRRRCEHHQRQRLSCPRREPRRRRHPQRSLVCRRRRERQRYLHQRRLPRR 
Phg 
Bap-9 
Consensus 
".  ".......  "...............................  "..........  ..................... 
Prn 
BrkR 
VagO 
Bap-5 
Tcf 
Bap-7 
Bap-8 
Bap-6 
Phg 
Bap-9 
Consensus 
451  460  470  480  490  500  510  520  530  540 
11 
LGR-RIRVGRGRRVTVPGGSLSRPHGIIYIETGGRRRFRPQR---RPLSITLQ-RGRHRQGK--RLLYRVLPEPV-KLTLTGGRDRQGDIV 
SGSSRRQLRNGTLYVS(K;  SLRSIWSGRISVTDTPLKLMPGRLRSSTVSVRLT-DGRTRQGGNGVFLQQHSTIPV-RVRLESGRLtNtGDIV 
TGDGRRRLLESGHLTVDGSVVHGHGRRGLEVDGES---------NVSLL-NGRRLSSDQPTRIRLIDPRSVLNLDIKDRRQLLGDIR 
T---PVRVTLSOGRRRSGETLIRNGGLLPMTLRLSSGVDRRGDIVTLPPSRPPDSREQPDREPEP  QVD 
VGPGMRESSGGHNPGVGGGTHENGLPGIGKVGGSRPGPGGLGRNDENSESSLNPGTLGPSPGPDTSTGSGPDRGMRSGRGSTSPGRSGGR 
RNRGRPENRVRGGRQLLRQTTPVPVRLVLRGRRVRQGDYVRRPETRPEKD 
VGLRSHLPELPTPSRCHE 
RRRGRPRHGRLNGPPGHGHRDPRHRLGHRRPGRRRRGGQPCVSGGQRHGGQPVRQLPHPDHRRRRLRLDLGRRVHRKRGPRHRNILSCRH 
.................  e........................................................................ 
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541  550  560  570  580  590  600  610  620  630 
1----------------  -------  -----f---------r----------------  ----  --------------  I 
Prn  RTELP----SIPGTSIGPLDVRLflSQflRNTGflTR-flVDSLSIDNH-TNVMTDNSNVGRLRLflSDGSVDFQQPR-ERGRFKVLTV-NTLRG 
Brkfl  flDGNK----PLDRG----ISLSVRSGRRHHGRTQ-YLQSflTLGKGGTNVVNRDSRVQDMSMRG-GRVEFQRPR-PERSYKTLTL-QTLDG 
VagB  PEflQQ----PDGSPEQflRVRVflLRDGGTNRGRTDGRVHTVRLLDRGVNTVTGDSRVREVKLEG-GTLRFflPPRQPKGRFKTLVRTQGISG 
Bap-5  GGEPVflVPIPflPSHPDflPIDVFIDSGflQNRGMTK-TVNflLRIED-GTHTVTGSSTVNSLHLQR-GKVRYRTPRESDGEFKHLRV-KTLSG 
Tcf  GKO------RMPPSEGERPDSGMSDSGRGGESS-----RGGLNPDGflGKPPREEGEPGSKSPflOGGQOGPPPPRDGGDflDPQP--PRODG 
Bap-7  GFGTPVRPGLRVGLDQRPLELDVRDGflQHHGRTQ-SLDRLflLGXGGQNRMSRflSSYGELSMEPGRRVVFGORRGPG--FQTLTV-RTLRG 
Bap-8  ILHTPLQLflSTPPXHXflRCTHLQTQPGRIQPIDSSQLDGNPVDDENGLITTIDLD--GTflIDDGHTHIDIPRPELDGRPVOSED--GRLPS 
Bap-6  RRQPGQPPGRRRGXGRHRHflGRRIflQRRRNPRRPERRQRLRRRDGRRXLHRRGRRRRRQHGRGRRRGRLGQXGHRIBZRRRRQH--PGHGG 
Phg  MKPTSILINILPRYLGRCRLRRLflflLflVRPLRPRQfl 
Bap-9 
Consensus 
...............................................  w.......................  Pa................  k 
631  640  650  660  670  680  690  700  710  720 
I--------+--------+--------+--------+---------+--------+-------+---------+---------I 
Prn  SGLFRHNVFRDLGLSDKLVVHQDRSGQHRLNVRNSGSEPRSRNTLL-LYQTPLGSRflTFTLflNKDGKVDIGTYRYRLRRNGNGQ-NSLVG 
Brkfl  NGVFYLNTNVRflGQNDQLRVTGRRDGQHRVLVRNflGGERDSRGRRLGLVHTQGQGNflTFRLRNYGKRYDLGTNRYSLflEDPKTHVNSL-- 
VagB  TGTIVHNRHLPSGTRDVLVRPQGFGDRQVLVVNNTDDGTESGRTKVPLIEDE-Q6HTRFTLGNHGGRYDRGflRQYELTRSERQRDKRRTN 
Bap-5  SGLFEIINRSRDLSDGDLLVVSDERSGQHKVLVRGflGTEP-TGVESLTLVELPEGSQTKFTLRNRGGVVDflGRFRYRLTPDNGV--HGL-- 
Tcf  NG----EQQPPKGGGDEGQRPPPRRGNGGNGGNGNRQLPERGDDflGPKPPEGEGGDEGPQPPQGGGEQDRPEVPPVRPRPPRGNGVY--- 
Bap-7  flGSFEIIRRDRflLEHRDQLVVTDQREGRHRVHLRRPRGflEPSKflQflV-LVRRPflDGKRSFELDGSDGRRDFGTYRYGLRQQPGGR-NGL-- 
Bap-8  PPEERPQRGPDRSKQRPEGLPRPDflNPQPDRKPGRENKPRPGVEPGPEREPGPQGQPGPQPGRR--PQDEPHRQPLPPRGNPGRGIYH-- 
Bap-6  QPGRRGRRDRGRRHXGGPGHQHRKLGRRRLLXNPPPSTPRHTSTGCTRRRPXRXRPDSNYXRSRRYLVEDQLRGSLRERERIRDDI6RRT 
Phg  QTPLPRGLGRREVRQYLSGLPSDRLRQQflSNLRPflLLRPYLSGLTDRQLRQYYQRLTPGQITQGLRRLTPRQRRRLQREFERQRRRQV-- 
Bap-9  DGGRRS6VTPXVXKPQGGXXGLTLRGIPVVVHQGGRTTRPGflFRLflQPLVRGRYEYQLLRGHGDGRflXQRQDNYLRTSRVERDKflGR- 
Consensus  g  .............  d.......  a.  g............  P..  g.......................  g..  d.....  y............... 
721  730  740  750  760  770  780  790  800  810 
I-------+---------+-------*--------+---------+--------t-------+-------+--------  I 
Prn  RKRPPRPKPRPQPGPQPPQPPQPQPERPRPQPPRGRELSRRRNRRVNTGGVGLRSTLNYRESNRLSKRLGE--LRLNPDRG---GRHGR 
BrkR  --------------  ---------------  QRRGQRLSGRRNRRVNRRDL---SSIRLRESNRLDKRLGE---LRLRRDRG---GPNRR 
Vag8  --------------  ------------QLTPTNELSTTRTRRVNRMRIRRSQRINQREMDVLLRNMSG---LHSIGSPG--GFNRR 
Bap-5  -----------------------------ERTSQLSRVRHRRLNTGGVGRRSSINYREGNRLSKRLGE---LRLDPGRG---GFNGR 
Tcf  ---------------------  w----DPGTHTLTTPRSRRVSLRS--SSHGVNQREMNRLSKRMGE---LRLTPVRG---GVIIGR 
Bap-7  ------------------------  ---VRTGYSSTRRRRLDTGGLGRVQGLNYRESNRLGKRMGE--LRLNPDRX---GRNGR 
Bap-8  --------------  -------M ------PRSGILTRPVLRVLGTRS--RPQGIUQREMNRLSKRMGE---LRLTPRRG---GVURR 
Bap-6  GE----------------------------RPSIEDTPLYRPEVRLYSSIPMLRRRMGLRQLGTFHERQGN---QRLLRRDGERVRRURR 
Phg  --------------------  ------QQRVRREVRRRSRRRVRMGQSRSMLLLDREMGTLRQRQGD--LRRGHDEG---RFURR 
Bap-9  --------------  ---------------  IVKVVPFYRPEVRLYRGTPHL"RHVGTERLGSYRERRGQPGRRRPERGHRRRRGVMRR 
Consensus 
.........  1...  a.  aal......  a....  u.  ae.  nal.  kR.  G#...  1r1...  ag...  g.  UaR 
811  820  830  840  850  860  870  880  890  900 
I--------+---------+---------+---------+°-------+---------+---------+---------+--------I 
Prn  GFR--QRQQLDNRRGRRFDQKVRGFELGRDHRVRV-RGGRHH-LGGLRGYTRGDRGFTGDGGGHTDSV---------HVGGYRTYIRDSG 
BrkR  TFS--ERQQISNRHRRRYQQTVSGLEIGLDRGHSR-SGGRHY-RGGLLGYTYRDRTYPGDGGGKVKGL--------HVGGYRRYVGDGG 
VagB  GLS--QRQRLDTGYGPHQKQTVSGIELGLDRRVRGGRTTRIIS-VGHLRGYSETRRDGGRYRRGHVHSR---------HVGRYVSYLNDSG 
Bap-5  TFR--QKQQLDNKRGRRFDQKVYGFELGRDHRIRG-QQGR{JH-VGGLLGYTRRRRSFIDDGRGHTDSR---------HIGRYRRYVRDNG 
Tcf  RFG--RRQDVDNRVSREFRQTISGFELGRDTRLPV-RDGRHH-VGRVRGYTNGRIKFDRGGTGDDDSV---------HVGRYRTYIEDGG 
Bap-7  RFS--QRQRISPRRXRIFQQGVSGIELGRDRRqIPV-RGGRNH-RGNLLGYTRRSRGFSGQGKGHTDSV---------HVGGYRTYIGRNG 
Bap-8  SFR--QRQRLDNQVVDRFTQTVGGIEIGRDTRLPR-REGRNH-VGRVRGYSRRRRKLRHSRRGNSDSL---------HVGRYRTYIGDGG 
Bap-6  RYGGNSKQRLDGDRQPGIDRRLRGVQLGQDLYSSVRPDGGQHRFGLFGGYGQRRGDTHGSRGGERDRRTGRLTIDGYSVGGYHTYVGPRG 
Phg  GSR--NRFKVDTPDTPRFDLRVEYLTLGRDHGNRL-DTGRLY-LGRYRGVSRRRHDDNDIHHGRIESR------FLGTYLTYVDNGG 
Bap-9  TFGRRFERSRGSERRPSFNGSLRGHQLGRDLYTRRSRTRHRDRFGVFGGYRTRRGQVRGLRRGEIQRV-GTSTLRRRQLGRYNTHTGPSG 
Consensus 
. 
f....  rq..  d..  a...  f.  q.  v.  g.  elGaD......  a.  grwh..  G...  Gy..  arr.......  G..  ds..........  hvGaYaty.  gd.  G 
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901  910  920  930  940  950  960  970  980  990 
I--------+---------+---------+---------+---------+--------+---------+---------+---------I 
Prn  FYLDRTLRflSRLENDFKVRGSDG-YRVKGKYRTHGVGHSLERGRRFTHflDGUFLEPQRELRVFRflGGGRYR-RRNGLRVRDEGGSSVLGR 
Brkfl  YYLDTVLRLGRYDQQYNIRGTDG-GRVTRDYRTSGRRNSLEGGRRFELPNDUFREPQHEVHLNRTSGKRYR-flSNGLRVKVDRNTRTLGR 
YagB  SYYDGVVKYNRFRHGFDIRTTDL-KRVDRKHRSHGLGRLLRGGRRIDIDGGNYVEPQRSVFNIFHRGGSRYE-HSNGLRVRRDGflHSIIVLR 
Bap-5  FYFDSTLRflSRFENDFTVTRTDfl-YSVRGKYRflNGVGRTLERGKRFTLHDGUFVEPQSEVSLFHRSGGTYR-RflNNLSVKDEGGTSflVLR 
Tcf  FYHDGIVRVSRIRHRFKVDDflKG-RRVRGQYRGNGVGHSLELGKRFTNPGRUYVEPQLEVRRFHHQGRDYT-RSNGLRIKDDGTNSHLGR 
Bap-7  YYflDRTLRRSRFENSFDRPGHflG-RTVSGSYRRNGVGVTLERGRRLRLDRHUFVEPQRELRNFRflGGGTYT-HSNGLRIEDDGGTSLQRR 
Bap-8  FYLDGIVRYNRYEHDFRflDGQRG-RRVTGKYRflNGIGLSLETGRRFTNRGDUFVEPQYEVRLFRSGGflDYT-flSNGYRVDVRSTKSLLGR 
Bap-6  NYYDRVLRNTNHDIDTDSKRGR-----DRDTRGQflFTRSLESGYPLRLSERUTLEPQRQLIYQHTRVDGFSDHYSEVRIRDD--NflLTflR 
Phg  FYVDflVSKLGRIDESVSFDLPLGLGDYDDDISHTTYTGSflERGYHFKLPQRUFVEPQflQVIYSRSS-----------------QTSYQGR 
Bap-9  NYVDTVLRGTRYKQQTSSSR-----NVGRTSRGNGNHflSVERGYPNQLNPRUQIEPQHQLVYQQLGIRNGRDRVSSVSYKTP--DRLTGR 
Consensus 
. 
Y.  D.  vlr..  r....  f......  g...  v...  yr..  g.  gaslEaG.  rf.  1...  UfvEPQaily..  f...  g..  y..  a.  nglr.......  s..  gR 
991  1000  1010  1020  1030  1040  1050  1060  1070  1080 
I-------+-------+---------+--------+--------+--------+---------  +----  ------------  --I 
Prn  LGLEVGKRIELRGGRQVQPYIKRSVLQEFDGRGTVHTNGI-RHRTELRGTRRELGLGIIRflRLGRGHSLYRSYEYSK--G--PKLRMPUTF 
BrkR  LGLRFGRRIRLRGGNIVQPYHRLGUTQEFKSTGDVRTNGI-GHRGRGRHGRVELGRGVDRRLGKGHMLYRSYEYRR--G--DRINIPUSF 
VagB  RGRERGRQMRLRNGNIVEPYRRLGURQELGRDNRVYTNGI-RHVTRSRGGFRERRVGVGRLLGKRHRLYRDYEYRK--G--RRFERPUTL 
Bap-5  LGLRRGRRIDLGKDRVIQPYRTLSULQEFKGVTTVRTNGY-GLRTDLSGGRflELRLGLRRRLGRGHQLYTSYEYflK-G--NKLTLPUTF 
Tcf  LGLHVGRQFDLGDGRVVQPYMKLSUVQEFDGKGTVRTNDI-RHKVRLDGGRTELRVGVRSQLGKHGSLFGSYEYRK--G--SRQTMPUTF 
Bap-7  VGRQRGRRFDLRGGRVVQPYRQLSUVQELKGVSTVRTNGI-RHRTDLGRGRVELGLGVflflRLGKGHNLYRSYEYflH--G--PRLSLPUTV 
Bap-8  RGLQVGRKLDLGNGKLVQPYRKLSULQEFDGVGKVRTNDI-GHDVKLRGGRRELDLGVHRRLGRHSSLFRSYEYSK--G--SRLTIPUSF 
Bap-6  LGRRLQGEYRflR-RQVNRPYRRLNFNRTFSGENTVVLGED-SIDTRRGRTSLELflRGRSVTLRRSLRLYGRLRYRT--SIDSQYLRGflSR 
Phg  RGVRRGRDFTLRGGRTLRPYVSRSYLHEFSHDDSVDFGGK-SYDflELPGSRUQLGRGRRLDVG-RHRRYRDLRYGH--G--RNISQDLSL 
Bap-9  LGTRLRGQYflYRKRQ-LRPFMGVSLLHDLTGXXXXTXXGVHSVRRSXQXTXVDLKRXVDTQLGKSVGLHXQVGYGKSVGSGDGSDXGUSR 
Consensus  1G...  gr...  1..  g..  vgP%a.  lswlgef.  g...  v.  tngi..  h...  l.  ggr.  qL..  gvaa.  lg..  h.  lyasyeYak..  g.......  pus. 
10811088 
Prn  HRGYRYSII 
Brkfl  HRGYRYSF 
Vage  QLGYRYSH 
Bap-5  HLGYRYTM 
Tcf  HVGYRYIN 
Bap-7  QLGYRYON 
Bap-8  HVGYRYRII 
Bap-6  QLGIIRYTII 
Phg  NIGYRYRF 
Bap-9  NLGLRVRY 
Consensus  .  1G9ry.  u 
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Figure  44:  A  matrix  to  demonstrate  amino  acid  similarities  between  the  B.  pertussis 
autotransporter  domains  described  to  date  and  those  that  have  been  identified  in  the 
Sanger  B.  pertussis  genome  sequence.  The  C-terminal  and  N-terminal  domains  were 
chosen  on  the  basis  of  known  or  putative  cleavage  sites.  All  similarities  were 
determined  by  BLASTp  analysis  and  are  displayed  as  the  %  positive  (identical  and 
similar)  amino  acids  /  extent  of  the  overlap.  The  extent  of  the  overlap  is  the  window  of 
amino  acids  which  have  been  analysed.  NS  represents  no  significant  similarity. 
Bap-5:  GenBank  Acc  No.  AF081494 
Pm:  GenBank  Acc  No.  AJ006152 
BrkA:  GenBank  Acc  No.  U12276 
Tcf  GenBank  Acc  No.  U16754 
Vag8:  GenBank  Acc  No.  U90124 
Bap-5  Prn  BrkA  Tcf  Vag8 
Bap-6  N:  NS  N:  NS  N:  NS  N:  NS  N:  NS 
C:  40  C:  43  C:  39  C:  41  C:  38 
280  279  256  277  280 
Bap-7  N:  53  N:  48  N:  NS  N:  NS  N:  42 
224  276  196 
C:  69  C:  74  C:  63  C:  63  C:  57 
278  278  278  278  266 
Bap-8  N:  NS  N:  NS  N:  NS  N:  43  N:  NS 
138 
C:  68  C:  57  C:  64  C:  78  C:  57 
279  279  279  279  279 
Bap-9  N:  NS  N:  NS  N:  NS  N:  NS  N:  NS 
C:  42  C:  Al  C:  41  C:  42  C:  37 
282  291  280  287  284 
Phg  N:  NS  N:  NS  N:  NS  N:  NS  N:  NS 
C:  43  C:  45  C:  43  C:  43  C:  39 
280  279  279  279  268 
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4.6  Processing  of  autotransporter  proteins 
The  mechanism  of  processing  of  the  bordetellae  autotransporters  is  unknown  at  present, 
although  autoproteolytic  release  from  the  cell  surface  does  not  seem  possible  as  no 
protease  catalytic  sites  have  been  reported  within  the  characterised  autotransporter 
proteins.  However,  a  eukaryotic  baculovirus  expression  system  was  able  to  process 
P.  93  to  P.  69  which  implies  a  general  protease  or  autoproteolytic  activity  (Charles  et  al. 
1993).  There  is  evidence  that  Tcf  is  not  autoproteolytic,  and  requires  a  B.  pertussis 
specific  serine  protease  (Chen  et  al.  1998).  Such  evidence  was  obtained  from  studying 
the  processing  of  Tcf  in  Vibrio  cholerae.  In  Bap-5,  no  site  with  homology  to  the  IgA 
protease  serine  protease  active  site  motif  (GDSGSPLF)  (Brenner  1988;  Bachovchin  et 
al.  1990)  was  identified. 
The  gonococcal  IgA  protease  is  processed  in  E.  coli  by  the  envelope  serine  protease 
OmpT  (Klauser  et  al.  1992).  Therefore,  the  most  likely  candidate  protease  for 
processing  other  autotransporter  proteins  might  be  a  serine  protease  in  the  the  cell 
envelope.  However,  the  processing  of  autotransporter  proteins  in  E.  coli  does  not 
necessarily  reflect  the  native  situation.  For  example,  although  OmpT  is  responsible  for 
the  processing  in  E.  coli  of  IgA  protease  (from  N.  gonorrhoeae)  this  process  is  thought 
to  be  autoproteolytic  in  N.  gonorrhoeae.  AIDA-I  (from  E.  col)  appears 
autoproteolytic,  as  processing  occurs  in  E.  coli  strains  deficient  in  ompT,  ompP  and 
DegP  (Suhr  et  al.  1996).  Other  E.  coli  autotransporters,  EspP  and  Pet,  and  the  Hap 
protein  of  Haemophilus  influenzae  contain  serine  protease  motifs  which  are  thought  to 
be  processing  targets  (Brunder  et  al.  1997;  Hendrixson  et  al.  1997;  Eslava  et  al.  1998; 
Navarro-Garcia  et  al.  1999).  Some  autotransporter  proteins,  such  as  VacA  (from 
H.  pylori),  may  possess  species-specific  transport  mechanisms  as  they  are  not  secreted 
or  processed  in  E.  coli  (Manetti  et  al.  1995). 
In  E.  coli,  OmpT  is  responsible  for  degrading  IcsA  (from  S  flexneri)  which  prevents  the 
intracellular  spread  of  the  bacteria  (Nakato  et  al.  1993).  However,  in  S.  flexneri,  a 
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candidate  protease,  Shigella  outer  membrane  protease  A  (SopA)  has  been  implicated  in 
the  polar  localisation  and  processing  of  IcsA  (Egile  et  al.  1997).  This  protease  exhibits 
60%  amino  acid  homology  with  OmpT  and  OmpP  proteases  of  E.  coll.  It  has  been 
suggested  for  IcsA  that  the  C-terminal  domains  may  have  high  affinity  for  components 
characteristic  of  domains  at  the  pole  of  the  bacterial  cell  surface  (Steinhauer  et  al.  1999). 
The  same  may  be  true  for  bordetellae  autotransporters  and  raises  the  possibility  of  a 
focal  point  for  adhesins  at  the  bacterial  surface.  Another  Shigella  autotransporter, 
SepA,  contains  a  serine  protease  catalytic  site  although  this  site  is  not  necessary  for 
cleavage  of  the  SepA  precursor  and  no  protease  activity  has  been  demonstrated  for  this 
protein  (Benjelloun-Toulmi  et  al.  1995). 
Several  E.  coli  envelope  proteases  have  been  characterised  and  such  information  may  aid 
identification  of  proteases  responsible  for  autotransporter  processing  in  other  bacterial 
species  (Lazdunski  1989;  Strauch  et  al.  1989;  Bayeyx  and  Georgiou  1991;  Meerman  and 
Georgiou  1994;  Pallen  and  Wren  1997).  To  investigate  candidate  enzymes  for  such 
proteolysis,  an  E.  coil  expression  system  could  be  used.  For  example,  E.  coli  strain 
BL21(DE3)  (see  Table  3)  which  is  deficient  in  ompT  was  used  as  a  host  strain  in  which 
to  express  Prn.  It  would  appear  that  this  protease  is  not  responsible  for  the  processing 
of  pertactin  as  both  P.  30  and  P.  69  was  recovered  following  expression  of  pertactin  at 
low  levels  in  this  E.  coli  strain  (M.  Roberts,  personal  communication).  In  addition, 
several  other  protease  mutants,  deficient  in  one  or  more  envelope  proteases  were 
donated  by  G.  Georgiou  at  the  University  of  Texas  at  Austin  and  are  described 
elsewhere  (Bayeyx  and  Georgiou  1991;  Meerman  and  Georgiou  1994).  Such  mutants 
were  intended  for  the  study  of  the  processing  mechanism  of  recombinant  bordetellae 
autotransporter  proteins  and  it  was  hoped  that  candidates  in  B.  pertussis  could  be 
identified  from  such  information.  Due  to  time  constraints,  and  the  emergence  of  the 
genome  sequence,  these  experiments  were  not  performed  in  the  present  study. 
In  light  of  the  of  the  B.  pertussis  genome  sequence,  perhaps  a  more  rational  approach 
would  include  identification  and  characterisation  of  potential  proteases  that  are  present 
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in  the  B.  pertussis  cell  envelope.  The  advent  of  bioinformatics  will  allow  rapid  analyisis 
of  the  genome  sequence  data  (Patterson  and  Handel  1998).  The  PEDANT  internet  site 
(http:  //pedant.  mips.  biochem.  mpg.  de/)  provides  information  regarding  categorised 
theoretical  open  reading  frames  from  the  B.  pertussis  genome  sequence  data  which  may 
suggest  candidate  proteases.  Such  proteases  could  be  mutated  (knocked-out)  and  the 
processing  mechanisms  of  autotransporter  proteins  evaluated  by  cell  fractionation  and 
Western  blotting,  using  specific  antisera  to  the  N-termini  and  the  C-termini,  of  strains 
expressing  autotransporter  proteins.  The  cellular  location  of  the  N-terminus,  C- 
terminus  and  unprocessed  protein  domains  in  such  strains  could  be  identified  by 
Western  blotting  with  the  specific  antibodies  that  were  raised  to  recombinant  domains 
during  this  study. 
4.6.1  Outer  membrane  processing  of  Bap-5 
The  presence  of  the  consensus  cleavage  site  in  Bap-5,  as  in  the  other  autotransporters, 
suggests  the  potential  for  cleavage  and  potential  release  from  the  cell  surface.  It  is 
perhaps  difficult  to  understand  why  the  organism  would  produce  adhesins  that  are 
released  from  the  cell  surface.  The  regulation  of  such  release  may  provide  information 
regarding  the  pathogenesis  of  pertussis.  The  control  of  processing  may  represent  an 
important  mechanism  for  alteration  of  adhesive  properties  of  B.  pertussis  at  different 
stages  of  infection  i.  e.  to  enable  adhesion  to  different  sites  in  the  host,  to  allow 
transmission  to  a  new  host,  or  cell  invasion  and  subsequent  intracellular  survival  may  be 
dependent  on  such  release.  Future  studies  on  mutants  which  have  an  altered  processing 
site  and  are  unable  to  correctly  process  the  precursor  protein  may  provide  vital 
information  regarding  autotransporter  protein  processing. 
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4.7  Expression  of  recombinant  domains 
4.7.1  Expression  construct  design 
To  express  Bap-5,  a  specific  portion  of  Bap-5  (NTS)  and  the  C-terminal  portions  of 
Bap-5,  Prn,  BrkA  and  Tcf,  primers  were  designed  to  allow  directional  cloning  into  either 
pETlla,  pET33b  or  pQE-60.  With  the  exception  of  the  BrkA  C-terminus,  all 
expression  constructs  contained  a  His6  tag  (N-terminal  for  pET33b  and  C-terminal  for 
PQE-60  constructs)  for  ease  of  purification.  Where  necessary,  translational  start  or 
stop  codons  were  introduced  (Table  6).  Prior  to  cloning  into  the  expression  vectors,  the 
amplicons  were  first  AT  cloned  and  sequenced  to  check  the  correct  target  sequence  and 
the  fidelity  of  the  amplification. 
The  amplification  of  the  C-terminal  encoding  DNA  was  difficult,  probably  due  to  the 
high  GC  content  of  these  domains  (72.1%  for  Prn,  70.55  for  BrkA  and  68.76  for  Tcf). 
This  is  higher  than  the  overall  GC  content  of  the  B.  pertussis  which  is  reported  to  be  66 
%.  Initial  attempts  to  amplify  these  domains  with  proof  reading  DNA  polymerase 
probably  failed  for  this  reason.  Early  in  this  study,  DMSO  was  considered  to  be  an  aid 
to  difficult  PCR,  but  since  then,  many  manufacturers  have  made  available  tools  which 
facilitate  amplification  of  such  difficult  templates.  For  example,  reagents  such  as  Q 
solution  (Qiagen)  are  now  available,  which  outperform  DMSO  for  amplification  of  GC 
rich  templates.  All  C-terminal  encoding  regions  could  be  amplified  under  the  same 
conditions. 
4.7.2  Expression  of  the  autotransporter  domains 
All  of  the  expression  constructs  that  are  described  in  this  study  could  be  induced  to 
produce  large  amounts  of  recombinant  protein.  It  was  also  possible  to  confirm  the  C- 
terminus  and  NTS  proteins  by  Western  blotting  with  mAbs  to  either  the  His6  tag  or 
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with  specific  mAbs  (sections  3.2.4  and  3.2.5).  The  over-expression  of  the 
autotransporter  domains,  and  also  Bap-5,  appeared  to  be  independent  of  the  IPTG 
concentration  within  the  range  tested  (0.2  -  1.5  mM),  and  in  all  cases  a  significant 
quantity  of  protein  was  present  within  the  host  cells  at  1h  post  induction.  Also,  there 
appeared  to  be  no  expression  of  recombinant  protein  prior  to  induction,  which  was 
evident  both  by  Coomassie-blue  staining  and  by  more  sensitive  Western  blotting 
techniques. 
All  of  the  recombinant  proteins  expressed  during  this  study  appeared  to  form  inclusion 
bodies  within  the  cell.  Such  structures  enabled  very  high  level  expression  of  potentially- 
damaging  hydrophobic  membrane  proteins  within  the  cells.  For  structural  and 
functional  analysis,  other  cell  fractions  could  be  analysed  and  purification  under  native 
conditions  may  be  desirable.  The  inclusion  bodies  were  solubilised  in  8M  urea  (Buffer 
B,  appendix  I),  which  provided  suitable  material  for  affinity  purification  under 
denatured  conditions,  where  appropriate.  The  solubilised  inclusion  bodies  proved  to  be 
stable  at  -20°C  for  at  least  18  months.  However,  when  stored  at  4°C  for  more  than  one 
week,  degradation  of  the  pertactin  C-terminus  was  apparent  on  SDS-PAGE  (other 
domains  not  tested,  results  not  shown). 
4.7.3  Affinity  purification  of  His6  proteins 
Further  purification  of  the  C-terminal  domains  and  NTS  was  possible.  On  most 
occasions  it  was  possible  to  produce  very  pure  protein  on  either  a  large  or  small  scale. 
The  Ni-NTA  microspin  columns  provided  a  very  rapid  and  convenient  technique  to 
purify  recombinant  protein  from  the  urea-solubilised  inclusion  bodies.  The  FPLC  was 
more  time  consuming,  although  a  much  greater  yield  was  possible.  A  preliminary, 
unsuccessful  attempt  was  made  to  purify  the  whole  Bap-5,  although  optimisation  of 
this  was  not  attempted  as  urea  extracts  provided  protein  of  sufficient  purity  for  the 
mouse  protection  tests.  No  Western  blot  was  performed  to  confirm  the  presence  of  the 
His6  tag  on  Bap-5  and  it  is  possible  that  the  protein  produced  was  not  as  intended. 
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However,  the  DNA  sequence  of  the  construct  was  confirmed  as  correct  and  the  Bap-5 
protein  was  identified  at  approximately  its  predicted  MW. 
Further  mouse  protection  tests  and  structural  studies  could  be  performed  now  that  the 
recombinant  proteins  can  be  readily  expressed  and  purified  in  large  amounts.  At 
present,  structural  analysis,  including  X-ray  crystallography,  of  the  purified  C-terminal 
domains,  is  currently  being  undertaken  in  collaboration  with  the  Protein  Crystallography 
Unit  at  the  University  of  Glasgow.  The  pertactin  C-terminus  would  complete  the 
structure  of  unprocessed  pertactin  (P.  93)  and  would  be  the  first  autotransporter 
structure  to  be  resolved.  Such  information  would  also  test  the  hypothesis  that  the  C- 
terminal  domain  forms  a  beta-barrel  in  the  outer  membrane  and  conclusions  from  such 
evidence  could  be  applied  to  other  autotransporters  (Maurer  et  al.  1999). 
4.7.4  Heterologous  antigen  display 
The  pertactin  C-terminus/linker  region  was  cloned  into  an  arabinose-inducible  vector 
which  encodes  a  signal  sequence,  pBAD/gIII.  Expression  was  tightly  controlled  by  the 
concentration  of  arabinose  in  the  medium  and  resulted  in  a  very  high  yield  of  pertactin 
C-terminus/linker,  BADPCTa  (43KDa)  in  the  E.  coli  outer  membrane  fraction.  Such 
control  may  be  a  useful  factor  in  the  expression  of  recombinant  proteins  that  are  toxic  to 
the  host  cell.  An  additional  protein  in  the  outer  membrane  was  identified  which  may  be 
the  processed  form  of  the  pertactin  C-terminus,  BADPCTb  (29  KDa)  which  remains  in 
the  outer  membrane  following  cleavage  within  the  linker. 
This  is  the  first  evidence  that  the  C-terminus  of  a  B.  pertussis  autotransporter  domain 
alone  is  capable  of  associating  with  the  outer  membrane  (when  expressed  in  conjuction 
with  a  signal  sequence).  To  a  much  lesser  extent,  a  construct  of  AIDA-I  fused  to  a 
leader  (signal)  sequence  was  capable  of  reaching  the  outer  membrane  (Suhr  et  al.  1996). 
The  lack  of  heat  modifiability  of  BADPCTa  when  solubilised  at  room  temperature  and 
100°C  and  run  on  SDS-PAGE  may  reflect  incorrect  folding  in  the  outer  membrane  and 
180 Blackburn  P.  E.  Discussion 
its  subsequent  interaction  with  SDS  (Figure  35).  The  heat  modifiability  of  the  smaller, 
BADPCTb  protein  may  reflect  correct  conformation  in  the  membrane  without  the 
constraints  of  the  linker  region.  The  nature  of  the  interaction  of  the  BADPCT  proteins 
at  the  membrane  needs  to  be  examined  further.  Use  of  immunogold-labelled  monoclonal 
antibodies  against  specific  portions  of  this  protein,  perhaps  BBO5  (section,  3.3.3.2),  in 
conjunction  with  electron  microscopy,  would  help  to  clarify  the  topology  of  the  C- 
terminus  in  the  membrane.  Alternatively,  a  whole  cell  ELISA,  with  antibodies  such  as 
BBO5,  may  detect  surface  exposure  of  the  linker  (and  therefore  future  passenger 
domains). 
Several  attempts  have  been  made  to  characterise  the  minimum  autotransporter  domain 
ie.  the  minimum  number  of  residues  that  are  essential  for  correct  targetting  and 
translocation  of  the  passenger  domains  (Miyazaki  et  al.  1989;  Klauser  et  al.  1993;  Suhr 
et  al.  1996;  Maurer  et  al.  1999).  Such  attempts  have  highlighted  the  importance  of  the 
linker  region,  which  appears  to  have  2  functions.  The  C-terminus  of  the  linker  region  is 
proposed  to  traverse  the  pore  formed  and  inhibit  leakage,  whereas  the  N-terminus  of  the 
linker  anchors  the  passenger  to  the  cell  surface  until  cleavage  from  the  cell  occurs. 
The  system  described  in  this  study  (section  3.3)  is  based  on  the  C-terminus  (pore 
forming  domain)  and  linker  region  of  pertactin.  The  linker  region  was  approximated  and 
designed  to  include  the  (PQP)5  region.  The  expression  and  processing  of  pertactin  in 
both  E.  coli  and  Salmonella  spp.  has  been  characterised  (Fairweather  et  al,  1990; 
Lipscombe  et  al.  1991;  Strugnell  et  al.  1992;  Charles  et  al.  1994;  Everest  et  al.  1996). 
Therefore  a  potential  exists  for  using  the  pertactin  C-terminus  is  in  the  development  of 
future  Salmonella  based  vaccines,  including  those  used  for  mucosal  immunisation. 
Maurer  et  al.  (1997)  expressed  a  heterologous  passenger  protein,  either  CtxB  or  a  five 
amino  acid  peptide  antigen  tag,  which  was  fused  to  the  AIDA-I  C-terminus.  Using  this 
system,  expression  of  the  protein  as  approximately  5%  of  total  cell  protein  was 
achieved  from  a  constitutive  promoter  (Maurer  et  al.  1997).  The  vector  system  used 
here  (pBAD/gIII)  allowed  excellent  control  of  expression  level  and  gave  a  yield  of 
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approximately  5%  of  whole-cell  protein  (Figure  32b),  although  no  heterologous 
passenger  domain  was  included  and  this  may  affect  the  eventual  level  of  expression 
achieved. 
4.7.4.1  Apparent  molecular  weights  of  BADPCTa  and  BADPCTb 
On  SDS-PAGE  (with  or  without  boiling  during  sample  preparation),  the  BADPCTa 
protein  migrated  at  apparently  43  KDa,  which  is  15  %  higher  than  the  predicted  size  of 
37.1  KDa.  The  presence  of  the  linker  region  in  the  BADPCTa  protein  appears  to  cause 
the  abberant  migration  of  this  protein  and  to  abolish  the  heat  modifiability  seen  with  the 
smaller  BADPCTb. 
The  migration  of  BADPCTb  in  SDS-PAGE  is  dependent  on  the  temperature  used  to 
prepare  the  sample  prior  to  gel  loading.  The  effect  of  solubilisation  temperature  on  the 
SDS-PAGE  migration  of  certain  "heat-modifiable"  outer  membrane  proteins  has  been 
described  elsewhere  (Inouye  and  Yee  1973;  Schnaitman  1973;  Armstrong  and  Parker 
1986;  See  and  Jackowski  1990).  When  the  outer-membrane  preparation  was  prepared  at 
room  temperature,  the  BADPCTb  protein  was  present  as  a  27  KDa  protein.  When  the 
sample  was  boiled  this  protein  migrated  more  slowly,  at  approximately  30  KDa.  This 
observation  is  consistent  with  the  findings  of  Parton  and  Wardlaw,  who  found  that  two 
major  outer  membrane  protein  in  the  outer  membranes  of  B.  pertussis  (now  confirmed  as 
the  Tcf  C-terminus  and  BrkA  C-terminus)  migrated  more  slowly  on  SDS-PAGE 
following  boiling  of  the  outer-membrane  preparations  (Parton  and  Wardlaw  1975). 
More  recently,  Maurer  et  al.  (1999)  found  that  AIDA-I  C-terminal  domain  migrated 
more  slowly  following  boiling  although  the  authors'  discussion  appears  to  contradict 
their  findings.  The  issue  of  heat  modifiability  has  been  discussed  previously  and  it  is 
apparent  that  different  proteins  are  modifiable  in  different  ways.  Generally,  the 
electrophoretic  mobility  of  proteins  on  SDS-PAGE  is  a  balance  between  the  shape  and 
size  of  the  protein  and  the  amount  of  SDS  bound  (Maurer  et  al.  1999).  Maurer  et  al. 
(1999)  also  proposed  that  the  increase  in  the  apparent  molecular  weight  of  the  AIDA-I 
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C-terminal  domain  following  boiling  is  consistent  with  the  presence  of  ß-sheets  in  this 
protein  which  are  only  completely  denatured  by  boiling  in  the  presence  of  SDS  and  the 
same  modifiability  is  seen  with  E.  coli  major  porins.  The  results  presented  in  Figure  35 
are  consistent  with  these  findings.  It  is  difficult  to  understand  why  the  BADPCTa 
protein,  which  is  presumed  to  be  BADPCTb  plus  the  linker  region  does  not  appear  to 
be  heat  modifiable.  It  is  possible  that  the  presence  of  the  linker  region  prevents  the 
normal  folding  of  the  C-terminal  domain  which  is  thought  to  confer  heat  modifiability. 
The  IgA  protease  carboxy  terminal  domain  is  protease  resistant  which  further  supports 
the  notion  that  this  region  is  embedded  within  the  outer  membrane  and  therefore  not 
accessible  (Klauser  et  al.  1993).  The  predicted  and  apparent  weight  of  the  P30  domain 
(purified  as  described  in  section  3.2.3.2),  run  in  parallel  (Figure  35)  is  29.8  KDa. 
4.7.4.2  Future  development  and  potential  constraints 
The  next  step  in  the  development  of  this  vector  may  be  to  introduce  a  multiple  cloning 
site  between  the  linker  and  the  signal  sequence  which  would  allow  convenient  cloning  of 
passengers  domains.  Alternatively,  the  NcoI  and  AhoI  vector-encoded  sites  (Figure  31) 
may  serve  as  suitable  sites  for  the  directional  cloning  of  passenger  genes.  In  addition, 
the  signal  sequence  and  BADPCT  encoding  sequences  could  be  amplified  together  from 
this  vector  and  introduced  into  an  alternative,  more  suitable  vector  for  use  in  Salmonella 
mucosal  vaccines.  Alternatively,  the  whole  cells  expressing  the  BADPCT  proteins 
could  be  investigated  as  vaccines  against  B.  pertussis  as  the  immunodominant  (PQP)5 
repeat  regions  are  encoded  by  the  linker  and  may  therefore  afford  protection. 
The  inclusion  of  the  linker  region  appears  to  have  enabled  processing  in  E.  coli  of  the  43 
KDa  protein  (BADPCTa)  to  a  putative  processed  form  in  the  outer  membrane  of  29 
KDa,  (BADPCTb).  If  the  processing  of  P.  93  in  E.  coli  could  be  better  defined,  it  could 
potentially  be  controlled.  There  are  two  approaches  to  enable  such  control  -  the  use  of 
altered  linker  regions  (see  below)  or,  alternatively,  the  use  of  E.  coli  host  strains  deficient 
in  specific  envelope  proteases.  The  latter  option  may  be  better  than  alteration  of 
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passenger  domains,  which  may  have  altered  properties  (Klauser  et  al.  1992;  Anderson  et 
al.  1997). 
Alteration  of  the  linker  region  may  include  incorporation  of  a  synthetic  protease  site 
which  could  be  engineered  into  the  vector  for  this  purpose  and  which  could  allow  very 
controlled  release  of  the  passenger  domains(s)  from  the  cell  surface.  Alternatively  the 
protease  responsible  for  P.  93  processing  could  be  co-expressed  in  a  regulated  manner. 
Such  a  fusion  protein  which  utilises  the  Hy1A  transport  system  has  been  evaluated  and 
the  release  of  passenger  protein  was  increased  by  co-expressing  OmpT  (Hanke  et  al. 
1992).  Such  control  may  simplify  purification  of  recombinant  proteins  from  the  cell 
surface  or  be  of  use  in  vaccine  formulation.  Perhaps  a  vaccine  vector  which  can  express 
a  variety  of  antigens  on  the  cell  surface  and  allow  the  controlled  release  of  some  factors 
may  be  useful  in  the  development  of  vaccines  that  can  protect  against  a  variety  of 
diseases  simultaneously. 
An  application  of  a  B.  pertussis  adhesin  has  recently  been  demonstrated.  The 
immunogenicity  of  a  liposome-delivered  antigen  was  enhanced  when  FHA  was  included 
in  the  liposome  (Poulain-Godefroy  et  al.  1998).  This  effect  was  probably  due  to  FHA 
adhesion  to  the  mucosal  tissues.  The  expression  of  heterologous  adhesins  on  cell 
surfaces  in  similar  systems  could  also  be  investigated  and  used  for  either  drug  or  antigen 
targetting  to  specific  tissues. 
4.8  Protective  properties  of  autotransporters 
No  protection  was  evident  from  the  any  of  the  recombinant  proteins  -  whole  Bap-5, 
NTS  (Bap-5  specific  portion)  and  the  C-terminal  domains  of  Prn,  BrkA,  Tcf  and  Bap-5 
under  the  stated  conditions.  The  mouse  protection  tests  were  validated  by  the 
confirmation  that  a  Smithkline  Beecham  acellular  vaccine  and,  to  a  lesser  extent,  purified 
native  P.  69  were  protective,  and  the  E.  coli  cell  lysate  and  alhydrogel  alone  controls 
were  not  protective  according  to  the  mouse  lung  count  data.  The  mouse  weight  gains  did 
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not  prove  to  be  a  useful  indicator  of  infection  by  the  challenge  strains  or  of  protection 
by  the  vaccine,  due  to  the  age  of  the  mice  and  the  time  of  the  challenge. 
The  protective  properties  of  mature  pertactin  (P.  69)  have  been  well  documented 
(section  1.10.5).  P.  69  is  an  important  component  of  the  new  range  of  multicomponent 
acellular  vaccines  and,  therefore,  the  N-termini  of  other  autotransporter  proteins  such  as 
mature  Bap-5,  with  significant  sequence  similarity  and  possibly  similar  virulence 
functions,  may  also  be  useful  immunising  agents  under  appropriate  conditions. 
The  urea  extracts  containing  recombinant  B.  pertussis  autotransporter  proteins,  were 
chosen  for  the  mouse  protection  tests  as  they  provided  a  readily  available  source  of 
relatively  pure  protein.  It  is  known,  and  is  confirmed  in  this  study,  that  E.  coli  proteins 
are  not  protective  against  B.  pertussis  challenge  in  a  mouse  model.  A  major  advantage  of 
testing  recombinant  proteins  is  that  no  other  B.  pertussis  candidate  antigens  were 
present  in  the  vaccine  doses,  unlike  earlier  native  vaccine  preparations,  many  of  which 
would  have  been  contaminated  by  trace  amounts,  of  pertussis  toxin,  which  is  known  to 
be  protective  and,  in  non-protective  doses,  confers  protective  activity  on  other  B. 
pertussis  components  in  the  mouse  intracerebral  challenge  test. 
The  abundance  and  homogeneity  of  the  B.  pertussis  autotransporter  proteins,  in 
particular  the  C-terminal  domains,  suggests  that  these  proteins  may  warrant  further 
consideration  as  components  in  acellular  vaccine  preparations.  Although  the 
recombinant  proteins  tested  within  this  preliminary  study  suggested  a  lack  of  protection 
against  infection  with  B.  pertussis,  it  may  be  possible  to  obtain  protection  under 
different  circumstances  and  many  other  variables  remain  to  be  explored.  For  example, 
inclusion  of  the  autotransporter  proteins  in  outer  membrane  vesicles,  or  combined  with 
other  virulence  factors,  especially  with  a  trace  amount  of  pertussis  toxin.  The 
importance  of  presenting  B.  pertussis  antigens  in  the  correct  form  has  been  studied  and  it 
appears  that  the  best  response  occurs  in  mouse  models  when  outer  membrane 
complexes  or  microspheres  are  used  (Hamstra  et  al.  1995;  Shahin  et  al.  1995).  Hamstra 
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et  al.  (1995)  reported  that  an  outer  membrane  complex  (protein-detergent  micelles) 
containing  a  32  KDa  protein  (now  confirmed  as  Tcf  C-terminus)  was  protective  in  an 
intracerebral  mouse  protection  tests.  The  92  KDa  protein  described  by  Hamstra  et  al. 
(1995)  which  has  now  been  confirmed  as  Vag8  was  protective  only  when  non- 
protetctive  levels  of  pertussis  toxin  were  added. 
Also,  the  experimental  design,  such  as  the  vaccine  and  challenge  doses  and  routes  of 
administration  of  the  vaccine,  different  adjuvant  formulations  or  different  experimental 
models  such  as  the  coughing  rat  model  could  be  investigated  (Hall  et  al.  1994).  Monji  et 
al.  (1986)  suggested  a  role  for  a  30  KDa  protein  in  B.  pertussis  outer  membrane 
preparations  which  potentiated  an  immune  response  to  Haemophilus  type  B  capsular 
polysaccharide,  which  suggests  a  role  of  the  C-terminal  domains  as  adjuvants. 
4.9  The  potential  for  rational  drug  design 
The  abundance,  highly  conserved  nature  and  importance  of  the  autotransporter  beta 
barrel  in  B.  pertussis  and  other  Gram-negative  species  may  provide  the  opportunity  to 
prevent  the  translocation  of  many  different  virulence  factors  to  the  cell  exterior.  The 
potential  may  exist  for  the  development  of  antibacterial  agents  which  specifically 
disrupt  the  autotransporter  export  mechanism.  Structural  information,  especially 
regarding  the  autotransporter  beta  domains  would  help  to  rationalise  such  drug  design. 
The  autotransporters  of  many  important  pathogens  could  potentially  be  targetted  and 
the  diseases  prevented. 
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6.1  Appendix  I 
Media  composition 
Luria  Bertani  broth  (LB) 
1  litre 
Tryptone  lOg 
Yeast  extract  5g 
Sodium  chloride  lOg 
Add  1.2%  agar  for  solid  media 
Cyclodextrin  Liquid  (CL)  media 
1  litre 
Sodium-L-glutamate  10.7g 
L-proline  0.24g 
Sodium  chloride  2.5g 
Sodium  di-hydrogen  orthophosphate  0.5g 
Magnesium  chloride  (6H20)  O.  lg 
Calcium  chloride  0.02g 
Tris  6.  lg 
Casamino  acids  lOg 
Methyl-ß-clyclodextrin  0.25g 
Potassium  chloride  O.  2g 
pH  to  7.6  and  add  vitamin  solution  to  0.5% 
Vitamin  Solution 
75  ml 
L-cysteine  0.04g 
Iron  sulphate  (7H20)  O.  Olg 
Nicotinic  acid  0.004g 
Glutathione  0.15g 
Ascorbic  acid  0.4g 
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Casamino  acid  (CAA)  solution 
1  Litre 
Casein  hydrolysate  lOg 
Magnesium  chloride  (61120)  O.  lg 
Calcium  chloride  0.016g 
Sodium  chloride  5g 
pH  to  7.1;  supplement  with  20%  glycerol  for  storage  at  -80°C 
2x  Yeast  tryptone  medium  (2x  YT) 
1  Litre 
Bacto-tryptone  16g 
Bacto-yeast  extract  lOg 
Sodium  chloride  5g 
SOC  Medium 
1  Litre 
Tryptone  20g 
Yeast  extract  5g 
Salts  1  (250  mM  KC1,1M  NaCl)  lOml 
After  autoclaving  add  10ml  of  2M  sterile  glucose  and  10ml  of  Salts  110  M  MgC12.6H20, 
1M  MgSO4.7H2O) 
Minimal  Media  (MM) 
Ix  M9  salts  (see  below  for  l  Ox  M9  salts  recipe) 
2%  Casamino  acids 
0.2%  Glucose 
I  MM  M902 
(Autoclave  casamino  acids  then  add  M9  salts,  glucose  and  MgC12) 
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lOx  M9  salts 
1  Litre 
Sodium  dihydrogen  orthophosphate  60g 
Pottasium  dihydrogen  orthophosphate  30g 
Sodium  chloride  5g 
Ammonium  chloride  lOg 
pH  7.4 
Molecular  biology  solutions 
Step  Solution 
SDS  0.5%  w/v 
Tris  50mM  (pH7.5) 
EDTA  0.4M 
Add  1  mg/ml  proteinase  K  immediately  before  use. 
Tris-Borate-EDTA  (TBE)  buffer.  5x  stock  solution 
Tris  54g 
Boric  acid  27.5g 
EDTA  (0.5M  stock)  20m1 
DNA  loading  buffer.  6x  stock  solution 
Tris  60mM 
EDTA  6mM 
Sucrose  40% 
Bromophenol  blue  0.25% 
Southern  blot  solutions 
Denaturing  solution 
Sodium  hydroxide  0.5M 
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Sodium  chloride 
Neutralising  solution 
1M 
Sodium  chloride  1.5M 
Tris  1M,  pH  8.0 
SSC.  20x  stock  solution 
Sodium  chloride  3M 
Trisodium  citrate  0.3M,  pH  7.0 
Chemiluminescence  wash  1 
dH2O  890m1 
x20  SSC  l00m1 
10%SDS  l  Omi 
Chemiluminescence  wash  2 
dH2O  895m1 
x20  SSC  5m1 
10%SDS  l  Omi 
Buffer  1 
Maleic  acid  OA  M 
Sodium  chloride  0.15M 
pH  to  7.5 
Buffer  2 
Blocking  stock  solution  (Boehringer  Mannheim)  (10%)  20m1 
Buffer  1  180m1 
Buffer  3 
Tris-HC1  0.1m 
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Sodium  chloride  OA  M 
pH  to  9.5 
Pre-hybridisation  solution 
Blocking  stock  solution  (10%)  30m1 
x20  SSC  75m1 
Sarcosine  (N-lauryl  sarcosinate)  3m1 
10%  SDS  6O0µ1 
dH2O  218.4m1 
Washing  buffer 
Tween  20  0.3% 
Buffer  1  500m1 
Protein  analysis  solutions 
Protein  sample  buffer 
Glycerol  5m1 
20%  SDS  2.5m1 
2-mercaptoethanol  0.5m1 
Tris  (0.5m1,  pH  6.8)  2.5m1 
Bromophenol  blue  0.25% 
Buffer  A 
Sodium  phosphate  50mM,  pH  7.4 
Sucrose  5% 
Stacking  gel  (6%) 
Acrylamide/Bis  solution  4ml 
dH2O  10.69m1 
Tris-HC1  (0.5M,  pH  6.8)  5ml 
20%  SDS  l00µ1 
TEMED  10µl 
10%  Ammonium  persulfate  (APS)  200µl 
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Separating  gel  (12%,  adjust  volume  of  Acrylamide/Bis  solution  and  dH2O  \  to  change 
percentage) 
Acrylamide/Bis  solution  4m1 
dH2O  12.6m1 
Tris  (1.5M,  pH  8.8)  lOml 
10%  SDS  0.4m1 
TEMED  30µ1 
10%  APS  0.3m1 
PAGE  running  buffer  (10x) 
1  Litre 
Tris  30g 
Glycine  144g 
SDS  lOg 
pH  8.3 
Coomassie  gel  stain 
Coomassie  blue  0.5g 
Methanol  500m1 
Acetic  acid  100ml 
dH2O  400m1 
For  destain,  omit  the  coomassie  blue. 
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6.2  Appendix  II 
Sequence  obtained  from  cosmid  3,  which  contained  bap-5 
781 
841 
901 
961 
1021 
1081 
1141 
1201 
1261 
1321 
1381 
1441 
1501 
1561 
1621 
1681 
1741 
1801 
1861 
1921 
1981 
2041 
2101 
2161 
2221 
1  GATTGCGCGG  CCGCGCCTGC  TGCTGCTGGA  CGAGCCGTCG  ATGGGCCTGG  CGCCGTTGAT 
61  GGTCGACAAG  GTGTTCGAAG  TGGTGCGCAC  CATCGCGGCC  GAGGGCGTGA  CCATTCTGCT 
121  GATCGAGCAG  AATGCCCGCC  TGGCGCTCGA  ACATGCCGAC  CGCGGCTATG  TGATGGAGTC 
181  GGGCGAGATC  ACGCTGTCCG  GCCCGGCCCG  CGAGATGCTG  CACGATCCCA  AGGTGCGCGC 
241  GGCCTATCTG  GGCGAAGTCG  AGGCCNGAGC  CAGTCCGCAC  GCACGGGCGC  CGGTTCTTCT 
301  TGCGGAACCG  GCGCCCGTGC  CGCGTTCAGG  CTTCGGCCAG  CGCCGTCGGG  CGCGGCTTGC 
361  GATTGATCAT  CAGGGCAATG  ACCGCGGCGA  TCAGGCCGGT  GCTGCCGGCC  AGTACGAAAG 
421  CCATCAGGTA  GCTGCCCGTG  GTTTCGCGTA  CCACGCCGCC  CATCCAGGCG  GCGCTGGCCG 
481  CGCCCAACTG  GTGGCCGGCG  ACGATCCAGC  CGAAGACGAT  GGGGGCGTCG  CGATCGCCAA 
541  AGGCTTCGGT  GGTCAGGCGC  AGTGTCGGCG  GCACGGTGGC  GATCCAGTCC  AGCCCGAAGA 
601  AAATCGCGAA  CAGCGACAGG  CTGTAGAACG  AGAAGTCCGA  GTAGGGCAGG  TACATCAGCG 
661  ACAGGCCGCG  CAGGCTGTAA  TAAACGAACA  GCAGCCTGCG  CGGGTCGTAG  CGGTCGGTCA 
721  GCCAGCCCGA  GGCCGTCGTG  CCCACCAGGT  CGAAGATGCC  CATCAGCGCC  AGCAGGCCGG 
CCGCCTGCAC  TTCGGNNATG  CCGNNGTNGC  CGCACAGGGC 
GGCCATTGGT  GGTAAAGCCG  CACACGAAGA  AGGTCGCGAA 
TGCGCGCNGC  GCNCCGCAAA  GCGCCGAAGG  TGGCGGCCAG 
CAGGAGCTCG  CATGTCCCGT  AAATCCGCTC 
TGGCCGCCGA  CCGTATCCGC  GCCACCGCGC 
CGGTGGGGGT  CGACGCCATC  GTATCGGCCG 
GCTTCTCGTC  CAAGGACGAA  CTGGCCGCGT 
GGAGCCGCTT  NGACGCCGGG  GCGCAACGCC 
CCGACGGCTC  GGGCGCGTCC  GGCGCGCTGC  CATAGGAGCG  CAGGCCGACA 
GGTCGGGCAC  CAGCCACCAG  GCAAGGGGCG  CCATCAGCGC  GGCGCCGGCA 
AGACCACGCG  GGTCCAGTCG  CCGGAAGCCG  CCAGGGCCGC  CAGCACGGGC 
GATTGCCGGT  GGCCGTGCiG  GNCGTCAGCA  AGCCCATCAT  CAGTCCGCGG 
ACCAGCGATT  GACGATGGTC  GCGCCCAGGA  CCACCGCCAC  CGCCCCCGAG 
AGAACACGCC  CCAGGTCAGC  AGCAGGTGCC  ACGACTCGGT  CATGAAGGCG 
ZGGAGGCGGC  CATCAGCAGC  AGGGCGCCGA  TCAACACGCG  GCGCAGGCCG 
TGGCGGCGGC  GGCGAACGGG  CCCGCCAGGC  CATACANGAA  AATACCGATC 
GNGAGATCGT  GCTGCGGCTC  CATCCGAAGG  CCiGCTCCAG  CGGCACGATC 
GCGTGGAGCG  CAGGCCGGCC  GACACCAGCA  GCGAGAAGAA  GATCACGGCC 
AGGCGTACTT  TTGTCCCAGG  TGC',  CGAAACG  GCGGTGGCAG  GCGCGTTATA 
TGACCGGTAC  GTAGTGTGGA  GCTCGCATCG  TACGTACCGG  TCAGTAACAT 
TTTTTGGCGA 
CGCCGCGCCG 
CTATCGCGAA 
CAAGCCCAGC 
CGANTACGAG 
TCCGCGCGCG 
GCCGTACCGC 
GGCGCGTCTG 
GCGCCGCATG 
GGGCGGTTTC 
TGTACCTGGA  AAGCCTGGCC 
TGAGCAACGC  CGCCGTGGAG 
CGCACAAGCG  CGAACTGCGC 
AGCCCGAAGT  GCTCGGCGAC 
AGCTATTTCA  CGGCGACGGG 
AAGCCAGTCT  GTAGCGATTC 
GGTTTTITTT  GGTGGGGGAG 
TCAGGTGCCG  ATTGCCGGTA 
GATCAGGTGC  GTGNCCACCA 
CAGATACCAG  AACGTGCGGG 
CAGGCCGGTA  CGCGGCGCGA 
TCGGCGGGCC 
GCGACCGCCC 
AGGAACAGCA 
CGCGTGGTGA 
CCTATCCCGG 
CTGGCCGCGC 
AAGTGCTCCA 
GCCGCNGCCA 
AGCACGCTGG 
ACCACGACGA 
CTCATGTTAC 
CGTCAAGCAG 
CGTCATCCAC 
GCGAACTGTT 
CCGGCGTCAC 
CGTACCTGCG 
ATCCCGACGA 
GAGCGCGCCG  CGAACGCGGG 
TATCCCGATC  CCGATCATCC 
CGTCGCCTGA  TCGATATGGC 
GGCTTGATGC  TGCTCATCGA 
CCGGCGCGTC  ACGTCGCGCG 
CGTTTCATAT  TCGTTCGATT 
GGCGATGTGC  CGCGTGTAAG 
TCGGGATATA  TGGGCZTATT 
CCCCGATTTC 
GCGCCCAAGC 
GGCATCCGCG 
CTGTACCGCA 
ACCGAATTNT 
CAGCTGCGGC 
GGCTGCGGGC 
GTGGCCGAAG 
GGCGCGCGCG 
ATTTCGGGCC 
2281  ATTGGCCGAC  AGATTGATCG 
2341  TTCAAGCCGC  CCCTCGGGGC 
2401  TCCGCCATTT  TCGTACGTGT 
2461  TGAAACTAGA  ACAGCTTZ"iT 
2521  ACTGTTTATT  GGCCTCCTTT 
2581  CGCCAGCGGC  GAGATACTTG 
2641  CGCTGCCTTC  GTCGGATGTC 
2701  TCGAGGCTCT  GTCGGATGCG 
2761  TGACGCCCGA  ZGGCAAGGAC 
CACCGGGTGC  CAGGCACCTG  TTCGCAGCAG  TTTTTTCACG 
ACCGATTTGA  ATATGAATGA  CAGAAAATCC  AATAGCATGT 
CGTTTCGGCG  TTGTCGCGGT  AGCGGGTGTG  GCGGCGGGCG 
GATGCCCAGG  CCGCGCCGGC  CGCCGCCGAG  GTAGCCAAGA 
GACATTTACA  GCGACTACGA  GCACGAGCAT  GGCATCGTGA 
GACTACATCA  GTTACAGGTC  CGCCGAGAGC  GGTCGTCCGA 
2821  AGCCCCCCCC  CCCCCCTTTC  AAACTTCAAA  CCATTGGGTA  ATGACGTCGT  AGCGGAGCGG 
2881  ATACGGGTAG  AAGTGCACGG  'IGACGAAACC  CTCGGCGTGT  ATGTCGACTC  GGAGCACCGT 
2941  TCGCTCACCG  TGCGTGACAG  CACGATAGAT  GCATACGGCA  AGCCGCCTTC  CGTCGACTCT 
3001  CCCGATTATT  ACGGTGCCGC  GGCTGTCTAC  GCCGGTACGC  TGAATATCGA  GAATTCCACG 
3061  GTTCACCATA  ACTATGCGGC  CCAGCCGTTC  GAAGACGCGG  TAGGAGTCGG  GGTAACCTCG 
3121  CTCGGGGATA  AGGCCATACT  CAACGTTACC  GACAGCGAGG  TATCGGGTGC  GAGGGGCGCG 
3181  GTCATCGGTT  GGGGGGGGGG  GCGAAGCGAC  ATTTACCGAT  TCGGTCCTGC  GTGGTTCGGC 
3241  CTTCGGGCTG  TACGCCGAAA  TGTGCGACAC  CTGCAGAGAT  GATGATGGCA  CCTCGCCTTC 
3301  GATTCGCGTC  CAAGGCGGGG  TTGTTCAGGG  CGGCATGGGT  GCAAATAACG  TCGCTGTGGT 
3361  GGCAACAGGG  TCTGGAAAGG  TCGCGATCGA  GAATGCGGAA  CTGCTCGGAG  CCAGCGGCAT 
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3421  GTACGCCACG  TTCGGCGCGC  AGGTCGATAT 
3481  CAATATCCTG  GGAAGCCAGG  GTTACGCCGA 
3541  GGACGGTCAA  GTCAACCTGG  AGGGCGCCAA 
3601  CTTGZY'ýGTTG  CTGGGCGACA  AGGACACCAG 
3661  CCACGGAGAG  GTCGCCGCCA  TIGCGCTGGG 
3721  CAGCTTGAGC  GTAGAGGATG  GGGCCGTGCr 
3781  TTACTACGAC  TACGCCTTGT  CCATGGAGCA 
3841  CCGCGTCACG  CTGTCCGATG  GCGCGCGCGC 
3901  GTIGTZGCCC  ATGACGCTGC  GCTIGAGCAG 
3961  GCTGCCGCCT  TCCGCGCCGC  CCGATTCCGC 
4021  TGCCGAGCTG  GAACCGGACG  CCGCGGCGCA 
4081  GGCGCAGGTA 
4141  TGCCCCGATC 
4201  CAATGCGTTG 
4261  CCTGCACCTG 
4321  CAAACACCTG 
4381  CGACCTGAGC 
4441  GCTGGTGCGA 
4501  GCCCGAGGGC 
4561  CGCGTTCCGC 
4621  GCTTT000CC 
4681  CTGGTATGCG 
4741  CGCGGGCGGC 
4801  CCGACGCTTC 
4861  ACAGCAAGGG 
4921  CATCGATGAC 
4981  GGCGGACAAC 
5041  CACGGTAACG 
5101  CGCCACCTTG 
5161  GTCCGAGGTG 
5221  GGTCAAGGAC 
5281  CATCGACCTG 
5341  ATTCAAAGGC 
5401  TGGCCGGGCT 
5461  CACTTCGTAC 
5521  CTATCGCTAC 
5581  CATTCCCGGA 
GATGGCGGGG  AACCTGTTGC 
GACGTGTTCA 
CGCATCGAGG 
CAGGCAGGCA 
CGGGTCAAGA 
GATGGCGACC 
GGAGCCGGCA 
AGCCAGACGA 
TATCGCCTGA 
GTCGCCAACG 
GAAGGCAATG 
TTCTGGGGGC 
GACCAGAAGG 
CGCTGGCACG 
GGCGCCGGGC 
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GAAAGGCGGG  CGCATTCTGG  CGCACAACAC 
TGGTCCCTAT  GGCGGCGTGG  TCGTGACAGA 
GGTCAGTGCA  ACTGGCCTGG  GGGCCGCCGG 
CCCGCGAGCC  AGCC'lGCGCA  ACACCGACGT 
GTTCAATGGC  GAGGCGAACA  TCTCGGGCGG 
CACCACCCTG  ACGCCCGATG  CAGTCGAGTA 
TCTGCCAGCT  GATGCGCCGT  TGACGCCGGT 
CAGCGGAGAA  ACGTTGATCG  CGCATGGCGG 
CGGGGTCGAC  GCCCGCGGCG  ACATCGTCAC 
GGAGCAACCG  GATGCCGAGC  CGGAACCGGP, 
GTCGGACGCC  AAGGCGAATG  CGCGGGTCAT 
CGTGCCGATC  CCGGCCCCTT  CGCATCCCGA 
CGGGGCA'IGA  CCAAGACCGT 
GGGTCGTCCA  CGGTGAACAG 
GCCGAAAGCG  ACGGAGAATT 
TTCGAGATGA  ACGCCAGCGC 
GCCAGCGGC',  C  AGCACAAGGT 
AGCCTGACGC  TGGTCGAGCT 
GGCGGGGTGG  TCGACGCCGG 
GGCCTGGAAC  GGACCAGCCA 
GTGGGCGCGG  CCAGCAGCAT 
GAGTTGCGGC  TCGATCCCGG 
CAGCTCGACA  ACAAGGCTGG 
GCCGACCATG  CCATCGCAGG 
ACCCGCGCAA  GGCGCAGCTT 
GGGGCCTACG  CGGCGTACGT 
TCGACAGCGG  TGCCCAATGG 
ACGGCACCTG  GACCGTCACC 
AGGTGGCGTA  CGCAACGCCT 
CCCTCTCGGG  AAGCGGCCTG 
TGCTGGTCGT  GTCCGACGAG 
CGGAACCCAC  CGGTGTGGAA 
AGTTCACGCT  TGCCAACCGG 
CGCCGGACAA  CGGTGTCTGG 
CGGCCTTGAA  TACCGGGGGC 
CGCTCTCCAA  GCGCCTGGGC 
GCACGTTCGC  CCAGAAGCAG 
TGTACGGTTT  CGAGCTGGGG 
TGGGCGGCCT  GCZGGGCTAT 
ATACCGACAG  CGCGCATATC 
GGCTTCPATT  TCGATTCGAC 
GCCACCGACG  CCGTTTCCGT 
GAGGCCGGCA  AACGTTTCAC 
TCGCTGTTCC  ATGCCAGCGG 
GAAGGCGGCA  CCTCCGCCGT 
GGCAAGGACC  GCGTGATCCA 
GTCACGACCG  TTCGCACCAA 
GAATTGGCGC  TGGGCCTGGC 
GAGTACGCCA  AGGGCAACAA 
ACCTGGTAGC  GGCGCATCGC 
CCG 
CCTGCGCGCC  AGCCGCTTCG  AGAACGACTT 
ACGGGGCAAG  TACCGGGCCA  ATGGGGTAGG 
GTTGCACGAC  GGCTGGTTCG  TCGAACCTCA 
CGGAACCTAC  CGTGCCGCGA  ACAACCTGTC 
GCTGCGCCTG  GGCTPGGCGG  CCGGGCGACG 
GCCCTATGCC  ACCCTGAGCT  GGCTGCAGGA 
CGGGTACGGG  CTGCGCACCG  ACCTGAGCGG 
CGCCGCGTTG  GGGCGCGGCC  ACCAGCTCTA 
GCTGACCTTG  CCTTGGACGT  TCCACCTGGG 
AACAACGGGG  TCATCGCGAC  CCCGTTGTTG 
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6.3  Appendix  III 
Mouse  lung  counts  after  immunisation  with  various  antigens  from  B.  pertussis  and 
intranasal  challenge  with  either  strains  Taberman  or  18-323. 
Experiment  Challenge  Antigen  Total  lung  counts 
preparation  from  individual 
mice 
R12  Taberman  ACV  <100,500,  <100, 
C*,  C 
P.  69  6.7x103,03,150, 
8.0x103,550, 
1.0x105 
Bap-5  urea  3.0x105,3.4x105, 
>3.0x106,5.5x105, 
2.2x105 
NTS  9.6x105,1.1x106, 
2.8x106,1.5x106, 
1.9x106 
E.  coli  lysate  >3.0x106,2.5x106, 
1.7x106,1.4x106, 
3x105 
Al  7.7x105,5.3x106, 
1.4x106,  >3x106,  C 
18-323  ACV  <100,150,200,  C, 
C 
P.  69  2.8x103,5.0x104, 
<100,  C 
Bap-5  urea  1.4x106,1.4x106, 
2.3x106,2.9x106, 
1.1x106 
NTS  1.3x106,1.5x106, 
1.5x106,1.5x106, 
1.7x106,  C 
E.  coli  lysate  2.8x106,2.0x106, 
>3x106,  >3x106, 
>3x106, 
Al  3.9x105,7.5x105, 
3.5x105,  >3x106, 
>3x106, 
R13  Taberman  ACV  1.2x105,  <100, 
<100,  <100, 
4.0x104 
PCT  1.8x106,  C,  >3x106, 
>3x106,  >3x106, 
BCT  2.7x106,  >3x106,  C, 
2.8x106,9x105 
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Appendix  III  (continued) 
Experiment  Challenge  Antigen  Total  lung  counts 
preparation  from  individual 
mice 
TCT  4.4x105,2.9x106, 
7.3x105,3.4x105, 
1.9X106 
Bap5CT  2.1x106,1.5x106, 
1.6x106,5.1x106, 
2.4x106 
Al  >3x106,7.2x105 
>3x106,1.2x106,  , 
>3x106, 
R14  Taberman  ACV  <100,1.0x105, 
<100,2.3x105, 
1.6x105 
P.  69  <100,3.7x106, 
1.2x106,2.6x105, 
5X104 
P.  69(urea)  1.2x105,1.0x104, 
2.0x104,4.4x105, 
1.2x106 
Bap-5(PBS)  9.0x106,1.0x107, 
5.0x106,2.7x106, 
1.0X106 
Bap-5(urea)  1.5x10,4.6x106, 
3.1x106,1.7x106, 
1.1x106 
Bap-5(dialysed)  5.5x106,5.2x106, 
2.3x106,2.7x106, 
2.3x106 
Al  4.2x106,6.0x106, 
2.0x105,4.0x105, 
3.5x106 
GP  2.6x107,1.6x107, 
1.0x106,3.4x106, 
1.3x106 
*C=  Plate  contaminated,  no  count  possible. 
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